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Recent advances in genome sequencing are improving our better  understanding of 
genetic variation. However, the investigation of the genotype-phenotype relationship 
is still challenging, especially for the interpretation of the myriad of discovered 
genetic variants that weakly relate to disease.  
Recently, researchers have confirmed that disease causing genetic variants typically 
occur at functional sites, such as protein-protein or protein-ligand interaction sites. 
Giving this observation, several bioinformatics tools have been developed. This 
thesis first details VarMod (Variant Modeller), an algorithm that predicts whether 
nonsynonymous single nucleotide variants (nsSNVs) affect protein function.  
  
The recent Ebola virus outbreak in West Africa demonstrated the potential for the 
virus to cause edipdemics and highlighted our limited understanding of Ebola virus 
biology. The second part of this thesis focuses on the investigation of the molecular 
determinants of Ebolavirus pathogenicity. In two related analyses knowledge of 
differing pathogenicity of Ebolavirus species is used. Firstly, comparison of the 
sequences of Reston viruses (the only Ebolavirus species that is not pathogenic in 
humans) with the four pathogenic Ebolavirus species, enabled the identification of 
Specificity Determining Positions (SDPs) that are differentially conserved between 
these two groups. These SDPs were further investigated using analysis of protein 
structure and identified variation in the Ebola virus VP24 as likely to have a role in 
determining species-specific pathogenicity. The second approach investigated 
rodent-adapted Ebola virus. Ebola virus is not pathogenic in rodents but it can be 
passaged to induce pathogenicity. Analysis of the mutations identified in four 
adaption studies identified that very few mutations are required for adaptation to a 
new species and once again the VP24 is likely to have a central role. Subsequent 
molecular dynamics simulations compared the interaction of Ebola and Reston virus 
VP24 with human karyopherin alpha5. The analysis suggests that Reston virus VP24 
has weaker binding with karyopherins and we propose that this change in binding 
may reduce the ability of Reston VP24 to inhibit human interferon signaling. 
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This thesis encompasses two main research lines, first the development of a 
computational algorithm (varMod) to predict the effects of nonsynonymsous single 
nucleotide variants (nsSNVs) and secondly an analysis of genetic variation in 
Ebolaviruses to understand how they affect human pathogenicity. The thesis is 
presented as a series of papers, one focusing on predicting the effects of genetic 
variation, while three consider genetic variation within Ebolaviruses.    
 
1.1 Genetic variation 
Each individual is unique as a result of genetic variation. Therefore understanding 
genetic variation and how it alters phenotype will advance our knowledge of the 
extent of genetic variation between individuals. This has been greatly increased in 
recent years as a consequence of the advances in genome sequencing. While it took 
multiple teams a decade to sequence the human genome (Hattori, 2005; Abecasis et 
al., 2010), there are now many projects that sequence large populations of humans, 
for example the 1000 genomes project in much shorter times (Auton et al., 2015; 
Sudmant et al., 2015; Abecasis et al., 2012). 
 
1.1.1 Types of genetic variation 
There are multiple types of genetic variation: 
¥ Single nucleotide variants (SNVs) Ð a single base differs between an 
individual and the reference genome 
¥ Copy number variation (CNV) Ð a region of the genome that has a different 
number of copies compared to the reference genome 
¥ Insertions and deletions (indels) Ð bases deleted or inserted into the genome 
¥ Structural Variants (SVs) Ð  changes in larger portions of the genome 
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sequence that result in a structural change of the genome and thus in a 
change of chromosome assembly. 
 
These types of variation can affect both coding and non-coding regions of the 
genome. However, given our limited understanding of the role of non-coding 
regions (The Encode Project consortium, 2004; Birney et al., 2007), it is difficult to 
interpret the effects of variation located in non-coding regions of the genome, unless 
they are located in known regulatory regions. 
 
SNVs are classified into synonymous, when the base change does not cause a 
change in the coded amino acid, non-synonymous where the encoded amino acid  is 
changed and nonsense when a stop codon in introduced. SNVs that occur fairly 
frequently in a population (typically more than 1% of a population) are referred to as 
single nucleotide polymorphisms (SNPs).  
 
1.1.2 Human Genetic Variation 
After the discovery of DNA (Watson and Crick, 1953), in 2003, human genetics has 
seen probably the most revolutionary discovery, with the first release of an entire 
reference sequence of the human genome (The Human Genome Project 
Consortium, 2004). Since then, the increased interest in understanding the biological 
basis of heredity, has led to the establishment of several international projects, in 
order to collect and catalogue human genetic variation, and among them the first 
two were the 1000 Genome Project (Gibbs et al., 2003; The International HapMap 
Consortium, 2004; Thorisson & Smith, 2005; Frazer et al., 2007; Buchanan et al., 
2012; Auton et al., 2015) and the HapMap project. This section describes these 
catalogues and other current projects. 
 
1.1.2.1 The Human Genome Project 
The Human Genome Project (HGP) started in 1990 and was completed in 2003 
with the initial draft published in 2000 (Lander et al. 2001). It was an international  
effort primarily by research groups in the US, UK, Japan, Germany, France and 
China. The project saw the introduction of shotgun sequencing that rapidly 
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increased the speed at which sequencing was performed. It also saw a notable 
conflict between public and private interests, when a private parallel project from 
Celera Genomics wanted to patent the genomic sequence (Williams-Blongero, 
2004).  
Along with sequencing the human genome, the project aimed also to develop new 
technologies, to study and interpret the human genome and also to establish Ethical, 
Legal and Social Implications of Human Genomics (ELSI). ELSI was the first 
regulatory body to assess issues in genomic research, for example privacy of the 
genetic information and other important issues that could affect individuals and 
society. Sequencing of the human genome revealed that the human genome contains 
approximately 20,500 genes a similar number to that found in mice. The human 
genome project took almost 13 years to complete and more than 10 billion dollars to 
sequence just a single reference genome. This was a milestone in genetics and paved 
the way for many advances, with scientists now able to sequence a genome for a few 
thousands dollars and taking less than a day.  
 
1.1.2.2 The HapMap Project 
The HapMap project was launched in 2002 and it was completed three years later. It 
is an international consortium of academic researchers and private companies 
(International HapMap Consortium 2003; International HapMap Consortium 2007;  
Gibbs et al., 2003). A haplotype is a combination of alleles within a region of a 
chromosome. The HapMap project was set up with the idea to create a haplotype 
map of the human genome, to describe how human genetic variation is shared 
among individuals in different populations. The main goal of this project is to 
understand how SNPs and other genetic variants organise in the different 
chromosomes and how genes can affect drug response by making the generated data 
available to the scientific community. The project used genotyping techniques and 
consisted of three main phases: the first, when more than 1 million SNPs where 
found in 269 DNA samples from different individuals coming from four main 
populations; the second phase, in 2007, where over 3.1 million of SNPs were 
genotyped in 270 individuals. In 2010, the same consortium published genotyping 
results for 1.6 million common SNPs in 1,184 individuals from 11 populations. This 
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latest analysis was called HapMap3 and represented an integrated data set of 
common and also rare alleles. The HapMap project was the first to perform a large-
scale Genome Wide Association study. 
 
1.1.2.3 The 1000 Genomes Project 
The 1000 Genome Project was launched in 2008 and concluded in 2015 (Wood et 
al., 2013; Abecasis et al., 2012; Abecasis et al., 2015). It is currently the largest public 
catalogue of human genetic variation with a frequency greater than 1% in the studied 
populations. The main goal of this project was the identification of human 
polymorphisms with a minor allele frequency (MAF) greater than 1%. The 1000 
Project was performed in multiple stages. The first one, a pilot phase which had the 
goal of developing and assessing strategies for sequencing a large number of 
individuals in the most informative way. It used three levels of sequencing. For two 
sets of trios (parents and child) high coverage genome sequencing was performed 
(average 42x). For 179 individuals low coverage (2-4 X) whole genome sequencing 
(WGS) was performed and finally target exon capture (906 randomly selected genes) 
was performed on a larger set of 697 individuals from four populations. This initial 
phase of the project identified nearly 15 million SNPs, 1 million indels and 20,000 
structural variants. They demonstrated that this dataset had identified the vast 
majority of common variants and that each individual had between 250-300 loss of 
function SNPs and between 50-100 variants associated with inherited disease 
(Abecasis et al., 2010). 
 
In the second phase, completed in 2012 (Altshuler et al, 2012) a total of 1,092 
genomes were sequenced from across 14 different populations. The techniques used 
in this phase were a combination of low-coverage (2-6 X), whole genome and whole 
exome sequencing (WES) (with coverage up to 100 X) and dense SNP genotyping. 
This phase discovered over 38 million SNPs, with 1.4 million short insertions and 
deletions (indels) and more than 14,000 larger deletions. This phase removed over 
1.7 million low quality SNPs from the first phase. 
 
The third phase was completed in 2015 (Sudman et al., 2015; Abecasis et al., 2015) 
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and considered both Structural variants (SVs) and single nucleotide changes. The 
study revealed 68,818 structural variants (SVs) in 2,504 unrelated individuals coming 
from 26 populations. It found 8 classes of structural variants, enriched on 
haplotypes identified in GWAS studies; these variants were largely shown to be 
specific to individual continental groups (Sudman et al., 2015).  
 
The final outcome of the project was the identification of 88 million variants, of 
which 84.7 millions were SNPs, 3.6 millions were short insertions and short 
deletions and over 60,000 were structural variants. Of this total 762,000 variants 
were rare (i.e. present in very few individuals). The main and conclusive finding of 
this third phase was the extent of genetic variants that were shared among 
individuals from different populations. 
 
Now that the 1000 Genome Project is complete, it is under the administration of the 
International Genome Sample Resource (IGSR) which is an entity formed within 
the EMBL-EBI institution with the aim of maintaining and ensuring usability of the 
1000 Genome Project data, to expand it by adding new genomic data and even by 
including new population data.   
 
1.1.2.4 Rare variation 
Rare variants occur in a small proportion of the population (MAF < 1%) but 
interestingly individuals have many of them (Nelson et al, 2012; Tennessen et al., 
2012). The identification of rare variants requires deep sequencing to enable these 
variants to be called with confidence and not classed as sequencing errors. 
 
The 1000 Genome Project (Phase II) classed rare variants as those with a MAF < 
0.1% and they found individuals did not have many, estimated at around 200. There 
are a few available catalogues of rare genetic variants, such as the Exome Sequencing 
Project (ESP) (Exome Variant Server) and others coming from independent studies 
(Tennessen et al., 2012; Nelson et al., 2012; Keinan and Clark, 2013).  
 
Nelson and collaborators sequenced 202 drug target coding genes in 14,002 
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individuals, through a Whole Exome Sequencing study. They identified a large 
number (1 every 17 bases) of novel variants that were population specific, 
geographically clustered and most interestingly they were more likely to be 
functional. In fact, more than 95% of the variants discovered were rare (MAF <0.1) 
and more than 74% were private variants (present only in a single individual) (MAF 
<0.01). The study considered how these rare variants could help our understanding 
of disease risk. The samples from 14,002 individuals included 10,621 samples from 
12 case control studies of common disease. The drug targets genes were selected 
according to a GlaxosmithKline set considered for drug repositioning candidates. 
Genes used for the study were reduced to 202 in order to make the analysis feasible. 
The genes included 12 genes coding for marketed drug targets, 44 genes encoding 
Phase I to III terminated drug targets, 76 genes encoding genes under clinical 
development targets and 70 genes encoding targets under (or interesting for) pre-
clinical development. The set of genes was compared to the NHGRI, catalogue of 
already published Genome Wide Association Studies (http://www.ebi.ac.uk/gwas/), 
with HGMD catalogue, where they found an overlap of fifty three genes and with 
the OMIM database (Hamosh et al., 2005; McKusick, 2007), where they found a 
notable overlap, for a total of 46 variants in 25 genes. Furthermore they compared 
their set of genes with the rest of protein coding genome defined by GENECODE, 
were they found an overlap of almost 20,503 and importantly they found Gene 
Ontology characteristics in terms of biological process, cellular components and 
molecular function for 20,340 genes.  This study has clearly opened a new window 
for the interpretation of rare variants, by discovering that 95% of variants that were 
rare, more than 74% were private variants and more than 90% were novel. The 
aggregation studies additionally showed that around the 37% of rare alleles were 
predicted to be deleterious. Their findings contrast with the initial results on rare 
alleles found by the 1000 Genomes, as they had predicted individuals would only 
have around 200 rare variants. 
 
Another project performed deep exome sequencing for 15,585 protein coding genes, 
in 2,440 individuals in two  populations (Tennessen et al., 2013). Like the Nelson 
study, they discovered more than 500,000 single nucleotide variants, over 86% of 
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these were rare, and 82% were rare and population specific. In order to prove that 
the variants were functional they used four different methods for non-synonymous 
variants (Polyphen2, SIFT, MutationTaster and a likelihood ratio test and 
additionally they used three conservation based methods, GERP (Genomic 
Evolutionary Rate Profiling, Cooper et al., 2005), Phylop (Cooper et al., 2005) and 
another tool designed by the authors and called SFS-Del). This study showed that 
rare variants and their high frequency can be explained by the explosive population 
growth in Europe and Africa. Furthermore they mapped over 31,000 non-
synonymous variants onto structure, whether the protein structure was available, 
they classified the variants according to structural categories (i.e. if the variant was 
buried, part of a ligand binding site or active site or involved in hydrogen bonding, 
or potential charge or if forming a cavity or if in a over packing region). They 
observed that rare variants were particularly enriched in ligand binding and active 
sites and involved in hydrogen bonding.  
 
1.1.2.5 Current projects 
Current projects are sequencing a larger number of individuals and with a focus on 
obtaining data and performing analysis that is relevant to disease and clinical 
treatment, to drive precision (or personalised) medicine. The 100,000 Genome 
Project aims to sequence the genome of 100,000 patients with a rare inherited 
disease or cancer, across 70,000 individuals and is being run by Genomics England 
and associated organisations (Cranage, 2015; http://www.genomicsengland.co.uk/). 
The Genomics England Project will compare individualÕs Genome data with health 
clinical data and medical records, including family information (for rare diseases, 
more than one individual in a family is being sequenced, e.g. a child with the disease 
and both of their parents), in order to find a better treatment for individuals and 
contribute precision medicine.  
 
The Personal Genome Project (PGP) (Church, 2005;  
http://www.personalgenomes.org/) has a similar aim and was founded in 2005, by 
Professor George M. Church of Harvard University. The goal of the PGP is to 
sequence the complete genomes of 100,000 individuals along with phenotypic data, 
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making the results available to the community in order to aid to the development of 
personal genomics and to enable personalised or precision medicine. The project is 
still ongoing and an increasing number of volunteers are taking part in the project. 
 
1.1.2.6 Databases of genetic variation 
The myriad genetic variants discovered with sequencing projects are available in a 
range of databases. dbSNP (Sherry et al., 2001) was founded by the National Center 
for Biotechnology Information (NCBI) and it collects variants across 53 different 
organisms, and the last release (146, March 2016) just for Humans contained over 
150 million referenced SNP (RefSNPs) and 538 million submitted SNPs (subSNP). 
 
Humsavar (http://www.uniprot.org/docs/humsavar) is a catalogue of Human 
Polymorphysms and disease mutations. It is developed by UniProt, the Swiss 
Institute of Bioinformatics (SIB), the European Bioinformatics Institute (EBI) and 
the Protein Information Resource (PIR). This database counts 27,861 disease 
variants, 38,352 polymorphisms and 7,549 unclassified variants, for a total of 73,762 
variants. The small number of variants is due to them being present in protein 
regions and also being a focus on the variants being classified into categories 
indicating if they have a role in disease. 
 
Clinvar ( http://www.ncbi.nlm.nih.gov/clinvar/) (Harrison et al., 2016) is a database 
of medically relevant variants, so it collects variants that are phenotypically 
significant. It is defined as a database of Òthe relationship between human variations 
and the phenotypeÓ and it is based on phenotypic information from MedGen 
(Halavi et al., 2013). 
 
VariBench (Sasidharan & Vihinen 2013) is a database of genetic variants that was 
developed primarily for benchmarking of methods that predict if SNVs are 
deleterious. It contains disease causing missense variants, neutral high frequency 
SNPs, protein stability affecting missense variants, variants affecting transcription 




1.2 The Genotype to Phenotype Relationship 
 
Knowledge of human genetic variation enables investigation of the genotype to 
phenotype relationship to understand how genetic variants are associated with 
particular traits, particularly those associated with disease.  
Diseases are often classified into monogenic, when a variant in a single gene is 
responsible for the trait and complex disease, such as coronary disease, where many 
variants contribute to the trait (Manolio et al., 2009; Eichler et al., 2010; Lehner, 
2013). Monogenic and complex diseases are complicated by environmental factors. 
The OMIM (Online Mendelian Inheritance in Man) (Hamosh et al., 2005; 
McKusick, 2007) catalogue is a resource that collects genetic variants that are 
associated with phenotypes. The last release contains nearly 24,000 entries and it is 
vastly used to interpret and associate variants with disease. 
Despite extensive research carried out to date, there is still a large gap in the 
interpretation of the myriad of the collected variation data, with much of the 
heritability remaining unexplained (Eichler et al., 2010). In fact, it still challenging to 
predict the predisposition to a certain disease or how many complex diseases, such 
as cancer or cardiovascular disease that are caused by many factors, or Mendelian 
disorders which are caused by abnormal alterations in a single gene, can be related to 
heritability (Zuk et al., 2014; Liu & Leal, 2012; Lippert et al., 2013).   
 
All these considered factors mean a need for new insights to personalised or 
precision medicine, which represents the efforts to combine genetic information of 
individuals and use them identify the predisposition to a disease and to design a 
Òindividuals-sizeÓ medical treatment. Precision medicine is described later, in section 
1.2.3. 
 
1.2.1 Genome Wide Association Studies 
In order to understand how genetics relates to a trait and therefore assess the 
heritability for that trait, genetic association studies have been developed. One of the 
most popular means for this purpose has been the development of Genome Wide 
Association Studies (GWAS) (Daly, 2012). GWAS are a combination of statistical 
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tests and genotyping techniques whose aim is to determine the effect of SNPs on a 
trait. This approach has been widely used for the International HapMap project. 
Genotyping techniques can detect simpler and less informative relationships in 
comparison to genome sequencing techniques. However, GWAS are able to 
perform a large number of association tests, and thanks also to the use of SNP chips 
they can associate SNPs to disease.  The use of SNP chips is a limitation of many 
GWAS as the study is limited to the number of SNPs tested on the chip and will not 
detect other novel SNVs. As a result many GWAS have considered common 
variants but with very low proportion of individuals in a population that carry the 
allele that is associated with the phenotype; this last concept is defined as penetrance 













Figure 1.1: Penetrance of Variants over their allele frequency is shown in this figure. Their effects on 
disease is shown in the graph meaning the missing heritability. The figure has been reproduced from 
Manolio et al., 2009. 
 
1.2.2 Use of Next Generation Sequencing (NGS) 
The advances achieved in sequencing techniques, such as Next Generation 
Sequencing (NGS) also referred to as high throughput sequencing can aid the 
discovery of new rare (MAF <0.1) and even de-novo (or private, MAF <0.01) variants 
(DePristo, et al. 2011).  
NGS represent improvements in the speed of sequencing but also in the costs and 
in the accuracy which is notably increased from the previous generation sequencing. 
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Importantly, NGS allowed the discovery of rare variants in many samples. GWAS 
studies as well as NGS have contributed to the ENCODE project (Birney et al., 
2007; Sloan et al., 2015), to annotate and experimentally validate gene loci in the 
Human Genome.  
 
1.2.3 Personalised/precision medicine 
Each individual has a unique set of variants in their genome that will determine 
traits, including the risk for disease and response to drugs. Personalised medicine 
can be used in two ways: firstly, in a preventative manner, for example knowledge of 
an individualÕs risk for particular disease could alter their behaviour or to even seek 
treatment. A good example of this is the identification of BRCA1 and BRCA2 
mutations, where women may choose preventative measures as they have a high risk 
of developing breast cancer (Brookes et al., 2015; Zeidan et al., 2015). 
 
Secondly personalised medicine can be used when an individual is ill and their 
genomic information used to identify the most suitable treatment. For example, if 
multiple possible treatments are available is there one that the patient will have a 
better response to? (Ng, et al., 2009). An example is the use of targeted molecules to 
to treat myeloid leukemia, by overcoming AML  (Acute Myeloid Leukemia) cell 
resistance to drug therapy (Gojo and Karp, 2014).  
 
More recently personalised medicine has been referred to as precision medicine 
(Peterson et al., 2013; Katsnelson 2013), meaning a more precise and effective 
approach to identify a specific patient strategy to identify the best therapy based on 
the patientÕs genetics, environmental and lifestyle factors.  
 
A branch of precision medicine is Pharmacogenomics, which is a combination of 
Pharmacology and genomics and whose main goal is to understand how genes affect 
individual's response to a certain drug (Karczewski et al., 2012; Altman et al. 2012; 
Hopkins & Groom, 2002).  
 
1.3 How genetic variation leads to altered phenotype 
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All types of genetic variation (SNVs, CNVs, SVs and indels) may be associated with 
a trait. The research in this thesis largely considers non-synonymous single 
nucleotide variants (nsSNVs) in protein coding regions and therefore this section 
focuses on such variation. Until recently, synonymous variants were thought to be 
non-functional as they do not alter the protein amino acid sequence. However 
recent research has observed positive selection of synonymous variants in cancer 
genomes and proposed that synonymous variants can be functional (Supek et al., 
2014). Hence, it is possible that such variants may alter regulatory regions or alter 
the speed of mRNA translation and affect protein folding (Shabalina et al., 2013). 
However, our understanding of the effects of synonymous variation are not well 
defined and therefore focus is placed on non-synonymous SNVs. 
 
1.3.1 Analysis of nsSNVs associated with disease  
A number of studies have analysed the properties of nsSNVs that are associated 
with disease. Such research typically considers the location of nsSNVs in protein 
sequence or structure and compares the prevalence of disease associated and neutral 
variants in different regions of the protein.  
 
It is a widely accepted theory that disease-causing sites are much more conserved 
than neutral ones (Kumar et al., 2001). Thus, the fact that functional sites are 
evolutionary conserved, has made sequence conservation one of the most important 
factors used by bioinformatics tools to pinpoint these functional residues in protein 
sequences and aid methods. The use of orthologues (orthologues are two or more 
sequences which descend from the same ancestors and they are separated by 
speciation events) in multiple sequence alignments, to calculate conservation has 
been used in methods such as SIFT (Kumar et al., 2013) and it has been shown to 
give a better perfomance.  
 
Initial studies of the location of SNVs in protein structure, showed that disease 
causing variants are enriched in the protein core, where they are most likely to affect 




David et al., (2012) extended  these previous structural analyses to consider the role 
of protein-protein interfaces. Using the humsavar database of variants (from 
UniProt, Pundir et al., 2016) they mapped variants onto protein complexes from 
Interactome3D (Mosca et al., 2012). In agreement with previous studies, they 
observed a preference for disease-associated variants to be located in the protein 
core. Additionally, they observed an enrichment of disease-associated nsSNVs in 
protein-protein interfaces, confirming the importance of protein-protein interactions 
in cellular function.  
 
Similarly Bordner and Zorman (Bordner & Zorman, 2013) considered nsSNVs 
present in ligand-binding sites. The authors performed large scale homology 
modelling of the human proteome to investigate disease-associated nsSNVs. They 
analysed variants from the Human Gene Mutation Database (HGMD) 
(http://www.hgmd.cf.ac.uk/ac/index.php), COSMIC 
(http://cancer.sanger.ac.uk/cosmic), UniProt and dbSNP  (Sherry et al., 2001). They 
performed a structure-based approach to infer the effects of variants on binding 
sites. In their pipeline they used homology modelling to predict binding sites and 
Machine learning approaches to classify variants.   
The authors found that disease-associated missense mutations were enriched in 
binding sites compared to neutral variants. 
 
Protein function is not only influenced by protein-protein or protein-ligand 
interactions but it is also dictated by other processes, including post translational 
modifications (PTMs). Nussinov et al. (2012) proposed  ÒAllosteric PTM codesÓ and 
described the influence of PTMs on protein function through two main 
mechanisms: by orthosterically influencing binding (for example they can disrupt 
protein-protein interactions) and by allosterical conformational changes in the 
functional site. More recently Li et al., (2014) showed that disease associated 
mutations affect PTM sites and thus protein function.  
 
1.4 SNV prediction methods  
The trends (described above) that show nsSNVs that are associated with disease are 
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enriched with particular properties enabled the development of methods that can 
predict if a nsSNV will affect protein structure and/or function and be deleterious. 
This section provides a summary of those methods that are most widely used.  
 
1.4.1 Sorting Intolerant from Tolerant (SIFT) 
Sorting Intolerant from Tolerant (SIFT; Kumar et al., 2013) classified amino acid 
substitutions for SNPs or indels; this method is based on the principle that 
mutations occurring in conserved regions are less likely to be tolerated and 
consequently more likely to be functional. SIFT generates a multiple sequence 
alignment including distantly related orthologues. Its fundamentals consist in 
building a theoretical model based on sequence homology that considers features 
such as conservation, hydrophobic conservation, difference from known mutations 
in a multiple sequence alignment and that is able to predict if the substitution is 
tolerated or not by using a score derived from position-specific scoring matrices 
with Dirichlet distributions. The obtained SIFT score is a probability that the 
mutation is functional and it ranges from 0 to 1. The closer the value is to 0 the 
more likely the mutation is functional. 
 
1.4.2 PolyPhen2 
PolyPhen2, Polymorphism Phenotyping V2 (Adzhubei et al., 2013), also predicts if 
genetic variants are deleterious. In contrast to SIFT, PolyPhen2 uses information 
from both orthologues and paralogues  (paralogues are two or more sequences 
which are separated only by gene duplication), protein structural features and 
machine learning. The sequence and structural features  comprise: sequence 
annotations from Uniprot and from DSSP,  bond annotations (disulphide bonds 
and covalent links in proteins), UniprotKB and Swiss-Prot functional site 
annotations (binding site information, enzyme active sites, metal binding sites, 
lipidated residues, glycosylated residues, non-standard amino acids and other 
modification sites), UniprotKB and Swiss-Prot region annotations (membrane 
crossing regions, membrane-contained regions with no crossing, repetitive sequence 
motif or domains, coiled coil regions, endoplasmic reticulum targeting sequences 
and sequences cleaved during maturation), PHAT score (only for positions 
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annotated as transmembrane) and multiple features relating to secondary structure 
from DSSP , Ramachandran maps, normalised B-factors, ligand contacts, inter-chain 
contacts and functional site contacts. The method uses all these features to classify 
the substitution, according to a Naive Bayes probabilistic classifier, through a 
supervised learning machine approach. PolyPhen2 is trained with two datasets, 
HumVar, which is most useful when considering Mendelian disease and HumDiv, 
which is best used for complex traits. PolyPhen2 can also classify variants as causing: 
loss of function, gain of function, drug resistance and switch of function mutations.  
 
1.4.3 Other SNV prediction tools 
PolyPhen2 and SIFT represent the most widely used methods for predicting if 
SNVs are deleterious. Other  methods are described briefly below. 
 
MutationAssessor (Reva et al., 2011) bases the prediction of the effect of variants on 
conservation and specificity (i.e. differential conservation between subfamilies). It 
was validated on a set of 60,041 variants, 78% of which predicted to be disease-
associated. The method is based on three hypotheses: mutations that are 
evolutionary conserved are more likely to be functional;  those that are not are more 
likely to be neutral; evolutionary conservation patterns can discriminate between 
functional and non functional mutations. According to this, the final functional 
score in derived from the conservation score and from the specificity score as well.  
 
Yates and collaborators developed Suspect (Yates et al., 2014), which uses both 
sequence and structural features. The unique feature of SuSpect is the use of 
interaction network centrality as a feature, which was demonstrated to improve 
predictions.  In benchmarking SuSpect obtained better performance than other 
existing methods. 
 
CONDEL (CONsensus DELeteriousness score of missense SNVs) (Gonzalez-
Perez and Lopez-Bigas, 2011) is another popular method for SNV effect prediction. 
Condel uses a combination of scores from SIFT, Polyphen2, MutationAssessor,  
FATHMM (Functional analysis through Hidden Markov Models,  
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http://fathmm.biocompute.org.uk/) and Ensembl-variation. The method 
performed better than other existing method during the benchmarking phase. It is 
now part of the FannsDB (Functional annotations for non Synonymous SNVs 
Database), a database of functional annotation for non-synonymous variants that 
integrates data from Ensembl (www.ensembl.org) and dbNSFP 2.1(Liu et al., 2011; 
Liu et al., 2013). 
 
However, one of the main problems observed with these methods is that they 
individually perform well in benchmarking but they often show little agreement 
between methods (Chun and Fay, 2009). This makes it important to continue to 
develop new methods that try to improve upon existing approaches. During the 
course of my PhD I have developed VarMod a method for predicting the functional 
effects of nsSNVs (Pappalardo & Wass, 2014), which is described in Chapter 2.    
 
1.5 Ebolaviruses 
Viruses are non cellular entities which use the host cell machinery to replicate and 
cause infectious disease.  Ebolaviruses (figure 1.2) are negative single stranded RNA 
viruses (RNA genome is complementary to the viral mRNA). The Ebolavirus genus 
belongs to the Filoviridae family and Mononegavirales order. Ebolaviruses are 
divided into four human pathogenic species, (EbolaÐ formerly called Zaire, Ta 
Forest, Sudan and Bundibugyo) and one non-human pathogenic species (Reston). 
The species are named after where they were discovered.  The first two Ebola virus 
species (Sudan viruses and Ebola viruses) were originally discovered in 1976 (Pattyn 
et al., 1977; International Commission Report, 1976; Report of a 
WHO/International Study Team, 1978) and until 2014 there had been a limited 
number of small outbreaks.  
 
To date Reston viruses have only demonstrated pathogenicity in non-human 
primates and were first identified in Reston (Virginia, USA in 1989-1990), then in 
Siena (Italy, in 1992-1993) and most recently in Texas (1996). In 2008 Reston virus 
was found in domestic pigs in the Philippines. Reston antibodies have been reported 
in a few human individuals, but none of them developed Ebola Hemorrhagic Fever 
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or Ebola Virus Disease (EVD), thus demonstrating the lack of pathogenicity in 
humans. 
 
In this section the Ebolavirus cycle of infection, its genome and details of the 
current outbreak in West Africa are introduced. 
 
 
Figure 1.2: The Ebolavirus particle and the Ebolavirus genome. The figure has been adapted from 
Takada et al., Front. Microbiol. 2012. 
 
 
1.5.1 The Cycle of Ebolavirus Infection 
The Ebolavirus infection cycle contains the following steps:  
1. First the virus particle detects the surface of the host cell though the protein 
GP binding to a host cell receptor  
2. it then penetrates the cell through a mechanism of Macropinocitosis  
3. once in the cytosol, it fuses to the endosomal membrane of the vescicle in 
which it is contained and the ribonucleocapsid is releases into the cytosol, 
where it will start to be processed  by host cell enzymes 
4.  the negative RNA uses the complementary strand to form mRNA, which is 
translated using the host cell machinery.  
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5. New replicated viruses follow an actin-dependent transport and they are 
released in the form of new virions through a mechanism of budding.  
 
Ebolavirus is responsible for EVD which is a deadly disease. During the last 
outbreak (2014) the WHO registered 11,325 confirmed deaths with the main locus 
in Guinea, Sierra Leone and Liberia. Other minor cases have been registered in 
Nigeria, Mali and Senegal. Four cases of Ebola infections have also been imported in 
United States and two in Europe, one in United Kingdom and another in Spain. In 
total  28,657 cases of infections have been confirmed, as of 8th May 2016. 
 
1.5.2 The Ebolavirus genome and protein function  
The Ebolavirus genome is around 19K nucleotide bases long and contains seven 
genes, which encode nine different proteins (figure 1.3). The proteins are: the 
nucleoprotein (NP), RNA dependent RNA polymerase (L), glycoprotein (GP), 
soluble GP (sGP), small soluble GP (ssGP) and four structural proteins that are 
called viral protein 24, 30, 35 and 40 (VP24, VP30, VP35 and VP40). The gene GP 
encodes GP, sGP and ssGP. These multiple forms of GP are generated as a result of 
RNA editing  (Mehedi et al., 2013). Given the small number of proteins in the 
Ebolavirus genome, the proteins need to be multifunctional (Xu et al., 2014).  
 
 
Figure 1.3: The Ebolavirus Genome. The 3' terminal and the 5' terminal are shown. Over each gene 
the correspondent protein with deposited PDB structure is shown in grey cartoon. For L protein 
there is no known structure but there are models available.  
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The Glycoprotein GP is the main protein responsible for viral entry into the host cell 
GP contains a mucin domain which has a highly glycosylated glycan caps (it is heavily 
glycosylated) which is important for the viral entry and probably also for immune 
system escape. The GP1 subunit binds to the host cell receptor(s), the actual 
receptor(s) remain unknown, although the Niemann-Pick C1 (NPC1) receptor is 
known to be required for virus entry (Miller et al., 2012). Subunit GP2 is involved in 
the fusion of the virus with the host cell membrane.  The function of sGP and ssGP 
remains unclear. 
The function of the protein L is as an RNA-dependent RNA polymerase. It forms a 
complex with NP, VP30 and VP35 to form the Ebolavirus RNA-dependent RNA 
polymerase nucleocapsid complex, essential for the generation of viral mRNA.  
 
VP35 is a multifunctional enzyme. As described above it is part of the RNA-
dependent RNA polymerase complex and it also has a role in preventing interferon 
signalling. This function is performed by VP35 dimers binding double stranded viral 
RNA and preventing them being recognised by the host cell immune system. This 
has made protein VP35 attractive as a therapeutic target and many scientists tried to 
study and develop VP35 inhibitors, but still without any positive outcome (Binning at 
al, 2014).  
 
The matrix protein VP40 exists in multiple different oligomeric forms, with each 
having a different function. The VP40 dimer has a role in membrane trafficking. The 
hexamer is functional in virus assembly and budding and the VP40 octamer has 
function in transcriptional regulation.  
 
The minor matrix protein VP24 which has probably on of the most intriguing role in 
the suppression of the immune response, since it blocks the whole Interferon 
Signalling Pathway by blocking the Janus/Kinase and Signal transductors and 
activators of transcription, the Jack/STAT pathway. 
Interferons Alpha and Beta, together with Natural Killer cells (NK), are the first 
agents that the human Immune system produces as innate response when a virus 
attacks the human cells. Interferons bind to their receptors and activate the JACK-
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STAT pathway and therefore activate the transcription of genes able to block the 
viral replication in the infected host cells. Ebolavirus is able to escape the human 
immune system in several ways and it is able to escape not only the innate but also 
the adaptive response, for example the production of antibodies. It has been recently 
observed that Ebolavirus is able to block the production of Interferons by mean of 
its protein VP24.  This last, in fact, competes with the phosphorylated transcription 
factor STAT1 for the binding with Karyopherins, which belong to the Importin 
complex. Proteins that are translocated into the nucleus, generally contain a 
sequence that is called classical nuclear localisation signal (cNLS) and that is 
recognized by Karyopherins. STAT1 is classified as non classical NLS (ncNLS) and 
it is recognized by Karyopherins by a mechanism of dimerisation and 
phosphorylation. When VP24 competes with STAT1, it binds Karyopherin and the 
transcription factor cannot be translocated into the nucleus and the whole 
Interferon Signalling Pathway is blocked, since the Jack/Stat pathway is inactivated. 





Figure 1.4: The mechanism of Inhibition of the Signalling pathway in normal cells (A) and in 
presence of Ebolviruses (B). Ebolavirus protein VP24 is shown in red spheres it prevents the binding 
of STAT1 (blue cartoon) to KPNA5 (cyan cartoon). In this way the Interferon Signalling gene 
Expression path is blocked. The figure has been adapted from Daugherty & Malik, Cell Host & 
Microbe, 2014. 
 
1.5.3 The current Ebola virus outbreak 
The current Ebola virus outbreak in West Africa has demonstrated that members of 
the Ebolavirus family pose a significant threat to human health on a large scale 
(Quaglio et al., 2016). It was of unprecedented size resulting in 28,639 confirmed 
cases and 11,316 deaths as of 28th February 2016 (www.who.int). Previous Ebola 
virus outbreaks were small ranging from a few to a few hundred infected individuals 
Until 2014 the outbreak in Uganda in 2000 was the largest, affecting 425 individuals 
and resulting in 224 deaths (La Vega et al., 2015). Given the limited size of previous 
outbreaks it was largely thought that Ebola outbreaks would remain small as they 
occurred in small villages in Africa with very limited travel connections and 
therefore effectively contained themselves. The current outbreak started in Guinea 
in December 2013 and with regular flare-ups it has still not been declared over 
(www.who.int). This outbreak has provided evidence of Ebola viruses persisting in 
immune-privileged sites and remaining infective for long periods. This includes 
persisting in the eye (Varkey et al., 2015)  and the presence of Ebola virus in semen a 
year after recover from the disease and possible sexual transmission (Christie et al., 
2015; Deen et al., 2015; Mate et al., 2015). This complicates effective outbreak 
control. The risk of new transmission from these persistent infections is not 
currently known; however, taken together, these findings caused concerns about 
future large outbreaks (Quaglio et al., 2016). 
 
Next generation sequencing has provided extensive sequencing data on Ebola virus 
genetics and evolution during the current outbreak (Gire et al., 2014; Loriere et al., 
2014; Tong et al., 2015; Carroll et al., 2015; Hoenen et al., 2015; Quick et al., 2016). 
These studies have enabled the identification of mutations in the virus and with 




The first study by Gire et al., (Gire et al., 2014)  sequenced 99 Ebola virus genomes 
from Sierra Leone. Their work suggested a high evolutionary rate of 1.9x10-3 
substitutions per site per year, approximately two fold more than the rate between 
outbreaks. Later studies indicated lower rates closer to 1.0x 10-3 substitutions per 
site per year, in agreement with previous rates observed between outbreaks (Loriere 
et al., 2015; Tong et al., 2015; Carroll et al., 2015; Hoenen et al., 2015). It has been 
suggested that a short sampling time used to obtain the 99 genomes did not allow 
deleterious mutations to be selected against and as such inflated the evolutionary 
rate (Gire et al., 2014; Carroll et al., 2015). The analysis of Gire et al., supported the 
outbreak being caused a single transmission from an Ebola virus reservoir followed 
by human-to-human transmission. 
 
Hoenen et al., (2015) sequenced Ebola viruses present in infected individuals in Mali. 
They identified a limited number of nonsynonymous amino acid changes and those 
observed did not map to functional regions of Ebola virus proteins. They propose 
that during the outbreak the virus has been undergoing limited evolution with no 
evidence of increased virulence or transmissibility (Hoenen et al., 2015). Phylogenetic 
analysis of a larger set of Ebola viruses from Sierra Leone identified three different 
lineages, and multiple sub-lineages (Tong et al., 2015). Carroll et al., (2015) sequenced 
179 Ebola virus patient samples from Guinea, phylogenetic analysis identified two 
lineages (A and B). Lineage A was present earlier in the outbreak (not observed after 
July 2014) and thought to have been contained by response to the outbreak. 
However, lineage B shows spread across Guinea, Sierra Leone and Liberia.   
 
Loriere et al., (2015) identified three lineages present in 85 patients infected in 
Guinea. The rate of substitutions is similar to the other studies but they observed 
nonsynonymous substitutions in the GP, L and VP35, proteins, some of which may 
be functional. Some GP variants are present in the mucin like domain and Loriere et 
al., (2015) proposed that they could alter the shape of the virus or affect glycoslyation 
of GP (Loriere et al., 2015). In VP35, mutations were identified in the domain 





An alternative approach considered 65 genomes from a range of outbreaks and 
infections in both great apes and humans (Azarian et al., 2015), with a focus on GP 
as it is the most variable Ebolavirus protein. Their findings suggest that the evolution 
observed is primarily due to neutral genetic drift and based on this they propose that 
it is unlikely that strained with altered transmission mechanisms or with altered 
pathogenicity will emerge. 
 
The most recent sequencing project from the West Africa outbreak performed Ôreal-
timeÕ sequencing in the field (results available within 24 hours) (Quick et al., 2016) by 
using MinION nanopore sequencers. Using this approach 142 Ebola virus genomes 
from Guinea were sequenced during 2015. They identified that the viruses largely 
belonged to two main lineages GN1 and SL3. SL3 originated in Sierra Leone and 
spreaded to Guinea, whereas GN1 was confined to Guinea. 
 
Combined together these studies suggest that Ebola viruses are not evolving towards 
easier transmission or changes in virulence. Importantly, the many sequences now 
available enable extensive computational analysis of Ebola to understand how it 
functions and what determines pathogenicity.  
 
1.6 Bioinformatics methods and resources used in this thesis 
In order to carry out the research described within this thesis, several Bioinformatics 
tools for variant modelling and for protein engineering have been used and this 
section describes the majority of them:  
  
1.6.1 3DLigandSite 
3DLigandSite (Wass et al., 2010) uses protein structural modelling to predict protein 
ligand binding sites. For a given query sequence 3DLigandSite models the protein 
structure using Phyre2 (Kelley et al., 2015) and uses the model to perform a 
structural search of a database of ligand-bound protein structures from the protein 
databank. Alignment of the model with similar structures from this database map 
the ligands onto the model structure. Clustering of the ligands is performed and 
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binding sites predicted based on these clusters. The method has performed well in 
the Critical Assessment of techniques for Protein Structure (e.g. CASP8, Tress et al., 
2009). 
 
1.6.2 Phyre2  
There is a large gap between the number of protein sequences present in UniProt 
and the number of solved protein structures. Phyre2 (Protein Fold 
Homology/Analogy Recognition Engine) (Kelley & Sternber 2009, Kelley et al., 
2015) build 3D structures of protein with no known structure by identifying 
templates for the query by using hhsearch (Soding et al., 2005) to search a fold 
library extracted from. The method predicts the secondary structure using Psi-pred 
(Buchan et al., 2013) and Diso-pred (Ward et al., 2004) (this last for disordered 
regions in proteins) and then it constructs HMM (Hidden Markov Model) models of 
the protein sequence. The 3d structure is build, the loops are refined by mean of 
loop libraries, accounting for loops up to 15 amino acids in length and the side 
chains are modelled too, with more than 80% accuracy.  
 
1.6.3 Interactome3d 
Interactome3D (Mosca et al., 2013) is a bioinformatics tool for the structural 
annotation of Protein-Protein Interactions. Interactome3D identifies complexes in 
the PDB that can be used as templates for known pairs of interacting proteins 
present in databases such as IntAct (Orchard et al, 2014). The templates either 
represent the full protein structures or they can just represent the interaction of 
individual domains within a protein sequence, using 3did (Mosca et al., 2013). The 
method initially collected over 12,000 protein-protein interactions, including 
experimentally validated and newly discovered interactions, in eight organisms. The 
last release in 2015 doubled the size of the resource, including data for a further 
eight organisms.  
 
1.6.4 FoldX 
Protein folding is tightly connected to protein function. FoldX (Schymkowitz et al, 
2005) is a force field for energy calculations and protein design. FoldX can predict 
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the effect of mutations on protein stability and it can calculate the energy of 
interaction in protein-protein and in protein-DNA complexes. The energy that is 




mCSM is a structure based method for predicting the effect of mutations in proteins 
by using graph-based signatures (Pires et al., 2014). The methods considers how 
mutations may affect protein stability, protein-protein affinity and  protein-DNA. 
The method uses a machine learning approach and the novelty of the method is the 
introduction of a graph-based signature that represents each mutation as a signature 
of a pharmacophoric count vector that will be considered to train the classification.  
The method uses a machine learning approach to predict the impact of the 
mutations. Like FoldX the method is a structure based predictor and they both are 
accurate, although mCSM showed a better performance than FoldX.  
 
1.6.6 Specificity Determining Positions (SDPs) 
The proteins in a protein family may have many different functions. For example in 
an enzyme family this may be different substrate specificities, with the enzyme 
performing effectively the same reaction but on different substrates. In the 1990Õs 
methods were initially developed to identify such positions    (Casari et al., 1995; 
Lichtarge et al. 1996) that could be present within a protein family. Such positions 
are now largely referred to as Specificity Determining Positions (SDPs) and they 
have been demonstrated to be enriched at functional sites such as ligand-binding 
and protein-protein interfaces (Rausell et al., 2010).  
 
In the research presented in Chapter 3 the s3det algorithm (Rausell et al., 2010) was 
used to predict SDPs. This method splits protein family into subfamilies and relates 
SDPs to functional regions, according to the structural proximity to catalytic sites, 
ligand-binding sites of small molecules and protein-protein interaction sites. 
 
s3det is based on a statistical method termed Multiple Correspondence Analysis 
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(MCA) which is very similar to Principal Component Analysis (described later). The 
program encodes a multiple sequence alignment (MSA) into a binary matrix, and the 
coordinates of the matrix are transformed into ÒPrincipal AxesÓ that are not 
correlated; the sequences are then projected onto these Principal Axes. The methods 
can be used in supervised manner, where the proteins are split into subfamilies 
determined by the user. Alternatively in the unsupervised format s3det can uses K-
mean clustering to group the sequences into subfamilies. The MCA analysis is based 
on the Òpseudovaricentric relationshipÓ between the projected sequences and the 
projected residues which infers that Òthe centre of the masses of any group of 
sequences points to those residues particularly associated to themÓ. This is the 
principle by which the authors determined the SDPs in their study.   Figure 1.5 shows 
an example of SDPs that are conserved within all the Ebolavirus species but differ 
between them, for example R (Arginine) and T (Threonine) which are conserved 
within Zaire, Sudan, Bundibugyo and Ta Forest but differ in all the Reston species 
(many Valine and Serine in this example). 
 
Figure 1.5: Specificity Determining Positions (SDPs) in the different Ebolavirus Species are shown in 
two different groups: group 1, for human pathogenic species and group 2 for Reston, the only non 
human pathogenic species. Arginine R and Threonine are conserved within group 1 but they change 





1.6.7 Machine Learning Ð Support Vector Machines (SVMs)  
Machine Learning is widely used in bioinformatics in the development of prediction 
algorithms. The basic premise of machine learning is to predict a particular property, 
for example protein function or whether a nsSNV is deleterious, using of a set of 
features. Machine learning algorithms are trained using a dataset where the 
properties are already known, so that the algorithm can learn how to associate the 
values of the features with the property being predicted. This often results in the 
algorithm learning rules or trends that associate the features with the predicted 
property.  
 
Machine Learnings consist of three main statistical fundamentals:  first, 
classification, which is a supervised method and for which we know to which class 
data belong to; second, clustering, which is unsupervised since it groups the data but 
ignores the labels and third, regression, which is supervised and consists on building 
a separation of the different groups according to the labels. In statistics, supervised 
learning can be divided into classification and regression. Classification is part of 
pattern recognition methods and it assumes that data labels are finite and discrete, 
whilst regression gives a function estimation and labels depend on a continuous set 
of data.  
 
Support Vector Machines (SVMs; Vapnik, 1995) are a widely used type of 
supervised machine learning method. SVMs have been successfully applied in the 
development of methods for the prediction of protein function (Wass et al., 2012), 
genetic mutations on protein stability, for protein folding recognition, for protein 
structure classifications, for secondary structure predictions or even for cancer 
classification using gene expression data (Petryszak et al., 2013; Kapushesky et al., 
2012).   
 
SVMs are based on the principle that algorithms ÒlearnÓ according to a class of 
tasks. Typically they depend on several parameters and their choice is not always 
straightforward. The larger is the number of parameters the more complex is the 
task.   
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SVMs are based on a similarity function that is referred to as a kernel. A kernel is a 
class of algorithm for pattern recognition that allows the use of implicit coordinates 
and obtaining high dimensional feature space. Whether the extraction of the features 
can be very expensive, kernels can decrease costs by computing inner products, 
implicitly. Kernels take into account the distances in a feature space, they compute 
matrices and they give an estimation of similarity. 
Given a set of data, one can embed it in a vector space and look for linear relations 
in that space. Kernels allow to specify the inner product function between points in 
that space, by considering all the pairwise inner products. So, for example, given a 




                                                                   
The use of kernels has been extensively used in multivariate statistics algorithms 
based on eigenproblems, for example Support Vector Machine Learnings (SVMs), 
Principal Component Analysis (PCA), Canonical correlation analysis and others. 
There are several types of kernels, among the most important the linear (also the 
simplest), polynomial kernels, radial basis function kernels and sigmoid kernels. 
Linear kernels are applied to linearly separable problems.  
 
The simplest SVM uses a linear kernel to build a hyperplane to separate two groups. 
The hyperplane separates two groups with the criterion to maximise the margins 
which separate the groups. The elements of the groups which intersect the two 






















Figure 1.6: Simplification of SVMs. The first group (blue spheres) is separated from the second 
group (red spheres) by an optimal hyperplane (green line) and it is called the maximum margin 
classifier. The spheres of each group that intersect the dotted margins are termed support vectors. 
The equation wx+b=0 describe the optimal hyperplane whilst wx+b=-1 and  wx+b=+1 represent the 
lines that describe the closest margins to one side and the other. 
 
1.6.8 Molecular Dynamics basis and principles 
Molecular dynamics simulations are computer calculations that model the motion of 
atoms and molecules as a function of time. The first molecular dynamics simulation 
was solved in 1977, when a bovine pancreatic trypsin inhibitor in a vacuum was 
simulated for less than 10 ps. (McCammon et al., 1977). MD can be a very 
informative method for protein folding, for conformational changes and on binding 
free energies. Molecular simulations can predict with good approximation the 
behaviour of molecules in solvent, in double phase or in membranes. MD can help 
the understanding and interpretation of molecular recognition with high confidence, 
especially where experiments are not possible; it can also aid in the refinement of X-
ray crystallography and NMR structures.  
 
Molecular dynamics simulations give, as output, an ensemble of configurations that 
essentially represent the coordinates and the velocities of the studied system as 
function of time. This output is referred to as a trajectory.  
 
The statistical basis of Molecular Dynamics is based on the principles described 
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below. Given a system with multiple components, its internal Energy can be 





where K(p) is the kinetic energy of the system, and U(r) is its potential energy. The 
Hamiltonian asserts that the sum of K(p) and U(r) is equal to the sum of the 
momentum p of a particle i divided by two times its mass and summed to its 
potential Energy U at each position ri. The probability distribution, for the atoms in 







where kBT is the Boltzmann constant. Given that it is impossible to know the 
Boltzmann probability for all states, when we study microscopic systems we refer to 
the ergodic hypothesis, which states that for an infinitely long system all the 








in this equation the first term in angle brackets [A(r,p)]T refers to thermodynamics 
averages and the second one [A(r,p)]Z to the dynamics averages, where T is the time 
length of the trajectory and Z is a canonical partition function referring to an integral 
over all space phase. Since MD deals with discrete (and not infinitesimal) objects 
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one can apply this principle.  
 
Classical Molecular dynamics allows the study of thermodynamics and kinetics 
properties, according the  Newton's second law: 
 
                                                  
 
            (1.6.5) 
                                                    
                                                      
 
 
where F is the force that is applied to the particle, m is the mass of the particle and a 
its acceleration.   
 
A force field describes all the intra and inter molecular interactions, in terms of the 
potential energy of the system. It is the sum of all the energetic terms that contribute 
to the potential energy of the system.  The force field follows two fundamental 
equations: SchrdingerÕs equation and the Born-Oppenheimer approximation. 
 
The Schrdinger equation describes a molecular system by a relativistic time-
dependent point of view.  
 
                 (1.6.6) 
                                                                     
This equation needs to be adjusted, especially for systems with many atoms. For this 
reason the Born-Oppeneimer approximation is fundamental in MD. This 
approximation asserts that electrons adjust their dynamics accordingly to the atomic 





         (1.6.7) 
 
The force field represent the ensemble of the bonded interactions, such as angle, 
dihedral and improper (plane-plane) and non bonded interactions such as Van der 
Waals and Electrostatics.  
 
The Periodic Boundary Condition (PBC) asserts that atoms interact with their 
neighbours and also with the periodic atom corresponding to the mirror image of 
itself. PBC are very useful in MD, especially for large systems. After the simulation 
one should be aware of this artefact and apply the Minimum Image Convention 
(MIC) which ensures that the atoms interact only with the closet image inside the 
box of the simulation.  
 
An Example of PBC is shown in the figure 1.7. Here the solvation box has been filled 
with waters and the protein is shown in the central black box. The other boxes show 
the closest periodic mirror image, necessary to make the system infinite-like.  When 
a particle leaves a simulation box (for example the circle inside the central box) it is 






Figure 1.7: PBC in a simulation box. The Protein is shown in blue cartoons and water molecules in 
red sticks. The central box marked in bold is the simulation box whereas all the others represent 
periodic images of the central one. In this example, Periodic Boundary Conditions allow atoms that 
interact with others outside the simulation box, to be replaced by other atoms coming from the 
bottom periodic image and keep the system in equilibrium during the simulation. Simultaneously the 
same substitution occurs across all the boxes. 
 
1.6.8.1 MD protocol:  
Each molecular dynamics simulation consists of different steps:   
1. defining the initial velocities (according to the Maxwell distribution) and 
creating the topology file. 
2. defining the unit cells  
3. adding solvent molecules 
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4. neutralising the system, adding ions 
5. Energy minimisation (relaxation of the structure to assure that there are not 
steric clashes or inappropriate geometries) 
6. Equilibration phase, which is a critical phase for the entire simulation; this 
step consists of two phases: stabilisation of temperature (isothermal-
isochoric), where the canonical ensemble NVT (where N refers to the 
number of particles in the system, V to the volume of the system and T to 
the absolute temperature) is defined (this ensures that the number of 
particles, volume and temperature is constant); and as second phase, the 
stabilisation of pressure (isothermal-isobaric) and thus of stabilisation of the 
density. During the equilibration, it is standard procedure to apply restraints, 
in order to equilibrate the solvent around the protein, and in this way getting 
a bigger control of the simulation. 
7. Production 
8. Analysis  
 
The protein structures used for MD simulations need to have a good crystal 
structure resolution without missing backbone atoms; then the molecule is fitted 
into a box which will be filled with solvent molecules (if the simulation is in solvent; 
simulations can also be performed in a vacuum); then the temperatures and the 
pressure are assigned and the system is energetically minimised according to the 
initial and the rescaled velocities, temperatures and pressures; during the 
minimisation phase at specific temperature one can also use restraints, in order to 
have more control of the whole simulation. Finally, the production phase, where the 
simulation starts for a specific length of time.   
 
1.6.9 Principal Component Analysis 
 
Principal Component Analysis (PCA) is a linear transformation, widely used to 
analyse the motion of proteins during Molecular Dynamics (MD) simulations. PCA 
is used to reduce the dimensionality of a problem and in the case of MD it can aid 
interpretation of the motion in terms of eigenvectors and eigenvalues. Given a 
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motion, the eigenvalue corresponds to the weight of the eigenvector to the motion 
of a protein.   
 
The aim of the PCA for MD trajectories is to determine the predominant direction 
for all the structural changes. Considering a system with N atoms, we can describe 
the internal motion according to the following covariance matrix:  





where the values in round brackets ( É ) are the values of the masses in Cartesian 
Coordinates and the ones in angle brackets < É > are  the average of all the 
sampled conformations. This covariance matrix is then diagonalised in order to 
obtain 3N eigenvectors (Vi) and eigenvalues (Vi ). These describe the motions and 
they can be projected into Principal Components:  
  
                                                                                                                     
(1.6.9)  
                                                                  
 
 
It has been shown that the majority of the fluctuations of a system can be described 
by the first principal component. There are several ways to visualise PCA and one of 
them is to use a porcupine visualisation, where Cα atoms are linked to cones which 
have the same direction of the eigenvector. Each cone has a length which is 
proportional to the amplitude of the corresponding motion.  An example is shown 

















Figure 1.8: Porcupine visualisation of Principal Component 1 and 2 in Ebola VP24 protein shown in 
blue cartoon, in complex with human Karyopherin Alpha 5, shown in gray cartoons. In red sticks a 
series of mutations occurring at the interface are shown. The yellow cones represent the amplitude of 
the C alpha movements, as obtained with Principal Component Analysis. 
 
 
1.7 Organisation of this thesis 
The two main research lines: 
¥ the development of VarMod, a computational algorithm to predict the 
effects of single nucleotide nonsynonymous single nucleotide variants  
¥ analysis of genetic mutations occurring in Ebolaviruses to understand how 
they affect human pathogenicity.  
 
The thesis is divided into the following six chapters:  
 
The Introduction Chapter has described the state-of-the-art for the analysis of human 
genetic variation, an introduction to Ebolaviruses and  the methods used to analyse 
mutations present in Ebolavirus genomes.  
 
Chapter 2, contains the article entitled ÒVarmod: Modelling the functional effects of 
nonsynonymous variantsÓ published in Nucleic Acid Research Journal (Pappalardo & 
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Wass, 2014).  
 
In Chapter 3, contains the article entitled ÒConserved differences in protein sequence 
determine the human pathogenicity of EbolavirusesÓ describes analysis to identify 
the molecular determinants of Ebolavirus Pathogenicity; published in Scientific Reports 
(Pappalardo et al., 2016).  
 
Chapter 4 - ÒAnalysis of Ebola virus mutations present in rodent adaption 
experimentsÓ. This manuscript considers the structural analysis of Ebolavirus 
mutations obtained from several adaptation studies inducing pathogenicity in mice 
and guinea pigs; this work is in preparation and will shortly be submitted to Genome 
Biology. 
 
Chapter 5 - ÒMolecular dynamics analysis of Ebola virus pathogenicityÓ This chapter 
builds upon the results from chapter 3 and uses molecular dynamics to investigate 
mutations in VP24 and how this may affect binding to the human protein 
Karyopherin alpha5. This work is in preparation and will soon be submitted to 
PLOS Computational Biology. 
 









VarMod: modelling the functional 
effects of non-synonymous variants 
 
M. Pappalardo & M.N. Wass (2014), ÒVarMod: modelling the functional effects of 
non-synonymous variantsÓ, Nucleic Acids Res., 42: W331ÐW336. 
 
 
This work was entirely developed by my supervisor, Mark Wass and me. I developed 
the vast majority of the back end scripts and analysis that are performed by VarMod. 
This includes: 
1. Generation of multiple sequence alignments and calculation of conservation 
2. Structural modelling of the query protein 
3. Analysis of structural properties (e.g. solvent accessibility and secondary 
structure) 
4. Analysis of protein-protein interactions and the proximity of variants to 
interfaces 
 
The machine learning element was implemented with my supervisor. My supervisor 
developed the front end of the webserver, we worked together on the overall design 











Unravelling the genotypeÐphenotype relationship in humans remains a challenging 
task in genomics studies. Recent advances in sequencing technologies mean there 
are now thousands of sequenced human genomes, revealing millions of single 
nucleotide variants (SNVs). For non-synonymous SNVs present in proteins the 
difficulties of the problem lie in first identifying those nsSNVs that result in a 
functional change in the protein among the many non-functional variants and in 
turn linking this functional change to phenotype. Here we present VarMod (Variant 
Modeller) a method that utilises both protein sequence and structural features to 
predict nsSNVs that alter protein function. VarMod develops recent observations 
that functional nsSNVs are enriched at proteinÐprotein interfaces and proteinÐ
ligand binding sites and uses these characteristics to make predictions. In 
benchmarking on a set of nearly 3000 nsSNVs VarMod performance is comparable 
to an existing state of the art method. The VarMod web server provides extensive 
resources to investigate the sequence and structural features associated with the 
predictions including visualisation of protein models and complexes via an 







The ability to sequence genomes has resulted in the identification of millions of 
genetic variants, particularly single nucleotide variants (SNVs), within the human 
population as highlighted by the 1000 genomes project (1000 Genome Project 
consortium, 2010; Abecasis et al., 2012). Additionally, other studies have 
demonstrated that individuals have many rare SNVs (Nelson et al., 2012; Tennessen 
et al., 2012). The data generated by such studies provide a unique resource for 
investigating the genotype to phenotype relationship. However, this is a complex 
problem as demonstrated by Genome Wide Association Studies (GWAS), which 
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have identified many variants associated with disease risk but have only explained a 
limited amount of heritability (Eichler et al., 2010). Additionally, in these studies, it is 
difficult to identify causal variants from a selection of candidate SNVs in the regions 
of the genome associated with the particular disease. 
There is therefore a need to develop methods to identify SNVs, in our case non-
synonymous SNVs (nsSNVs), that are likely to affect the function of the protein in 
which they are present and are more likely to be associated with a change in 
phenotype. A number of methods have been developed previously (reviewed in 
(Peterson et al.,2013), with the Sorting Intolerant From Tolerant algorithm (SIFT, 
Sim et al.,2012) and PolyPhen (Adzhubei et al., 2010) being among the most well 
known. SIFT uses residue conservation in multiple sequence alignments to identify 
function altering nsSNVs, while PolyPhen uses machine learning to combine features 
from both sequence and structure. 
Here we have developed VarMod a new method for identifying functional nsSNVs. 
VarMod develops our recent research in which we demonstrated that disease 
associated nsSNVs are enriched at proteinÐprotein interfaces (David et al., 2012). 
Additionally, in GWAS, we have previously used structural modelling of ligand 
binding sites to identify likely candidates for association with disease (Chambers et 
al., 2010; Chambers et al., 2011; Chambers et al., 2009). For example, in a kidney 
disease genome wide association study (Chambers et al., 2010), we demonstrated that 
the variant rs13538 results in a phenylalanine to serine change located in the acetyl 
Co-enzymeA binding site of the protein NAT8 and proposed that the variant may 
have an effect on the activity of the enzyme (Chambers et al., 2010). VarMod builds 
upon these observations and uses structural modelling of ligand binding and proteinÐ
protein interface sites to generate features that are combined with other features such 
as residue to conservation to identify functional nsSNVs. The VarMod web server 
provides an overall prediction made using a machine learning approach (a support 
vector machine) to combine the data from the different individual analyses. 
Additionally the server provides users with extensive resources to investigate the 
results from the separate analyses. 
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2.3 Methods 
2.3.1 The Varmod Algorithm 
VarMod obtains features from multiple analyses, which are combined using a 
support vector machine (SVM) (Vapnik, 1999) to make an overall prediction. The 
data sources used are described below. Sequence conservation is calculated using 
JensenÐShannon divergence (Capra and Singh, 2008). Homologues of the query 
sequence are identified by PSI-BLAST (Altschul et al., 1997) using an approach 
shown to optimise results (Chubb et al., 2010), where the query sequence is initially 
searched against UniRef50 to generate a sequence profile that is used to search 
against the full UniProt sequence database (Uniprot Consortium, 2012). The query 
sequence and homologues are aligned using MUSCLE (Edgar, 2004) and the 
resulting multiple sequence alignment used to calculate the JensenÐShannon 
divergence. 
To perform the structural analysis, a structural model of the query protein is 
generated. To do this, template structures in the protein databank (PDB) (Rose et al., 
2013) are identified using hhblits (Remmert et al., 2012) by searching a PDB 
sequence database representative at 70% sequence identity. Templates are selected 
with an hhblits probability (probability that the template and query sequence are 
homologous) score >80% and such that as much of the sequence is covered without 
redundantly modelling the same region of the protein multiple times. Initial structural 
models are generated using an approach based on the one used by Phyre2 (Kelley 
and Sternberg, 2009; Bennet-Lovsey et al., 2008). Side chains are added and 
optimised using pulchra (Rotkiewicz and Skolnick, 2008). Small molecule binding 
sites are modelled using 3DLigandSite (with default parameters) (Wass et al., 2010) 
with the structural model used as the input. 
ProteinÐprotein interface sites are modelled using an approach based on 
Interactome3D (Mosca et al., 2012). The Interactome3D high confidence set of 
proteinÐprotein interactions with template complexes in the PDB was used to 
generate models of the complexes. For each sequenceÐtemplate pair the sequence is 
modelled using the template by applying the structural modelling approach described 
above. 
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The features used in the SVM fall into two areas of sequence and structural features 
(a full list is available in Supplementary Table S1). The sequence features include 
residue conservation (the JensenÐShannon convergence) and three features that 
represent the change of amino acid properties of size/mass, charge and functional 
group. The size/mass change of the amino acid is represented by the ratio of the 
mass of the two amino acids. To consider the change in charge between the two 
amino acids, the 20 amino acids are grouped according to charge (Supplementary 
Table S2). The feature representing the change in the charge of the amino acid 
considers changes between these charge groups, with values set in Supplementary 
Table S3. A further feature represents the change of chemical functional group 
present in the amino acid side chain. The amino acids are grouped as described by 
Innis et al. (Innis et al., 2004) (Supplementary Table S4) and the feature captures 
changes between these functional groups. 
The structural features use the ligand binding site, interface site and general structural 
features of the model. Where ligand-binding sites have been identified the distance of 
the variant to the binding site is calculated and used as a feature. When a variant is in 
a binding site, two further features capture results from the 3DLigandSite analysis. 
Where interface sites have been predicted, a further feature represents the distance of 
the variant to an interface site. Two features represent the type of secondary 
structure that the variant is located in. The first uses the secondary structure types 
classified by DSSP (Joosten et al., 2011; Kabsch and Sander, 1983), while a second 
feature reduces these to the three main categories of helix, sheet and coil. A final 
feature represents the solvent accessibility (calculated using DSSP). 
The features generated are input into each of the five optimised SVM models 
generated during cross-validation (details below) to predict whether each variant is 
functional or non-functional. The outputs from each of the SVM models are 
converted to probabilities as described in Platt (Platt, 1999). An ensemble approach 
is taken with the probability from each SVM model weighted according to its 
accuracy in cross validation. The weighted probabilities are summed and normalised 
to generate a final probability for the VarMod prediction. 
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2.3.2 Generating a test set 
Dataset 5 from VariBench (Sasidharan and Vihinen, 2013) was used to train and test 
VarMod. This dataset contains human pathogenic and neutral variants, excludes 
cancer mutations and is clustered so that protein sequences share no >30% 
sequence identity. This set was initially split with 1401 pathogenic and 1527 neutral 
variants retained for final testing. The remaining 11 336 pathogenic and 12 737 
neutral variants were split into five groups by protein sequence to perform 5-fold 
cross-validation to ensure that variants from each individual sequence appear in only 
1-fold. 
 
2.3.3 SVM training  
The SVMs were generated by SVMlight (Joachims, 1999) using a linear kernel. For 
each of the 5-folds, three were used for training, a further fold was used for 
validation and the SVM tested on the remaining fold. The SVMs were optimised for 
the trade off between training error and margin and also the cost factor to identify 
how training errors on positive examples should outweigh those on negative 
examples. 
 
2.3.4 Comparison with Polyphen 
To compare VarMod performance with PolyPhen-2, the final test set of nsSNVs 
was run on the PolyPhen-2 web server (on 1 March 2014).  Predictions were made 
using the two different classifiers available (HumDiv and HumVar) with default 
settings. The ROC and PrecisionÐRecall analyses of PolyPhen-2 were performed by 
varying the Ôpph2_probÕ score. Additionally VarMod performancs was compared to 
SuSpect (Yates et al., 2014). The final test set of nsSNVs was submitted to the 
SuSpect web server in June 2016. The ROC and Precistion-Recall analysis for 
SuSpect was performed by varying the threshold for the probability score associated 
with SuSpect predictions. 
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2.3.5 Evaluating VarMod Performance  
The performance of VarMod was assessed using the set of sequences from 
VariBench that were not used in cross-validation. The performance of VarMod on 
the test set of sequences was assessed using the measures of specificity, sensitivity 
(recall), precision and a Receiver Operator Characteristic (ROC) analysis. The ROC 
curve and PrecisionÐRecall graph in Figure 2.1 show the performance of VarMod 
and the comparison with PolyPhen-2 and SuSpect. The ROC analysis shows that 
VarMod performance is comparable to both PolyPhen-2 and SuSpect. Interestingly, 
in the ROC analysis, neither of the PolyPhen-2 classifiers reaches the point 0,0 
which is due to a small number of high confidence false positive predictions (i.e. 
neutral variants predicted to be pathogenic). This may reflect that PolyPhen-2 has 
been trained using different sets of pathogenic and neutral variants. It has also been 
previously observed that there is limited overlap between the predictions of different 
methods (Chun and Fay, 2009). The precision-recall analysis shows similar 
performance between VarMod and PolyPhen-2. However, SuSpect outperforms 
both methods. It is possible that SuSpect is simply better than the other methods, 
however for both PolyPhen-2 and SuSpect we do not know if sequences present in 
this final test set were also used in training. SuSpect was trained using the UniProt 
Humsavar dataset and then benchmarked using VariBench, ensuring that they 
removed any sequences from VariBench that were present in the training set (Yates 
at al., 2014). To fairly test the methods the test set should not contain any sequences 















Figure 2.1: Benchmarking VarMod. Analysis of the VarMod and PolyPhen-2 predictions on the non-




2.4.1 The VarMod web server 
The VarMod web server is available at  http://www.wasslab.org/varmod. Users are 
required to submit a protein sequence (raw sequence or FASTA formatted) or a 
UniProt accession, and a list of variant positions (e.g. A45C, where the single letter 
code is used to define the amino acids). A UniProt accession is required to perform 
the proteinÐprotein interface analysis (optional). Processing time for each 
submission varies from 5 min to a few hours. Structural data has been pre-computed 
for all of the UniProt human principal protein isoforms, so submissions using these 
sequences are processed in a few minutes. Where other sequences are submitted, the 
structural models and binding sites need to be modelled thereby increasing the 
running time to a few hours. 
 
2.4.2 Results Output 
 
The display of VarMod results is split into multiple sections (Figures (Figures 2.2 
and 2.3). The first section provides a summary table of the analyses performed and 
the overall prediction made for each of the submitted nsSNVs. This table is colour 
coded to highlight the results from the individual analyses/features to indicate if 
they suggest the variant could affect protein function. For example, the binding site 
column is coloured red if the variant is in the binding site and the colour changes to 
blue the more distant the variant is from a known ligand-binding site. The summary 
table enables the user to see the overall result and to identify analyses that may be of 
interest for further inspection. 
The sequence and structure sections display the main analyses. The sequence section 
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displays the protein sequence, colour coded to highlight multiple features including 
residue conservation, ligand binding sites and proteinÐprotein interfaces. The 
summary results and sequence view can be downloaded as a PDF file. 
The structural section first displays the details of the structural templates and models 
of the protein that have been generated (one for each region/domain for which a 
template was identified). A JSmol ( www.jmol.org) molecular viewer forms the main 
part of the structural section and initially displays the model with the highest 
confidence (probability from hhblits alignment). The JSmol viewer enables 
visualisation of the modelled protein and by default is coloured to highlight the 
functional regions of the protein (ligand-binding and proteinÐprotein interface sites) 
and the nsSNVs (red). A control panel to the right of the display enables the user to 
investigate the nsSNVs by displaying a different model, or modifying the display style 
(cartoon/spacefill or sticks representations) and colour of the whole protein, nsSNVs 
or functional sites. The user is able to generate high quality images of the displayed 
model by clicking on the Ôgenerate imageÕ button, enabling the analysis to be used for 
reports or publications. 
The location of the nsSNVs in relation to the proteinÐprotein interface sites can be 
explored further via the modelled complexes. The complex models are listed in a 
table, which also indicates the nsSNVs that are present in the model and if they occur 
within an interface. The complexes can be viewed in a separate JSmol viewer 
accessed from a link for each of the entries in the list. 
 



















Figure 2.2: Display of VarMod results. The results for variants in Phosphorylase b kinase gamma 
catalytic chain (UniProt accession P15735). The variants shown are known to have a role in Glycogen 
storage disease 9C. (A) The prediction summary table, showing the overall VarMod prediction and 
summarising the output from the different analyses. Results are colour coded to indicate the likely 
relevance of the changes, with features that suggest the variant is likely to be functional coloured red 
with the colour scale ranging to blue for features that are least likely to lead to functional changes. (B) 
The VarMod sequence display, residues are coloured to indicate conservation and the presence of 

























VarMod was developed to use recent observations that disease associated nsSNVs 
are frequently located at ligand-binding and proteinÐprotein interface sites and to 
automate manual approaches that we have previously used to analyse GWAS 
candidate nsSNVs. We have demonstrated that VarMod performance on a large and 
established benchmark set is comparable to an existing state of the art method 
(PolyPhen-2). The VarMod server provides a resource for users to identify 
functional nvSNVs and to investigate the individual features associated with these 
variants. Plans for future improvements to the server include increasing the number 
of interface and binding site features such as considering how variants may alter 
binding energies and options to submit variants in alternative formats such as 
Variant Call Files (VCF), which will facilitate high throughput analysis of nsSNVs 
identified from sequencing studies. 
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3.1 Abstract 
Reston viruses are the only Ebolaviruses that are not pathogenic in humans. We 
analyzed 196 Ebolavirus genomes and identified specificity determining positions 
(SDPs) in all nine Ebolavirus proteins that distinguish Reston viruses from the four 
human pathogenic Ebolaviruses. A subset of these SDPs will explain the differences 
in human pathogenicity between Reston and the other four ebolavirus species. 
Structural analysis was performed to identify those SDPs that are likely to have a 
functional effect. This analysis revealed novel functional insights in particular for 
Ebolavirus proteins VP40 and VP24. The VP40 SDP P85T interferes with VP40 
function by altering octamer formation. The VP40 SDP Q245P affects the structure 
and hydrophobic core of the protein and consequently protein function. Three VP24 
SDPs (T131S, M136L, Q139R) are likely to impair VP24 binding to human 
karyopherin alpha5 (KPNA5) and therefore inhibition of interferon signaling. Since 
VP24 is critical for Ebolavirus adaptation to novel hosts, and only a few SDPs 
distinguish Reston virus VP24 from VP24 of other Ebolaviruses, human pathogenic 
Reston viruses may emerge. This is of concern since Reston viruses circulate in 
domestic pigs and can infect humans, possibly via airborne transmission.  
 
3.2 Introduction 
Four of the five members of the genus Ebolavirus (Ebola viruses, Sudan viruses, 
Bundibugyo viruses, Taϊ Forest viruses) cause hemorrhagic fever in humans 
associated with fatality rates of up to 90%, while Reston viruses are non-pathogenic 
to humans (Feldmann and Geisbert, 2011; Weingartl et al., 2013)  (see Materials and  
Methods for the Ebolavirus nomenclature). So far there have been three Reston virus 
outbreaks in nonhuman primates:  1989-1990 in Reston Virginia, USA, 1992-1993 in 
Siena, Italy, and 1996 in a licensed commercial quarantine facility in Texas. All cases 
were traced back to a single monkey breeding facility in the Philippines. During these 
outbreaks five human individuals were tested positive for IgG antibodies directed 
against Reston virus. Moreover, Reston virus was found in 2008 in domestic pigs in 
the Philippines. Seroconversion was detected in six human individuals. None of the 
11 individuals that were seropositive for Reston virus antibodies reported an Ebola-
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like disease (Miranda and Miranda, 2011) . 
The reasons underlying the differences in human pathogenicity between Reston 
viruses and the members of the other Ebolavirus species remain unclear. 
Understanding of the molecular causes of these differences would enhance our 
understanding of Ebolavirus function and pathogenicity and aid investigation into 
treatment of Ebolavirus infection.  Here, we performed an in silico analysis of the 
genomic differences between Reston viruses and human pathogenic Ebolaviruses to 
identify conserved changes at the protein level that explain the differences in 
Ebolavirus pathogenicity in humans. 
 
Ebolaviruses encode nine proteins including nucleoprotein (NP), glycoprotein (GP), 
soluble GP (sGP), small soluble GP (ssGP), RNA dependent RNA polymerase (L), 
and four structural proteins termed VP24, VP30, VP35, and VP40 (Feldmann and 
Geisbert, 2011; Mehedi et al., 2011; La Vega et al., 2015). GP, sGP, and ssGP are 
produced from the GP gene by alternative RNA editing (Feldmann and Geisbert, 
2011; Mehedi et al., 2011; La Vega et al., 2015). Many of the Ebolavirus proteins 
have multiple functions. In the virion, the NP-encapsulated RNA genome associates 
with VP35, VP30, and L to form the transcriptase-replicase complex. VP35 and 
VP24, a membrane-associated structural protein, antagonize the cellular interferon 
response. The matrix protein VP40 fulfills critical roles during virus assembly and 
release. GP, the only transmembrane surface protein, is responsible for host cell 
binding and virus internalization ( Feldmann and Geisbert, 2011; Basler, 2014). Little 
is known about the functional roles of the secreted proteins sGP and ssGP 
(Feldmann and Geisbert, 2011; Miranda and  Miranda, 2011; Mehedi et al., 2011; 
Hoenen et al., 2015). 
 
Despite the small Ebolavirus genome we still have a limited understanding of 
Ebolaviruses and what causes their pathogenicity and why Reston viruses are not 
human pathogenic (Feldmann and Geisbert, 2011; Basler, 2014; Zhang et al., 2012). 
The importance of understanding these differences is highlighted by the current 
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Ebola virus outbreak in Western Africa, which is the first large outbreak and has 
resulted in 27,345 suspected cases and 11,184 deaths to date (www.who.int, as of 14th 
June 2015). During this outbreak many additional Ebola virus genomes were 
sequenced enabling us to perform the first comprehensive comparison of the non-
human pathogenic Reston virus to all four human pathogenic Ebolaviruses. While 
some studies (Zhang et al., 2012; Bale et al., 2013; Clifton et al., 2014) have compared 
the differences between individual Reston virus proteins derived from a certain strain 
with their equivalent derived from one strain of a human pathogenic species, none 
have performed a systematic analysis of all available protein sequence information 
from all (known) Ebolavirus species.  
 
Our large scale analysis of nearly 200 different Ebolavirus genomes focussed on 
combining computational methods with detailed structural analysis to identify the 
genetic causes of the difference in pathogenicity between Reston viruses and the 
human pathogenic Ebolavirus species. Central to our approach was the identification 
of Specificity Determining Positions (SDPs), which are positions in the proteome 
that are conserved within protein subfamilies but differ between them (Casari et al., 
1995; Rausell et al.,2010) and thus distinguish between the different functional 
specificities of proteins from the different Ebolavirus species. SDPs have been 
demonstrated to be typically associated with functional sites, such as protein-protein 
interface sites and enzyme active sites (Rausell et al.,2010). The SDPs that we have 
identified and that distinguish Reston viruses from human pathogenic Ebolaviruses, 
arguably, contain within them a set of amino acid changes that explain the 
differences in pathogenicity between Reston viruses and the four human pathogenic 
species, although a contribution of non-coding RNAs (that may exist but remain to 
be detected) cannot be excluded (Basler, 2014; Teng et al., 2015). The subsequent 
structural analysis was performed to identify the SDPs that are most likely to affect 
Ebolavirus pathogenicity, using an approach that is similar to those used to 
investigate candidate single nucleotide variants in human genome wide association 
and sequencing studies by us and others (Chambers et al, 2011; Chambers et al., 
2010; Chambers et al., 2014; Palles et al., 2013). 
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3.3 Results 
3.3.1 Specificity Determining Positions (SDPs) Analysis 
196 Ebolavirus genomes were obtained from the Virus Pathogen Resource (ViPR, 
Pickett et al., 2012), consisting of 156 Ebola viruses, 7 Bundibugyo viruses, 13 Sudan 
viruses, 3 Taϊ Forest viruses, and 17 Reston viruses (online Methods). Phylogenetic 
analysis of the whole genomes and the individual proteins separated the Ebolavirus 
species from each other (Supplementary Figure S1). There is good agreement 
between all the trees. The Reston virus sequences are most closely related to Sudan 
virus than the other three Ebolavirus species. In accordance with previous studies 
(Morikawa et al., 2007; Gire at al., 2014; Liu et al., 2015; Vogel, 2015; Hoenen et al., 
2015), we observed high intra-species conservation with greater inter-species 
variation (Figure 3.1 and Supplementary Table 1). The surface protein GP exhibited 
the greatest variation (Figure 3.1), most likely as a consequence of selective pressure 
exerted by the host immune response (Liu et al., 2015). 
 
Using the S3Det algorithm (Rausell et al., 2010) (Materials and Methods), we 
identified 189 SDPs that are differentially conserved between Reston viruses and 
human pathogenic Ebolaviruses (Figure 3.2, Supplementary Figure 2, Supplementary 
Tables 2-9). These SDPs represent the most significant changes between the Reston 
virus and the human pathogenic Ebolaviruses so 
 
























Figure 3.1. Conservation of Ebolavirus proteins. Heatmaps of intra- and inter species sequence 
identity for Ebolavirus proteins. (EBOV, Ebola virus; BDBV, Bundibugyo virus; SUDV, Sudan virus; 
TAFV, Taϊ Forest virus; RESTV, Reston virus). 
 
a subset of these SDPs must explain the difference in pathogenicity. SDPs were 
present in each of the Ebolavirus proteins representing between 2.4% of residues in 
sGP to 5.9% of residues in VP30 (Figure 3.2B). Comparison of the SDPs with 
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previously published mutagenesis studies (Xu et al., 2014) (online Methods) provided 




Figure 3.2. Ebolavirus SDPs. A) genomic overview of Ebolavirus conservation. SDPs are shown as  
red lines with protein conservation (blue graph). B) The number of SDPs in each of the Ebolavirus 
proteins is shown with details on: the number of SDPs that were mapped onto protein structures and 
the numbers that were identified to have potential roles in changing pathogenicity by either affecting 
protein-protein interactions (interface) or changing protein structure-function. These changes were 
classed as probable, where there is high confidence of the effect and possible where there is a lower 
level of confidence in the observations. 
 
 
3.3.2 Structural Analysis 
Full-length structures for VP24 and VP40 were available, as well as structures for the 
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globular domains of GP, sGP, NP, VP30, and VP35 (Supplementary Table 11). It 
was not possible to model the oligeromerization domains of VP30 and VP35 nor the 
structure of L apart from a short 105 residue segment of the 2239 residue protein, 
which contained a single SDP. 47 SDPs could be mapped onto Ebolavirus protein 
structures (or structural models where structures were not available, see online 
Methods). Most SDPs are located on protein surfaces (Supplementary Figure 3) and 
are therefore potentially involved in interaction with cellular and viral binding 
partners and/or immune evasion. Based on our combined computational and 
structural analysis we find evidence for eight SDPs that are very likely to alter protein 
structure/function, with six affecting protein-protein interfaces and two that with the 
potential to influence protein integrity and hence affect stability, flexibility and 
conformations of the protein (Table 3.1). Five additional SDPs may alter protein 
structure/function but the evidence supporting them is weaker (Supplementary 
Tables 12-18). Two of these weaker SDPs were present in NP (A705R, R105K - all 
SDPs are referred to using Ebola virus residue numbering and show the human 
pathogenic Ebolavirus amino acid first and the Reston virus amino acid second). 
A705R is likely to introduce a salt bridge with E694 and R105K will alter hydrogen 
bonding (Supplementary Table 12). The three other SDPs with weaker evidence were 
present in the glycan cap in GP (see below). The eight confident SDPs were present 
in V24, VP30, VP35, and VP40. The VP40 and VP24 SDPs revealed the most 
changes that may  relate to differences in human pathogenicity (see below). 
 
 
Table 3.1. SDPs that are likely to alter Reston virus protein structure and function. 
Protein   SDP      Interface  Protein Integrity 
 VP24 T131S KPNA5 interface  
 VP24 M136L KPNA5 interface  
 VP24 Q139R KPNA5 interface  
 VP24 T226A  Loss of Hydrogen bond 
 VP40 P85T Octamer interface  
 VP40 Q245P  Breaks α helix 
 VP30 R262A Dimer interface Ð loss of Hydrogen bond   
 VP35 E269D Dimer interface  
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3.3.3 Multiple SDPs are present in the GP glycan cap 
GP is highly glycosylated and mediates Ebolavirus host cell entry. Subunit GP1 binds 
to the host cell receptor(s). Subunit GP2 is responsible for the fusion of viral and 
host cell membranes. However, their cellular binding partners remain to be defined 
(Feldmann and Geisbert, 2011; Miller et al., 2012; Dahlmann et al., 2015; Herbert et 
al., 2015). Reverse genetics experiments have suggested that GP contributes to 
human pathogenicity but is insufficient for virulence on its own (Groseth et al., 
2012). We identified SDPs in both GP1 and GP2 (Supplementary Figure 4 and 
Supplementary Table 12). Three SDPs (I260L, T269S, S307H) are located in the 
glycan cap that contacts the host cell membrane (Supplementary Figure 4B-C).  
These changes (particularly S307H at the top of the glycan cap) alter the electrostatic 
surface of GP (Supplementary Figure 4D) and may therefore alter GP interactions 
with cellular proteins, however given the glycosylation of GP, it is unlikely that these 
residues would physically contact the host cell membrane and none of them are near 
glycosylation sites. So it is not clear what role they may have. GP binding to the 
endosomal membrane protein NPC1 is necessary for membrane fusion (Miller et al., 
2012). However, residues important for NPC1 binding (identified by mutagenesis 
studies in Miller et al., 2012) were conserved in all analyzed Ebolaviruses and the 
SDPs were not located close to them (Supplementary Figure 5). Thus differences in 
NPC1 binding do not account for differences in Ebolavirus human pathogenicity. 
This finding is in concert with very recent data indicating that NPC1 is essential for 
Ebolavirus replication as NPC1-deficient mice were insusceptible to Ebolavirus 
infection (Herbert et al., 2015). 
 
It was not possible to predict the consequences of SDPs in sGP and ssGP (Fig. S23), 
as there is a lack of functional information available for these proteins (Miranda and 
Miranda, 2011; Mehedi et al., 2011). A 17 amino acid peptide derived from Ebola 
virus or Sudan virus GP exerted immunosuppressive effects on human CD4+ T cells 
and CD8+ T cells while the respective Reston virus peptide did not (Yaddanapudi et 
al., 2006). We identified one SDP in the peptide, which represents the single amino 
acid change (I604L) previously observed between Reston virus and Ebola virus 
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(Yaddanapudi et al., 2006), demonstrating that this difference is conserved between 
Reston viruses and all human pathogenic Ebolaviruses. 
 
 
3.3.4 Changes in the VP30 dimer may affect pathogenicity 
Analysis of the VP30 SDPs provided novel mechanistic insights into the structural 
differences previously observed between Reston virus and Ebola virus VP30 (Clifton 
et al., 2014) and that may contribute to the differences observed in human 
pathogenicity between Reston virus and Ebola virus. VP30 is an essential 
transcriptional co-factor that forms dimers via its C-terminal domain and hexamers 
via an oligomerization domain (residues 94-112) (Hartlieb et al., 2003). The VP30 
hexamers activate transcription while the dimers do not, and the balance of hexamers 
and dimers has been suggested to control the balance between transcription and 
replication (Hartlieb et al., 2007). Crystallization studies have shown that Ebola virus 
and Reston virus dimers are rotated relative to each other (Clifton et al., 2014). We 
observed two SDPs (T150I, R262A) in the dimer interface that can at least partially 
explain the structural differences between Ebola virus and Reston virus VP30 
dimers. Ebola virus R262 is part of the dimer interface and forms a hydrogen bond 
with the backbone of residue 141 in the other subunit, whereas Reston A262 does 
not and is not part of the dimer interface (Figure 3.3). The removal of the two 
hydrogen bonds (in the symmetrical dimer) is likely to lead to the different Reston 
and Ebola virus dimer structures. mCSM predicts this change to be destabilizing with 
a ΔΔG-0.969 Kcal/mol. The Reston virus conformation also buries functional 
residues A179 and K180 potentially affecting protein function (Clifton et al., 2014) 
(Figure 3.2). Moreover, our findings show that the Ebola virus conformation is 
conserved in all human-pathogenic Ebolaviruses suggesting that it is relevant for 
human pathogenicity.  
 
 




















Figure 3.3. SDPs present in the VP30 dimer. The dimer structure of both Ebola virus (PDB structure 
2I8B) and Reston virus (PDB structure 3V7O) VP30 are shown with SDPs indicated (red Ð Ebola 
virus, blue Ð Reston virus) and functional residues (brown Ð A179, K180). a) Cartoon representation: 
For the Ebola virus the hydrogen bond of R262 with the residue 141 of the other subunit is shown. b) 
enlarged display of the hydrogen bond between R262 and the backbone of residue 141. c) Surface 
representation of the reverse face of the dimer from A, showing the location of the functional residues 
A179 and K180 within the dimer. 
 
3.3.5 VP35 SDP present in dimer interface 
VP35 is a multifunctional protein that antagonizes interferon signaling by binding 
double stranded RNA (dsRNA). Structural data are available for both the Ebola virus 
and Reston virus VP35 monomer and an asymmetric dsRNA bound dimer (Bale et 
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al., 2013; Leung et al., 2010; Leung et al., 2009; Kimberlin et al., 2010). These 
structures are highly conserved, however functional studies have demonstrated that 
Reston virus VP35 is more stable, has a reduced affinity for dsRNA, and exerts 
weaker effects on interferon signaling (Leung et al., 2010). The increased stability is 
proposed to be due to a linker between the two subdomains having a short alpha 
helix in the Reston virus structure (Leung et al., 2010). Our analysis shows that the 
sequence of this linker region is completely conserved in all of the genomes, however 
an SDP is located close to the linker (A290V). One SDP (E269D) is present in the 
dimer interface and the shorter aspartate side chain in Reston virus VP35 results in 
increased distances with the atoms that this aspartate forms hydrogen bonds with: 
R312, R322, and W324 (Ebola virus numbering; Supplementary Table 13). mCSM 
predicts this change to be slightly destabilizing to the complex (ΔΔG -
0.11Kcal/mol). This has the potential to alter the stability of the dimer and thus the 
ability of VP35 to prevent interferon signaling. 
 
It has recently been demonstrated that a VP35 peptide binds NP and modulates NP 
oligomerization and RNA binding to NP (Leung et al., 2015). There are two SDPs 
(S26T, E48D) in this region. S26T is located on the periphery of the interface. E48D 
lies outside the solved structure but is within the region required for binding to NP. 
Both SDPs represent minor changes that maintain the chemical properties of the side 
chains. Thus, there is no evidence suggesting substantial differences in the binding of 
this peptide to NP. 
 
3.3.6 VP40 SDPs may alter oligomeric structure 
VP40 exists in three known oligomeric forms (Bornholdt et al., 2013). Dimeric VP40 
is responsible for VP40 trafficking to the cellular membrane. Hexameric VP40 is 
essential for budding and forms a filamentous matrix structure. Octameric VP40 
regulates viral transcription by binding RNA. Two SDPs (P85T and Q245P) can 
affect VP40 structure. P85T occurs at the VP40 octamer interface site (Figure 3.4) in 
the middle of a run of 14 residues that are completely conserved in all Ebolaviruses 
(Figure 3.4a). In the Ebola virus structure, it is located in an S-G-P-K beta-turn, 
Chapter 3: Conserved differences in protein sequence determine the human pathogenicity of Ebolavirus  
 67 
where the proline at position 85 (P85) confers backbone rigidity. The change to 
threonine (T) at this residue in Reston viruses introduces backbone flexibility and 
also provides a side chain with a hydrogen bond donor, potentially affecting octamer 
structure and/or formation. mCSM predicted this change to have a destabilizing 
effect (ΔΔG -0.626Kcal/mol). The Q245P SDP introduces a proline residue into an 
alpha helix (Figure 3.4B), which most likely breaks and shortens helix five, resulting 
in the destabilization of helices five and six and a change in the hydrophobic core. 
Interestingly mCSM predicted this change to have little effect on the stability of the 
protein (predicted ΔΔG 0.059Kcal/mol). Thus, P85T and Q245P may affect VP40 





















Figure 3.4. The P85T SDP is present in the VP40 octamer interface. a) Consensus sequence for the 
region around P85T in Ebolavirus species (R, Reston virus; E, Ebola virus; S, Sudan virus; B, 
Bundibugyo virus; T, Taϊ Forest virus). Black squares indicate positions that are completely conserved 
in all genomes, red squares SDPs. b) segment of VP40 showing the Q245P SDP (red) from PDB 
structure 1ES6. c) The VP40 dimer, with SDPs colored red and shown in stick format (PDB structure 
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4LDB). d) The VP40 octamer, P85 shown in red (side- and top-view) from PDB structure 4LDM. e) 
Two subunits from the VP40 octamer, P85 is colored red in sphere format, and the SDP I122V is 
shown as yellow in stick format. 
 
 
3.3.7 VP24 SDPs affect KPNA5 binding 
VP24 is involved in the formation of the viral nucleocapsid and the regulation of 
virus replication (Feldmann and Geisbert 2011; Morikawa et al., 2007;Mateo et al., 
2011; Mateo et al., 2011; Watt et al., 2014). VP24 also interferes with interferon 
signaling through binding of the karyopherins α1 (KPNA1), α5, (KPNA5), and α6 
(KPNA6) and subsequent inhibition of nuclear accumulation of phosphorylated 
STAT1 and through direct interaction with STAT1 (Xu et al., 2014; Reid et al., 2006; 
Reid et al., 2007; Zhang et al., 2012). Eight VP24 SDPs are in regions with available 
structural information (Supplementary Tables 17-18). Seven of these are present on 
the same face of VP24 (Figure 3.5A) suggesting that they affect VP24 interaction 
with viral and/or host cell binding partners. The SDPs T131S, M136L, and Q139R 
are present in the KPNA5 binding site (Figure 3.5). M136 and Q139 are part of 
multi-residue mutations in Ebola virus VP24 that removed KPNA5 interactions 
(Supplementary Table 17) (Xu et al., 2014) and are adjacent to K142 (Figure 3.5A), 
mutants of which have shown reduced interferon antagonism (Llinykh et al., 2015). 
Xu et al., investigated the effect of VP24 mutations on binding to KPNA5 using 
coimmunoprecipitation pull down experiments and compared the bands obtained in 
the gel with wild type protein. This approach is not quantitative but the strength of 
the band provides an indication of the extent to which binding is affected. For 
R137A and R137A, T138A,Q139A the band is very weak. For F134A/M135A it is 
intermediate between these previous two mutations and the wild type. Therefore, 
M136L and Q139R can exert significant effects on VP24-KPNA5 binding. 
Additionally, T226A results in the loss of a hydrogen bond between T226 and D48 
in Reston virus VP24 (Figure 3.5B), with the potential to alter structural integrity and 
influence protein function. Analysis using mCSM predicts the T226A change to be 
destabilizing with a ΔΔG -0.935 Kcal/mol. mCSM predicted seven of the eight 
analysed SDPs to be destabilizing (Supplementary Table 2). 
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VP24-mediated inhibition of interferon signaling may be critical for species-specific 
pathogenicity (Xu et al., 2014; Mateo et al., 2011; Reid et al., 2006; Reid et al., 2007; 
Zhang et al., 2012). In this context, VP24 was a critical determinant of pathogenicity 
in studies in which Ebola viruses were adapted to mice and guinea pigs that are 
normally insusceptible to Ebola virus disease(La Vega et al., 2015; Mateo et al., 2011; 
Volchkov et al., 2000; Ebihara et al., 2006; Dowall et al., 2014). The adaptation-
associated VP24 mutations in rodents are located in the KPNA5 binding site with 
some of them being very close to the VP24 SDPs T131S, M136L, and Q139R that 
we determined to be in the KPNA5 binding site (Figure 3.5C-D, Supplementary 
Table 19). Additionally some of the mutations are similar to the SDPs in that they 
would remove hydrogen bonds within VP24 (e.g. T187I, T50I, Figure 3.5E-F, & 
Supplementary Table 19) or alter hydrogen bonding with KPNA5 (H186Y, Figure 
5F & Supplementary Table 19). Thus there is strong evidence suggesting that the 
VP24 SDPs have a role in rendering the Reston virus non-pathogenic in humans. 
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Figure 3.5. Ebola virus VP24 SDPs and complex with KPNA5. a). VP24 Structure (grey) in complex 
with KPNA5 (cyan) (PDB structure: 4U2X), with VP24 SDPs (red) and K142 colored blue. b) T226 
(red) hydrogen bond with the backbone of D48 (blue). c) VP24 showing residues mutated in rodent 
adaptation experiments (magenta) and SDPs identified in this study (red). d) Ebola virus VP24 in 
complex with KPNA5, reverse view shown from A. SDPs are coloured red and residues mutated in 
adaptation experiments are coloured magenta; VP24 (grey) and KPNA5 (cyan) complex with residues 
mutated during adaptation (magenta) and SDPs (red). F) Hydrogen bonds formed by VP24 T50. G) 
Hydrogen bonds formed by VP24 H186, and T187. Intrachain bonds are colored black and hydrogen 
bonds between VP24 and KPNA5 are colored blue.  
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3.4 Discussion 
In this study, we have combined the computational identification of residues that 
distinguish Reston viruses from human pathogenic Ebolavirus species with protein 
structural analysis to identify determinants of Ebolavirus pathogenicity. The results 
from this first comprehensive comparison of all available genomic information on 
Reston viruses and human pathogenic Ebolaviruses detected SDPs in all proteins but 
only few of them may be responsible for the lack of Reston virus human 
pathogenicity.  
Our analysis mapped 47 of the 189 SDPs onto protein structure, so additional SDPs 
may be relevant but the structural data needed to reliably identify them is missing. 
Although it is difficult to conclude the extent to which each individual SDP 
contributes to the differences in human pathogenicity between Reston viruses and 
the other Ebolaviruses, we can identify certain SDPs that have a particularly high 
likelihood to be involved. SDPs present in the oligomer interfaces of VP30, VP35, 
and VP40 may affect viral protein function. VP24 SDPs may interfere with VP24-
KPNA5 binding and affect viral inhibition of the host cell interferon response. These 
findings suggest that changes in protein-protein interactions represent a central cause 
for the variations in human pathogenicity observed in Ebolaviruses. VP24 and VP40 
in particular contain multiple SDPs that are likely to contribute to differences in 
human pathogenicity. Where possible the SDPs have been considered collectively, 
such as for VP24, where most of the SDPs are present on a single face of the protein 
(Figure 3.5A) and three of them are present in the interface with KPNA5. Beyond 
this it is difficult to interpret how any combination of SDPs might be responsible for 
the differences in human pathogenicity.  
Our data also demonstrate that relevant changes explaining differences in virulence 
between closely related viruses can be identified by computational analysis of protein 
sequence and structure. Such computational studies are particularly important for the 
investigation of Risk Group 4 pathogens like Ebolaviruses whose investigation is 
limited by the availability of appropriate containment laboratories. 
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The role of VP24 appears to be central given the large number of SDPs we identify 
as likely to affect function, particularly KPNA5 binding. This is also highlighted by 
the similarity between these SDPs and the mutations that occur in adaptation 
experiments in mice and guinea pigs (Basler, 2014; Leung et al., 2009; Watt et al., 
2014; Reid et al., 2006; Reid et al., 2007). Consequently, the mutation of a few VP24 
SDPs could result in a human pathogenic Reston virus. Given that Reston viruses 
circulate in domestic pigs, can be spread by asymptomatically infected pigs, and can 
be transmitted from pigs to humans (possibly by air) (Weingartl et al., 2013; Barrette 
et al., 2009; Marsh et al., 2011), there is a concern that (a potentially airborne) human 
pathogenic Reston viruses may emerge and pose a significant health risk to humans. 
Notably, asymptomatic Ebolavirus infections have also been described in dogs 
(Weingartl et al., 2013) and Ebola virus shedding was found in an asymptomatic 
woman (Akerlund et al., 2015). Thus, there may be further unanticipated routes by 
which Reston viruses may spread in domestic animals and/or humans enabling them 
to adapt and cause disease in humans. 
 
In summary our combined computational and structural analysis of a large set of 
Ebolavirus genomes has identified amino acid changes that are likely to have a crucial 
role in altering Ebolavirus pathogenicity. In particular the differences in VP24 
together with the observation that Ebolavirus adaptation to originally non-
susceptible rodents results in rodent pathogenic viruses (Basler, 2014; Leung et al., 
2009; Watt et al., 2014; Reid et al., 2006; Reid et al., 2007)  suggest that a few 
mutations could lead to a human pathogenic Reston virus. 
 
3.5 Materials and methods 
3.5.1 Ebolavirus nomenclature 
The nomenclature in this manuscript follows the recommendations of Kuhn et al., 
(2010). The genus is Ebolavirus. It is only italicized if the name refers to the genus but 
not if it refers to physical viruses or virus parts or constituents such as proteins or 
genomes. The species are Zaire ebolavirus (type virus: Ebola virus, EBOV), Sudan 
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ebolavirus (type virus: Sudan virus, SUDV), Bundibugyo ebolavirus (type virus: 
Bundigugyo virus, BDBV), and Taϊ Forest ebolavirus (formerly Cte dÕIvoire 
ebolavirus; type virus: Taϊ Forest virus, TAFV). 
 
3.5.2 Ebolavirus Genome Sequences 
196 complete Ebolavirus genomes were downloaded from Virus Pathogen Resource, 
VIPR (http://www.viprbrc.org/brc/home.spg?decorator=vipr) (Pickett et al., 2012). 
The 196 genomes comprise 156 Ebola virus (EBOV), 17 Reston (RESTV), 13 Sudan 
(SUDV), 7 Bundibugyo (BDBV) and 3 Ta Forest (TAFV) species (Supplementary 
Table 20). Open Reading Frames (ORFs) in the genomes were identified using 
EMBOSS (Rice et al., 2000). The ORFs were then mapped to the nine Ebolavirus 
proteins. 
 
3.5.3 Multiple Sequence Alignments and identification of specificity 
determining positions 
Multiple sequence alignments were generated for each of the Ebolavirus proteins 
using Clustal Omega (Sievers et al., 2011), with default settings. Protein sequence 
identities between the different sequences were obtained from the Clustal Omega 
output. The effective number of independent sequences (or effective number of 
sequences, see table S21) in an alignment indicates given redundancy in the 
sequences, how many different sequences there are effectively. So if all of the 
sequences are highly similar, there is little diversity in the alignment and the effective 
number of sequences is low. The effective number of independent sequences present 
was calculated for the alignment for each protein by building an HMM for the 
alignment using hmmer (Mistry et al., 2013). The effective number of independent 
sequences identified ranged from 88 for the VP24 and L proteins to 148 in NP 
(Table S21). 
 
The s3det algorithm (Rausell et al., 2010) was used to predict specificity determining 
positions (SDPs) using a supervised mode with sequences assigned to predetermined 
groups/subfamilies with all of the human pathogenic sequences in one group and the 
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Reston virus sequences in a second group.  The sensitivity of the SDP analysis to the 
number of sequences used was considered by subsampling the sequences (see 
Supplementary Methods and Supplementary Figs S6-S8). SDPs were compared to 
known functional residues (many from mutagenesis studies) in Ebolavirus proteins 
catalogued in UniProt (Uniprot Consortium, 2014) and in the literature. 
 
 
3.5.4 Phylogenetic Trees 
Bayesian Phylogenetic trees were generated using BEAST v1.8.2 (Bouckaert et al., 
2014), then the consensus tree for each set of 10000 trees was calculated with 
TreeAnnotator and the node labels obtained analyzing the trees with FigTree 
(http://tree.bio.ed.ac.uk/software/figtree/). TreeAnnotator and BEAUti, are part of 
the BEAST package. 
 
The Maximum Likelihood Phylogenetic trees were generated using RaxML8 
(Stamatakis, 2014). A full Maximum Likelihood analysis and 1000 Bootstrap replicate 
searches were run in order to obtain the best scoring ML tree for each set of 
sequences. 
 
Phylogenetic trees were generated using default settings in both BEAST and 
RaxML8, according to the type of input data. All phylogenetic trees were analyzed 
and plotted using the R ÒapeÓ package (Paradis et al., 2004).  
 
3.5.5 Structural Analysis 
Where available, protein structures for the Ebolavirus proteins were obtained from 
the protein databank (Rose et al., 2015). Where full length protein structures were 
not available the proteins were modelled using Phyre2 (Kelley et al., 2015). SDPs 
were mapped onto the protein structures using PyMOL. Solvent accessibility for 
SDPs was calculated using DSSP (Joosten et al., 2011).  
 
The Reston virus structures of GP1 and GP2 were modeled using one-to-one 
threading in Phyre2 (Kelley et al., 2015) with the EBOV GP trimer structure (PDB 
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code 3CSY) used as a template. A model of a Reston virus GP trimer structure was 
generated by aligning the modelled Reston virus GP1 and GP2 structures to their 
corresponding chains in the Ebola virus trimer.  
 
The Coulombic Electrostatic Potential for the proteins was calculated using Delphi, 
with default parameters (Smith et al., 2012). The electrostatics map was visualized 
and analyzed using Chimera (Pettersen et al., 2004). 
 
mCSM (Pires et al., 2014) was used to predict the effect of each individual SDP on 
the stability of the protein. The Ebola virus structures were used as input and the 
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Chapter 4: 
Structural consequences of the 
genomic changes associated with 
Ebola virus adaptation to rodents 
 
 
Morena Pappalardo, Mark J Howard, Jeremy S Rossman, Martin Michaelis, Mark N 
Wass 
 
This manuscript is currently in preparation for submission to Genome Biology. In this 
project I have performed the research, which is primarily protein structural analysis 
of mutations that occur in adaptation of Ebola virus to rodents. Interpretation of the 
likely effects of the mutations was performed in discussion with my supervisor.  
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1. Abstract 
The potential for Ebola virus to cause large outbreaks and many thousands of deaths 
has recently been demonstrated in West Africa. Ebola viruses are pathogenic in 
humans and primates but not in rodents. We have analysed the mutations identified 
in four different experiments that adapted Ebola virus to rodents to identify and 
understand the molecular determinants of host-specific Ebola virus pathogenicity. 
We identified 33 different mutations across the four studies, with only two mutations 
present in more than one study. For three proteins, VP24, GP and NP, mutations 
were observed in all four studies. Structural analysis suggests that the changes in GP 
and NP may have an effect on protein function but with limited functional 
knowledge of the regions of the protein they are located in, it is not possible to infer 
further. Clear functional effects were identified for six of the seven mutations present 
in VP24. Three of these mutations are located in the VP24 interface with 
karyopheerin a5 and we propose that they may have a role in adapting Ebola VP24 
binding to karyopherins from novel hosts. A further three mutations either change 
hydrogen bonding or will result in conformational changes in the protein. Based on 




4.2. Introduction  
The recent Ebola virus outbreak in West Africa, which is still seeing flare-ups in 
infection, http://www.who.int/ was the first outbreak of a member of the Ebolavirus 
family in humans that reached epidemic size (Frieden, et al., 2014; Alexander, et al., 
2015). It has resulted so far in 28,639 confirmed cases and 11,316 deaths as of 28th 
February 2016 (www.who.int), though these figures are thought to underestimate the 
actual numbers (Meltzer, et al., 2014). Hence, this epidemic provided the first 
evidence that Ebolaviruses can sustainably spread among humans and cause large 
outbreaks that affect tens of thousands of individuals, possibly even more. 
 
The research on Ebola viruses is limited by the availability of safety level 4 
laboratories and a lack of disease models in small rodents. A major issue in the 
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establishment of rodent models is that species including mice, guinea pigs, and 
hamsters are generally not susceptible to Ebola virus infection and disease. 
Therefore, Ebola viruses that cause lethal disease in rodents need to be established 
by virus adaptation via serial passaging in these species (Shurtleff & Bavari, 2015). 
Despite indications that these models reflect human disease at least in part, a better 
understanding of the similarities and differences between natural Ebola virus disease 
in humans and the disease caused by rodent-adapted Ebola virus strains in rodents is 
needed (Shurtleff & Bavari, 2015; Cross et al., 2015). 
A number of studies reported on the genetic changes associated with Ebola virus 
strains to mice, guinea pigs, and hamsters (Ebihara et al., 2006; Dowall et al., 2014; 
Cross, et al., 2015; Volchkov,  et al., 2000). Here, we applied an in silico approach to 
predict the consequences of these sequence changes in the virus genome on the 
structure and function of the Ebola virus-encoded proteins in order to improve our 
understanding of the processes, underlying Ebola virus adaptation to rodents and to 
gain further insights into the differences of Ebola virus replication in experimental 




We focus our analysis on four studies that adapted Ebola virus in rodents. Three of 
them adapted Ebola to guinea pigs (Dowall, et al., 2014; Volchkov et al., 2000; Cross 
et al., 2015) and one in mice (Ebihara, et al., 2006). In each study multiple passaging 
of the virus in the rodent species was performed, three of the studies sequenced the 
virus once it had become pathogenic, while Dowall et al., (Dowall, et al., 2014) 
sequenced the virus after each passage, thus providing greater detail on the mutations 
occurring during the adaptation process and the ability to identify whether they are 
lost or retained during passaging.  
 
Ebolaviruses have a small genome containing seven genes that encode nine proteins.  
The proteins are glycoprotein (GP), soluble GP (sGP), small soluble GP (ssGP), 
RNA dependent RNA polymerase (L), nucleoprotein (NP), and four structural 
proteins that are called VP24, VP30, VP35 and VP40. Therefore, there are a small 
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number of proteins to investigate for having a role in determining host pathogenicity. 
However, given the small size of the genome, most Ebolavirus proteins are 




Table 4.1 Summary of mutations identified in Ebola virus rodent adaptation experiments. *L26F is 
present in two studies so total number of unique mutations is 5 for VP24. Two different adaptations 
experiments were performed in Volchkov et al., and these are listed separately in the table. ¤data is 
only available for VP24 mutations in Volchkov-2. 
 
 Ebihara Dowall Volchkov-1 Volchkov-2 Cross Total 
NP 1 1 1 N/A 2 5 
GP 3 2 1 N/A 1 7 
L 1 11 1 N/A 0 13 
VP24 1 1 3 1 2 7* 
VP30 0 0 0 N/A 0 0 
VP35 1 1 0 N/A 0 2 
VP40 0 0 0 N/A 0 0 
       
Total 7 16 6 1¤ 5 32 
 
 
4.3.1. Initial comparison of the different adaptation experiments 
Over the four studies 33 unique protein coding mutations were identified in the 
rodent adapted Ebola virus genomes. In all four studies mutations were present in 
multiple proteins (Table 4.1), with mutations in the glycoprotein (GP), nucleoprotein 
(NP), the RNA dependent RNA polymerase (L) and viral protein 24 (VP24) in each 
of the separate studies (Table 4.1). Mutations in VP35 were observed in two studies. 
No mutations were observed in the remaining proteins, VP30 and VP40, although 
mutations were present in both VP30 and VP40 (as well as the other Ebolavirus 
proteins) during passaging in the Dowall study but these mutations were not retained 
in later passages (Dowall, Matthews, et al., 2014).  
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Only two mutations were observed in multiple studies (GP I554T and VP24 L26F), 
which may provide stronger evidence for a role of these mutations in the adaptation 
process. The GP I554T mutation was observed in both the Ebihara et al.,(Ebihara, et 
al., 2006) and Cross et al., (Cross, et al., 2015) studies, while VP24 L26F was observed 
in the Dowall et al., (Dowall, et al., 2014) and Cross et al., (Cross, et al., 2015) studies. 
Further investigation revealed that threonine is commonly observed at residue 544 in 
GP (see methods), while isoleucine is present in the original Mayinga strain. 
Therefore, it seems unlikely that this mutation is relevant to adaptation in guinea 
pigs. For VP24 L26F reverse genetics studies have associated the mutation with 
increased virulence in rodents (Mateo, et al., 2011).  
 
Overall analysis of the four studies suggests that only a small number of mutations 
are required to adapt Ebola virus to rodents (Table 1), with six mutations present in 
the Volchkov and Cross studies, seven in the Ebihara study and 16 in the Dowall 
study (most of these in L). However, without further analysis it is not clear if all of 
these mutations play a role in the adaptation process or if there are a few specific 
mutations present in each study that are responsible for the change in pathogenicity. 
Nor is it apparent if there is a single adaptation mechanism (i.e. mutation to a 
particular protein or set of proteins) or if there are multiple different pathways to 
pathogenicity. 
 
To gain insight into this set of mutations we performed a structural analysis, mapping 
the mutations onto the available Ebola virus proteins and complexes, supplemented 
with structural modelling where structures were not available (see methods). The 
potential structural effects of the mutations were manually investigated and 
additionally their effect on protein stability predicted using mCSM (Pires, 2014), a 
computational method designed to predict the effect of point mutations on protein 
structure and stability. Our structural analysis was performed to investigate the 
mutations present in all four studies 1) to identify  structural elements that are most 
relevant to the development of Ebola virus pathogenicity in a new host and 2) to 
estimate how easily Ebolaviruses may adapt to new hosts. 
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In total 22 of the 33 mutations were mapped onto protein structures or models. 
Neither of the two mutations (A12V, N204D) present in VP35 could be modelled. 
The A12V mutation appears to be a conservative change of amino acid and is located 
in the N terminal dimerisation domain, while the N204D mutation is located just 
before the RNA binding domain. Notably, VP35 was only found mutated in two out 
of four studies suggesting that mutations in VP35 are not essential for Ebolavirus 
adaptation to a novel species. 
 
4.3.2 Mutations in the glycoprotein may affect protein structure  
The glycoprotein (GP) mediates host cell entry and has long been speculated to have 
a role in pathogenicity (Feldmann & Geisbert, 2011). GP consists of two subunits: 
GP1 binds to the host cell surface receptor(s). GP2 is needed for the fusion of the 
virus membrane with the host cell membrane. The exact process and host cell 
binding partners during virus binding and membrane fusion remain only partially 
understood (Miller, et al., 2012). However, GP binding to the endosomal membrane 
protein NPC1 appears to be required for membrane fusion (Miller, et al., 2012). 
Across the four studies six different mutations are observed in GP (Table 4.2). Four 
of these mutations could be mapped onto available GP structures (Figure 4.1). The 
most striking mutation is S65P. S65 is a buried residue. The mutation S65P 
introduces a proline into the middle of a beta sheet, this is likely to alter or disrupt 
the beta sheet and it will also result in the loss of a hydrogen bond with E100 (Figure 
4.1). Both of these effects are likely to result in conformational change within GP. 
However, the extent of the conformational change, how it would affect GP function, 
or how it may have a role in adaptation remain unclear from the structural analysis. 
The second mutation D49N is located at the edge of the interface between GP1 and 
GP2. The D49 side chain is not present in the crystal structure suggesting that the 
side chain is moving. Analysis of the possible side chain conformations indicated that 
it could form a hydrogen bond with N595. However, mutation would reduce the 
charge and asparagine would still enable a hydrogen bond to be formed between the 
subunits. So it may be that a hydrogen bond is formed with asparagine at position 49 
but not aspartate. However, it is not clear what functional effect this change would 
have. The third mutation S246P is located on a surface loop towards the area of the 
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protein that binds the host cell membrane, so it is possible that this mutation could 
alter host cell interactions but without knowledge of the receptor and binding site, 
there is no evidence to support this. Finally, GP is heavily glycosylated (Lennemann 
et al., 2014; 2015), which further aggravates the interpretation of the functional 






















Figure 4.1. Mutations in GP during adaptation to rodents. The GP trimer consists of GP1 (grey 
colours) and GP2 (blue, yellow, green) dimers. A) Adaptation mutations in GP are shown in red. B) 





4.3.3. Mutations present in the nucleoprotein 
Three of the five mutations present in NP could be mapped onto the protein 
structure (Figure 4.2). Adjacent residues S647 and F648 (mutations: S647Y and 
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F648L) in the C terminal domain are mutated in separate studies, suggesting that 
either this is a region that can tolerate mutations or that the mutations could be 
linked to adaptation to the new host. F648 is tightly packed with side chains from the 
adjacent alpha helix (Figure 4.2). The change to leucine will reduce the size of the side 
chain and could  result in local conformational change. S647 is located on the protein 
surface, the mutation to tyrosine results in a large increase in side chain size but 
retains the ability to form hydrogen bonds (possibly with interaction partners). 
 
The third mutation (S72G) in NP is located in the N terminal domain. S72 forms a 
hydrogen bond with the backbone of P42, which is lost on mutation of S72 to 
glycine (Figure 4.2B). This may result in increased flexibility in this region but the 
functional consequences cannot be reliably predicted. 
 
The function of these regions of NP are not well established, making it difficult to 
interpret the possible effect they may have on protein structure and function and 
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Figure 4.2. Adaptation mutations in NP. A) Adaptation mutations S647Y (red spheres) and F648L 
(red sticks) in the C terminal domain of NP occurred in separate adaptation mutations. B) NP residue 
S72 forms a hydrogen bond with the backbone of P42 (black dashed line). This bond is lost with the 
adaptation mutation S72G.  
 
4.3.4. Mutations in the RNA dependent RNA polymerase may not be related 
to pathogenicity 
Thirteen mutations were reported in the RNA dependent RNA polymerase (L) from 
three of four studies (Table 4.1),   11 of them from the Dowall et al., study (Dowall, et 
al., 2014). This study monitored the mutations that occurred in every passage until 
the virus had adapted to Guinea pigs and caused disease. Notably, 10 out of these 11 
mutations were only identified in the final passage, whereas mutations in NP, VP35, 
and GP had become visible within the first three passages. Thus, it remains unclear 
whether these mutations would have been maintained during further replication 
cycles in Guinea pigs. In this context, as only three out of four adaptation studies 
reported mutations in L does not suggest an essential role of L in Ebolavirus host 
tropism. Additionally, the Y1271STOP mutation results in a stop codon and, hence, 
in a truncated protein, that is unlikely to be functional (full length L is 2212  residue 
so long so nearly half the protein would be missing). This mutation is therefore 
unlikely to be associated with enhanced pathogenicity and further questions a pivotal 
role of L for Ebolavirus adaptation to a novel species.  
 
4.3.5. Multiple mutations in VP24 are likely to be associated with Ebola virus 
pathogenicity 
VP24 is multifunctional and is involved in the formation of the viral nucleocapsid, 
the regulation of virus replication and the prevention of interferon signalling 
(Feldmann & Geisbert, 2011; Mateo, et al., 2011; Watt, et al., 2014; Reid, Leung, 
Hartman, et al., 2006). VP24 interferes with interferon signalling through binding of 
STAT1 and the karyopherins α1 (KPNA1), α5, (KPNA5), and α6 (KPNA6) (Xu, et 
al., 2014). This binding prevents nuclear accumulation of phosphorylated STAT1 and 
therefore inhibits interferon signalling. 
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Changes in the sequence of VP24 were detected in all of the studies that investigated 
the genomic consequences associated with Ebola virus adaptation to rodents (Table 
4.1). VP24 may need to adapt to interfere with STAT1 and/or the karyopherins of a 
novel species. Structural analysis using the complex of VP24 with human KPNA5 
provided insight into the likely effects of six of the seven  VP24 mutations found in 
rodent-adapted Ebola virus strains. Only the possible consequences of the M71I 
mutation remained elusive. Three mutated residues (H186Y, T187I, K142E) are 
present in or adjacent to the interface site with human KPNA5 (Figure 4.3). Hence, it 
is possible that these mutations enable or alter the interaction of VP24 with rodent 
karyopherins. The wild type H186 forms a hydrogen bond in the interface with 
residue T434 in human KPNA5 (Figure 4.3B). The hydroxyl group in the mutated 
tyrosine would still be able to form a hydrogen bond with KPNA5 T434, but may 
also enable its interaction with rodent karyopherins. The T187I mutation removes 
intramolecular hydrogen bonds with the backbone of residues H186 and E203 (Figure 
4.3C). This is likely to increase flexibility in this area. K142E is adjacent to the human 
KPNA5 interface site and mutations in K142 have been shown to inhibit the 
interferon signalling (Ilinykh, et al., 2015). This mutation reverses the charge of the 
side chain. It is possible that this could result in local conformational changes. 
Overall mutations in the residues that interface with KPNA5 may modulate VP24 
interactions with rodent karyopherins. 
 
The other three mutations (L26F, T50I and L147P) all have some effect on the 
structure of VP24. mCSM predicted L26F to have the most destabilising effect on 
VP24 (Table 4.2). L26 is located at the end of an alpha helix and is packed against two 
other alpha helices, resulting in the side chain being largely buried (Figure 4.3D). 
Given the tight packing it is possible that the mutation to a larger side chain 
associated with the change from leucine to phenylalanine requires some 
conformational change to accommodate the increased size, although there is no 
indication of what effect this would have on VP24 function. However, given that this 
mutation was observed in two independent adaptation experiments (Dowall, et al., 
2014; Cross, et al., 2015) and also in reverse genetics studies (Mateo, et al., 2011), it 
seems likely that it has a role in the adaptation to rodent hosts. 
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T50I removes intramolecular hydrogen bonds with the VP24 backbone residues Q36 
and K52 (Figure 4.3E). This is likely to increase flexibility in this region of the protein. 
L147P is located towards the end of an alpha helix. The mutation to proline is likely 
to result in the breaking of this helix, reducing its length and leading to 
conformational change in this region. So both of these mutations, while it is not clear 
how they relate to adaptation, will have an effect on VP24 structure and or dynamics. 
 
Many of these mutations would typically be considered to be unfavourable to a 
protein, with changes present in interface sites, resulting in the loss of hydrogen 
bonds and others likely to cause conformational changes. This makes it likely that 
these mutations are relevant to the adaptation of Ebola virus to rodent hosts. This 
contrasts with other mutations identified during passaging in the Dowall et al study, 
which are similarly unfavourable but are not retained in later passages (see below). 
This makes it likely that these mutations are relevant to the adaptation of Ebola virus 















Figure 3. Mutations in VP24 during adaptation to rodents. A) VP24 (grey) in complex with 
karyopherin a5 (PDB code: 4U2X), adaptation mutations are colour red and shown in stick format. B) 
VP24 H186 forms a hydrogen bond with KPNA5 T434. C) H186 forms intramolecular hydrogen 
bonds (black dashed lines) with the backbones of H186 and E203. D) Residue L26 is buried so 
mutation L26F may affect the conformation of the protein. E). Adaptation mutation T50I will result 




4.3.6. Mutations that are not retained during passaging may have detrimental 
effects on protein structure and function 
The extensive sequencing analysis in the Dowall study (Dowall,  et al., 2014) enabled 
the investigation of mutations that occurred during the passaging process but were 
not retained in later passages and instead reverted to wild type. We were able to 
analyse 24 of these 40 mutations. Our analysis demonstrates that many of these 
mutations are likely to be destabilising to the Ebolavirus proteins (Table 4.3 and Figure 
4.4A). The mutations that are not retained tend to have lower BLOSUM substitution 
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scores than the adaptation mutations (Figure 4.4A), showing that such amino acid 
changes occur less frequently in nature and therefore may be more likely to alter 
protein structure/function. Additionally, a group of four non retained mutations are 
predicted by mCSM to be highly destabilising (ΔΔG > -2.5 Kcal/mol) whereas only 
one of the adaptation mutations has a similar prediction (Tables 4.2 and 4.3). 
However for the rest of the mutations there is not much difference in the predicted 
effect on stability (Tables 4.2 and 4.3). 
 
In NP both W191R and V323D are predicted to be highly destabilising to the 
protein structure (ΔΔG of -2.973 and -3.339 Kcal/mol respectively). Structural 
analysis indicates that mutation of W191 to arginine would introduce a charged 
residue in the interior of the protein in a hydrophobic region (Figure 4.4A). This may 
also alter the hydrogen bond that W191 forms with E61, although arginine at 
position 191 would still retain functional groups to form a hydrogen bond with E61. 
Similarly, V323D introduces a charged residue in a buried region, part of this region 
is hydrophobic, although H327 and E351 form a hydrogen bond and are adjacent to 
V323. Mutation V323D introduces further negative charge into this region and a 
hydrogen bond acceptor  so this mutation is likely to alter the protein conformation 
(Figure 4.4C). 
 
In VP40, M259R introduces a larger, charged side chain, in a region that is partially 
exposed but is surrounded largely by hydrophobic residues. Our analysis also 
suggests that arginine at residue 259 could give hydrogen bond with N257, so there is 
also the possibility that  may form hydrogen bonds with adjacent side chains.  
 
Both temporal changes in VP30, L214P and Q248R, are likely to affect the structure 
and or function of VP30 (Figure 4.4D). L214 is buried and located in the last turn of 
an alpha helix. Mutation to proline is likely to shorten the helix and therefore result 
in conformational change. Q248R is in the VP30 homodimer interface site (Figure 
4.4D). The backbones of adjacent residues L247 and L249 form hydrogen bonds 
with the other subunit (Hartlieb, et al., 2007) (Figure 4.4D). Although this is a 
relatively conservative substitution, it will increase the charge and size of the amino 
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acids and it seems likely that the proximity of this mutation to the interface will have 
an effect on VP30 dimer stability. 
 
So it seems likely that some of these mutations that are not retained in later passages 
is because they are deleterious to Ebola protein function and therefore are selected 




Figure 4. Analysis of mutations that occur during passaging that are not retained in later passages. A) 
Barchart showing BLOSUM substitution scores for the adaptation mutations (i.e. those mutations that 
are retained; red) and those that are not retained (blue). B) Mutation W191R (cyan) in NP is observed 
during passaging. The mutation is located in a buried region. C) Mutation V323D (cyan) in NP, is 
located close to H327 and E351 (blue; which form a hydrogen bond Ð black dashed line). D 
Mutations L214 and Q248R (red) in VP30 are not retained during passaging. Zoom in region shows 




The relevance of the mutations in GP is not clear. The high level of glycosylation of 
this protein makes it difficult to predict whether (and if yes, how) the mutations may 
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modulate virus tropism and pathogenicity. Notably, reverse genetics experiments 
indicated that GP contributes to human pathogenicity but is insufficient for virulence 
on its own (Groseth, Marzi, Hoenen, et al., 2012). This appears to indicate that Ebola 
viruses tolerate a substantial number of changes in the sequence of GP without 
losing virulence. It is also difficult to predict the relevance of the five NP mutations 
identified in rodent-adapted Ebola virus strains. Some evidence suggests that at least 
some of the mutations may well be involved in the determination of virus virulence 
in a certain host, but conclusive evidence is missing. Notably, GP and NP display 
together with L the greatest variability in their sequences (Jun, et al., 2015). Therefore, 
some variation in these sequences may not be surprising. 
 
Modelling of the VP24 mutations suggests that they are all likely to modulate the 
virus-host cell interaction. In particular, H186Y, T187I, and K142E are likely to be 
relevant for the modulation of the host cell interferon response. Therefore, there is 
strong evidence that changes in VP24 are required to enable Ebola virus adaptation 
to a novel host. This notion is in accordance with evidence suggesting that VP24 may 
be a determinant of pathogenicity among different Ebolaviruses (Zhang, et al., 2012). 
The retention of these mutations while other mutations that occur during passaging 
of the Dowall study but are not retained in further passages, suggests that these 
mutations have a role in rodent pathogenicity.  
 
We have recently suggested that VP24 may be central to explaining how Reston 
viruses are the only Ebolavirus species that are not pathogenic in humans 
(Pappalardo, et al., 2016). We identified multiple residues in VP24 that are 
differentially conserved between Reston viruses and the four human pathogenic 
Ebola virus species. Three of these residues are located in the VP24-KPNA5 
interface site and we proposed that they result in impaired binding of Reston VP24 
with karyopherins and thus a reduced ability to inhibit interferon signalling. So in two 
different contexts we have observed differences in VP24 that are related to species-
specific pathogenicity, thus together they provide strong evidence for VP24 in 
determining host pathogenicity.  
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Given our analysis, how many mutations are required to alter Ebola virus host 
pathogenicity? Notably, our analysis has shown that only very few mutations may be 
required for the adaptation of an Ebolavirus to a novel host. In total, the different 
adaptation experiments resulted in 5 (Cross), 6 (Volchkov-1), 7 (Ebihara), or 16 
mutations (Dowall) (Dowall, et al., 2014). As described above, 11 of the 16 mutations 
in the Dowall et al. study (Dowall, et al., 2014) occurred in L, it remains unclear 
whether these mutations would have been sustained during further passaging in 
guinea pigs (see above). This also means that only 4 to 5 mutations were detected in 
these genes per individual adaptation experiment. So this may represent a minimum 
number of coding mutations required in an Ebola virus genome to enable 
Ebolaviruses to cause disease in a novel, previously non-susceptible host. It is 
reasonable to assume that not every mutation is essential for Ebolavirus adaptation 
to a novel host, so this required number of mutations may be even lower.  
 
The adaptation of the human-pathogenic Ebolavirus species, Ebola, Sudan, 
Bundibugyo, and Taϊ Forest viruses to humans that might result in increased 
virulence does not appear to be a major concern. Their virulence in humans is 
extremely high they  are still considered to be deadly to humans (Feldmann & 
Geisbert, 2011; Gray, et al., 2014). Hence, adaptation of human-pathogenic 
Ebolaviruses to humans (which would ultimately result in Ebolaviruses that circulate 
in humans as reservoir species) would be expected to result rather in a decrease of 
pathogenicity to achieve a balance between virulence and pathogen fitness and/or 
transmission. However, the potential of Ebolaviruses to adapt to novel host species 
may be of relevance with regard to the potential threat exerted by the non-
pathogenic member of the Ebolavirus genus, the Reston viruses. Reston viruses and 
Ebola viruses are known to circulate in pigs, and can be transmitted from pigs to 
humans (possibly by air) (Weingartl, 2013; Barrette, et al., 2009; Marsh, et al., 2011; 
Osterholm, et al., 2015; Atherstone, et al., 2015; Pan,  et al., 2014; Olson, et al., 2012; 
Miranda & Miranda, 2011). Moreover, dogs have been suggested to become infected 
and may play a role during virus transmission to humans and as potential reservoir 
species (Osterholm, et al., 2015; Weingartl, 2013) (Olson, et al., 2012). 
 




Table 4.2. Mutations identified during serial passaging of rodents. The table details protein structural 
analysis of the mutations including their BLOSUM62 substitution score, solvent accessible surface 
area and the predicted change in protein stability from mCSM. All studies considered adaptation in 
Guinea pigs with the exception of the Ebihara et al., study, which used mice, indicated with * in the 
study column. #The mutation in GP I544T, is commonly a T in Ebola virus and the structure 
available contains a threonine at this position. Therefore the mCSM analysis considered the mutations 
from threonine to isoleucine. 
 











NP S72G Ebihara* 0 0 -1.126 destabilizing 
NP N566S Dowall -1 - - - 
NP A575T Cross 0 - - - 
NP S647Y Cross -2 86 -0.652 Destabilizing 
NP F648L Volchkov 0 21 -0.86 Destabilizing 
VP35 A12V Ebihara* 0 - - - 
VP35 N204D Dowall 1 - - - 
GP D49N Dowall 1 71 0.398 Stabilizing 
GP S65P Ebihara* -1 6 -0.011 Destabilising  
GP V203I Dowall 3 - - - 
GP S246P Ebihara* -1 49 -0.253 Destabilising  
GP D397G Volchkov -1 - - - 
GP I544T Ebihara* -1 54# -0.556# Destabilising  
GP I544T Cross -1 54# -0.556# Destabilising 
VP24 L26F Dowall 0 0 -0.644 Destabilizing 
VP24 L26F Cross 0 0 -1.656 Destabilizing 
VP24 T50I Ebihara* -1 9 0.109 Stabilizing 
VP24 M71I Volchkov 1 75 -0.216 Destabilizing 
VP24 L147P Volchkov -3 94 -0.636 Destabilizing 
VP24 L147P Mateo -3 94 -0.636 Destabilizing 
VP24 H186Y Volchkov-2 2 7 0.563 Stabilizing 
VP24 T187I Volchkov -1 4 -1.157 Destabilizing 
VP24 K142E Cross 1 52 -0.082 Destabilizing 
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L N38K Dowall 0 18 0.062 Stabilizing 
L G707A Dowall 0 1 -0.497 Destabilizing 
L T820A Volchkov 0 6 0.081 Stabilizing 
L T930A Dowall 0 0 -2.245 Destabilizing 
L L940P Dowall -3 8 -1.713 Destabilizing 
L F934L Ebihara* 0 0 -3.187 Destabilizing 
L Y1271stop Dowall - - - - 
L N1478I Dowall -3 - - - 
L I1532V Ebihara* 3 - - - 
L A1546E Dowall -1 - - - 
L S1998T Dowall -2 - - - 
L N2144K Dowall 0 - - - 






Table 4.3. Analysis of mutations identified during passaging in Dowall et al., (Dowall, Matthews, 
Garcia-Dorival, et al., 2014) but not retained in later passages. 
Protein Mutation BLOSUM62 score 
Solvent Accessible 
surface Area (2) 
mCSM ΔΔG 
(Kcal/mol) 
NP W191R -3 0 -2.973 
NP V323D -3 7 -3.339 
NP L414R -2 - - 
VP35 S129P -1 - - 
VP35 I246A -1 0 -2.783 
VP40 E15Q 2 - - 
VP40 P66S -1 63 -0.431 
VP40 M259R -1 27 -1.569 
GP M1K -1 - - 
GP R11K 2 - - 
GP V92L 1 20 -0.345 
GP P187L -3 63 -0.357 
GP I465T -1 - - 
GP S493P -1 - - 
GP R638K 2 - - 
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GP Y652F -1 - - 
GP Y668C -2 - - 
VP30 L214P -3 0 -1.935 
VP30 Q248R 1 118 -0.269 
VP24 F29V -1 2 -1.342 
VP24 A43P -1 0 0.55 
VP24 K218R 2 47 -0.759 
L G30W -2 - -1.123 
L R161W -3 - -0.155 
L N525D 1 - 0.288 
L K537R 2 - -0.058 
L L538P -2 - -0.564 
L I669S -2 - -3.029 
L M705T -1 - -1.14 
L S826Y -2 - -0.642 
L S868P -1 - 0.207 
L F879L 0 - 0.376 
L I943R -3 - -1.589 
L T993A 0 - -1.262 
L L1096S -2 - -1.977 
L S1308P -1 - - 
L F1733Y 3 - - 
L L1763P 3 - - 
L H1949Q 0 - - 
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Table 4.4: Ebola virus protein structures and templates used for modelling;  
PROTEIN OLIGOMERIC 
STATE 
PDB/TEMPLATE REGION IN 
SEQUENCE 
GP Trimer of 
Heterodimers 
3CSY (structure) 31-310 
502-599 
sGP Dimer 3s88I (model) 32-287 
L Monomer 5a22T (model) 8-1140 
L Monomer 4n48A (model) 223-328 
NP (C-
terminal) 
Monomer 4QB0 (structure) 645-739 
NP (N-
terminal) 
Monomer 4YPI (structure) 39-384 
VP24 Heterodimer 4M0Q (structure) 10-231 
VP24 Heterodimer 4U2X (structure) 16-231 
VP30 Dimer 2I8B (structure) 140-266 
VP35 Heterodimer 4IBB (structure) 218-340 
VP35 Dimer of heterodimers 3L25 (structure) 209-340 
VP40 Monomer 1ES6 (structure) 44-321 
VP40 Dimer 4LDB (structure) 44-319 
VP40 Hexamer 4LDD (structure) 45-188 




The mutations identified during Ebola virus adaptation to rodents were extracted 
from four studies (Dowall, et al., 2014; Ebihara, et al., 2006; Volchkov, et al., 2000; 
Cross, et al., 2015). 
 
Available Ebola virus proteins were obtained from the protein databank, where 
structures were not available they were modelled using Phyre2 (Kelley et al., 2015). 
The structures used and templates for models are listed in Table 4.4. The adaptations 
were mapped onto the protein structures and their location in the structure analysed 
using PyMOL. mCSM was used with default parameters to calculate the effect of the 
adaptation mutations on protein stability (Pires, et al. 2014). Solvent accessible 
surface area was calculated using DSSP (Joosten, et al., 2011).  
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For the I554T mutation in GP, the protein structure (pdb code: 3CSY) already had a 
threonine at position 554. To UCSC genome browser (Kent et al., 2002) was used 
determine what residues are typically present at this position. This revealed that the 
original Mayinga 1976 strain has isoleucine at position 554, but the the vast majority 
of other Ebola virus genome sequences have threonine at position 554. As a result 
I554T was not classed as an adaptation mutation.  
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The extent of Ebolavirus pathogenicity and ability to cause epidemics has recently 
been demonstrated by the outbreak in West Africa. Of the five Ebolavirus species 
(Ebola, Tai Forest, Bundibugyo, Sudan and Reston), only Reston viruses are not 
pathogenic in humans. We have recently proposed that conserved amino acid  
differences in the Ebolavirus protein VP24 between Reston viruses and the four 
human-pathogenic Ebolaviruses may explain this difference in pathogenicity. VP24 
inhibits interferon signalling by binding to both STAT1 and karyopherins to prevent 
STAT1 accumulation in the nucleus and this consequently blocks interferon 
signalling. Here we used molecular dynamics to investigate the effect of these 
conserved differences on the interaction of VP24 with Karyopherin alpha5. In the 
simulations we observed that Reston virus VP24 has many anti-correlated 
movements with KPNA5 in comparison to the interaction of Ebola virus VP24 with 
KPNA5. Additionally the dynamics of the Reston virus VP24 with KPNA5 more 
closely resemble those of Ebola virus VP24 with mutation R137A, which is known 
to remove binding of Ebola virus VP24 with KPNA5. Our results therefore support 
the basis that the interaction of Reston virus VP24 with KPNA5 is different to that 
of Ebola virus VP24 and given the anti correlated interactions observed it is likely 




The pathogenicity of Ebola virus has been highlighted by the recent outbreak in 
West Africa (Quaglio et al., 2016) with more than 11,316 thousand deaths and 28,639 
confirmed cases as of 28th February 2016 (www.who.int). Suppression of the host 
immune response is a prominent feature of Ebola virus infection, which may explain 
the high fatality rate observed in the last outbreaks. Ebolaviruses do this through at 
least three proteins, GP, VP35 and VP24 (Hoenen et al., 2015; Ilinykh et al., 2015; 
Bale et al., 2015; Kimberlin et al., 2009). The Ebola virus protein VP24, binds the 
transcription factor STAT1 and karyopherins (known to bind Karyopherin  α1, α5 
and α6 in humans) to prevent transport of STAT1 to the nucleus and it therefore 
inhibits interferon signalling (Xu et al, 2014). VP35 prevents interferon signalling by 





binding to viral double stranded RNA, which prevents triggering interferon 
signalling. Additionally, GP is a surface protein responsible for interaction with the 
host cell receptors and entry of the virus into host cells. It is thought that GPÕs 
glycan cap provides a mechanism for escaping the immune system.  
 
We are interested in identifying the molecular determinants of Ebolavirus 
pathogenicity to further our understanding of how Ebolaviruses infect and kill hosts 
and how we can combat this.  There are five known Ebolavirus species, Ebola virus 
(formally called Zaire), Sudan virus, Bundibugyo virus, Taϊ forest virus and Reston 
virus (Kuhn et al., 2010). Reston viruses are not pathogenic in humans, while the 
four other species are. In a recent study we identified differences between the four 
human-pathogenic Ebolavirus species and Reston viruses that are likely to explain 
their difference in human pathogenicity (Pappalardo et al., 2016). Our key finding 
was the presence of amino acid differences between the Ebola and Reston VP24 
proteins that correspond to the interface site between Ebola virus VP24 and human 
karyopherin alpha 5 (KPNA5). We proposed that the different interface amino acids 
present (T131S, N132T, M136L, Q139R ÐEbola virus residue listed first and Reston 
virus residue second) at this site in Reston VP24 are likely to reduce the affinity for 
Reston VP24 with human karyopherins and therefore limit the ability of Reston 
viruses to inhibit interferon signalling via this mechanism. 
 
Xu et al. (2014) characterized the Ebola VP24 and KPNA5 complex by a 
combination of structural and biochemical analysis. They crystallised the Ebola VP24 
with the Armadillos 7-10 of KPNA5 and investigated the effect of VP24 mutations 
on binding to KPNA5 using coimmunoprecipitation pull down experiments and 
compared the bands obtained in the gel with wild type protein. This approach is not 
quantitative but the strength of the band provides an indication of the extent to 
which binding is affected. For R137A and R137A, T138A,Q139A the band is very 
weak. For F134A/M135A it is intermediate between these previous two mutations 
and the wild type. Additionally the same study also observed that while most single 
point mutations in the VP24 interface (except R137A) had little effect on binding to 
KPNA5, combinations of mutations in VP24 (F134A/M136A and 





R137A/T138A/Q139A) resulted in near loss of binding to KPNA5 (Xu et al., 2014). 
These included some of the positions that vary between Ebola and Reston viruses, 
which further support our hypothesis that Reston VP24 has different binding 
properties with KPNA5. In the previous chapter mutations present in experiments 
adapting Ebola virus to rodents, Figure 5.1 shows mutations coming from both 
analyses. 
 
Figure 5.1: Adaptational and experimental mutations in protein VP24; protein VP24 is shown in gray 
cartoon and protein KPNA5 is shown in blue cartoon. Adaptation mutations are shown in yellow 
sticks and experimental mutation coming from Xu et al. (2014) are shown in red sticks. 
 
In this study we use protein structural analysis and molecular dynamics simulations 
to investigate Ebola and Reston VP24 and their interaction with KPNA5 to consider 
our hypothesis that amino acid changes in Reston virus VP24 affect binding to 
KPNA5. This is done in the context of the mutagenesis data from Xu et al., (2014), 
enabling comparison of simulations with experimental (in vitro) data and their use to 









5.3.1. Modelling of a RESTV-VP24 KPNA5 complex  
The EBOV and RESTV VP24 sequence share 81.3% sequence identity and 96% 
similarity. The protein structures were aligned using Chimera (Pettersen et a., 2004) 
and a model for RESTV VP24 in complex with human Karyopherin Alpha 5 built 
using MODELLER 9.0 (Webb et al., 2014). The RESTV VP24 crystal structure 
(PDB 4D9O) and the EBOV VP24-KPNA5 complex (PDB 4U2X) were used as 
templates for the new model. 200 models were obtained and the one with the lowest 
DOPE score was selected.    
 
5.3.2. Comparison of interfaces 
PISA (Krissinel et al., 2007) and mCSM (Pires et al., 2014) were used to analyse the 
interfaces in the complexes. POPSCOMP (Kleinjung & Fraternali, 2005) was used to 
determine the contribution of the individual residues to the hydrophilicity and 
hydrophobicity at the interface, according to their solvent accessible surface area 
(SASA), using default parameters. The residues were classified as being part of the 
core, support or rim regions of the interface according to the change in SASA (when 
% of hydrophobicity was greater than 40 and difference in SASA was less then 10 2 
the residue was considered as core, otherwise it was rim).   
 
5.3.3. Molecular Dynamics simulations 
Molecular dynamics simulations were performed for the wild type forms of EBOV-
VP24 and RESTV-VP24 in complex with human KPNA5. Other simulations were 
performed on the EBOV-VP24-KPNA5 complex with mutations introduced into 
VP24 where the effect on KPNA5 binding had been experimentally determined (Xu 
et al., 2014). The mutations considered were: 1)R137A, 2)Q139A, 3)F134A,M136A 
and  4) R137A-Q139A.  
 
Molecular dynamics simulations were performed using Gromacs 5.0.5  (Abraham et 





al., 2015) using the GROMOS96 53a6 force field (JCC 2004 vol 25 pag 1656). 600 ns 
trajectories were obtained for the Ebola virus VP24-KPNA5 complex and the model 
of Reston VP24-KPNA5 complex. 200 ns trajectory was obtained for R137A and 
F134A,M136A and 100 ns  for all other simulations. 
We applied our in-house protocol to prepare the molecules for the simulations: to 
neutralise each system counter atoms Na+ were added to the solvated proteins, 
according to the different total charge in each system. The system was then 
minimised and equilibrated according to the Maxwell distribution temperature 
(300K), passing through three different temperatures,  at 100K, 200K and 300K 
using restraints,  and then equilibrated again using the same temperature steps but 
without restraints. This approach is generally done to avoid artifacts. Velocities were 
generated using the gen-vel option, using a random seed (gen-seed). 
 
5.3.4. Molecular Dynamics Analysis 
Trajectories were analysed using the GROMACS analysis tools, VMD tools and the 
Bio3D package for R (Grant et al., 2014). Analyses for the wild type complexes were 
carried out from 280ns to 600 ns, which is the range of simulation where the RMSD 
reached the plateau in the two cases. 
For the analysis, standard Periodic Boundary Conditions were removed and 
Minimum Image Convention (MIC) were applied to all the trajectories. Rotational 
and translational movements were then deleted in order to perform the Principal 
Component Analysis. Secondary structure plots for trajectories were obtained using 
the DSSP (Kabsch and Sander, 1983)  tool in gromacs. Root mean square deviation 
(RMSD) and fluctuation (RMSF) from the initial starting complex were obtained 
using Bio3D, as well as the PCA analysis and correlation plots.  
 
5.4. Results 
To investigate how the interactions of Ebola and Reston virus VP24 with KPNA5 
may differ we performed molecular dynamics simulations of both of these 
complexes. We then performed simulations of the Ebola virus VP24 complex with 
KPNA5 with mutations introduced in VP24 that are known to alter binding. This 
was done to enable comparison with the Reston virus simulation.  






5.4.1 Initial Comparison of the interface between EBOV and RESTV VP24 
with KPNA5 
A model of RESTV VP24 and human KPNA5 was generated using the RESTV 
VP24 structure and the recently solved crystal structure of EBOV VP24 complex 
with human KPNA5 as a template (see methods). The interface residues, as well as 
the energies and bonds in this model and in the EBOV VP24-KPNA5 complex were 
first compared using PISA (Krissinel & Henrick, 2007) and POPSCOMP (Kleinjung 
& Fraternali, 2005).  The PISA analysis identified a smaller interface area in the 
RESTV complex with a slightly lower binding energy but with seven fewer hydrogen 
bonds (nine in the RESTV complex compared to 16 in the EBOV complex).  We 
then compared the interfaces after minimisation during the initial state of the 
molecular dynamics trajectory (zero ns) and at the end of the simulation (600 ns). In 
the EBOV complex nine hydrogen bonds were found at the beginning of the 
trajectory (0 ns) but only seven remained at the end of the trajectory. For the RESTV 
complex, eleven hydrogen bonds were present at zero ns and nine remained at 
600ns. In total three hydrogen bonds were equivalent in the two complexes in the 
first snapshot, whilst only two of them overlapped at the end of the simulation 
(Figure 5.2B), (between VP24 137- KPNA 480 and VP24 138- KPNA5 480). The 
hydrogen bonds involving residue Q139, which is one the residues that is mutated in 
our study, and the proximal residue R140 are lost in the RESTV complex. This is 
interesting since residue R140 forms a hydrogen bond with E474 and a salt bridge 
with E475 at the interface.5.  The H-bond given with residues E474 has 1.91  
distance. Residue R140 has an accessible surface area of 191.04 2, a buried surface 
area of 117.29 2 (70% of the interface is buried) and a solvation energy effect of  -
0.99 Kcal/mol. Interestingly at the end of the simulation in the RESTV complex, the 
VP24 residue R137 forms a hydrogen bond with L479 and two salt bridges residues 
with D480 and E483 in KPNA5 (Figure 5.2B).  Mapping the hydrogen bonds at the 
interface (figure S1) we observed that residue R137 undergoes different 
conformational changes that make it essential for the stability of the interface, 
according to the mCSM and the FoldX predictions and our MD results (see later).  
 





POPSCOMP (Kleinjung & Fraternali, 2005) is an extension of the POPs server 
(Fraternali and Cavallo, 2002), it calculates the buried solvent accessible surface area 
(SASA) in protein complexes. We found that the total difference in the buried SASA 
differs in the two complexes, it is slightly higher for the EBOV complex with respect 
to the RESTV complex which has  a smaller interface. Seven of the twelve EBOV 
VP24 residues in the interface are also present in the RESTV VP24 interface with 
KPNA5 (Figure 5.2, Figure 5.3). Five of the ten EBOV KPNA5 residues are 
equivalent in the RESTV_KPNA5 interface with their respective VP24. This shows 
that while there is overlap, there are also considerable differences between the known 
EBOV VP24-KPNA5 complex and the modelled RESTV VP24-KPNA5 complex 
(Figure 5.3). POPSCOMP predicted that the interface is weaker in the RESTV 
complex at the end of the trajectory the interface area with KPNA5 is much smaller 
than the initial conformation. 
 
 





PISA results  
Interface Area ( 2 ) 1065.9 977 
Solvatation Free Energy 
(ΔΔG, Kcal/M) 
-9.2 -9.5 
H-Bonds 16 9 
PISA results at 0 ns  
Interface Area ( 2 ) 1099.7 1055.1 
Solvatation Free Energy 
(ΔΔG, Kcal/M) 
-8.5 -8.6 
H-Bonds 9 11 
PISA results at 600 ns  
Interface Area ( 2 ) 1119.2 1076 
Solvatation Free Energy 
(ΔΔG, Kcal/M) 
-10 -9.1 
H-Bonds 7 11 

































Figure 5.2: Ebola virus VP24 complex with KPNA5. A) VP24 is coloured grey and KPNA5 is blue. 
Residues differentially conserved between Ebola and Reston viruses in the interface site are shown in 
red stick format and labeled with the Ebola virus amino acid, residue number followed by the Reston 
virus amino acid. B) Hydrogen bonds present at the beginning of the MD trajectory (EBOV 0, 
RESTV 0) and at the end of the (EBOV 600, RESTV 600), red squares indicated that a hydrogen 
bond is present. C) Residues present in the VP24-KPNA5 interface at 0 and 600ns for both EBOV 
and RESTV VP24. Interface part indicates if the residue is part of the core (C), support (S) or rim (R) 
































Figure 5.3: Interface Residues predicted by POPSCOMP were mapped onto structure. On the top of 
the figure the EBOV Interfaces for VP24 (gray cartoon) and KPNA5 (yellow cartoon) are shown. 
Residues that contribute to the interfaces are shown in stick (red for VP24 and blue for KPNA5). On 
the bottom of the figure the RESTV Interfaces for protein VP24 (gray cartoon) and for KPNA5 (cyan 
cartoon) are shown. Residues that contribute to the Interfaces are shown in sticks (magenta for VP24 
and yellow for KPNA5).   
 
5.4.2. Predicted effects of Mutations at the Interface VP24-KPNA5 interface 
Next we used mCSM (Pires, Ascher & Blundell, 2014) and FoldX (Schymkowitz, 
Borg, Stricher, et al., 2005) to consider how each of the residues in the EBOV VP24 
interface that is a different amino acid in RESTV VP24 may affect the stability of the 
complex. mCSM also predicted the effect on the affinity of the complex (see 
methods).  For the mutations with experimental data mCSM predicts that both point 
changes reduce the stability and the affinity of the complex, with the R137A 





mutation having a greater effect (predicted (ΔΔG -1.066 Kcal/mol change in 
complex affinity) than Q139A (Table 2). The FoldX predictions agree with mCSM 
for both point mutations. Additionally FoldX was able to consider combinations of 
mutations simultaneously and predicted that both the F134A/M136A, and R137A-
Q139A mutations reduce stability of the complex with a very large reduction of more 
than 7Kcal/ml for the F134A,M136A combination. These predictions are generally 
in agreement with the experimental observations that R137A and the two multiple 
mutation sets nearly remove all binding of EBOV VP24 with KPNA5 (Xu, Edwards, 
Borek, et al., 2014a).  
 
Next we considered how the conserved amino acid differences between EBOV and 
RESTV VP24 may affect stability of the EBOV VP24 complex when the RESTV 
residues are introduced into the EBOV structure (Table 5.2). Again mCSM predicted 
that all of the changes would reduce the stability and affinity of the complex (with 
the exception of M136L, where a small increase in affinity is predicted). The changes 
in stability are similar to the predicted change for R137A, which is known to reduce 
binding. FoldX also predicts reduced stability for two of these four point changes, 
with increased stability predicted for M136L and Q139R, although the ΔΔG for 
M136L is predicted to be very small (0.18Kcal/mol). It also predicts a slightly less 
stable complex with all four amino acid changes present (Table 5.2). Overall these 
predictions suggest that individually the amino changes are likely to reduce the 
stability and affinity of the complex. This provides some initial support for our 
















Table 5.2: mCSM and FoldX stability changes for single amino acid changes in the EBOV VP24 Ð
KPNA5 complex.  
 
Mutation mCSM stability 








Experimental point mutations 
R137A -0.805 -1.066 -0.68 
Q139A 
 
-0.386 -0.239 -0.33 
F134A,M136A NA NA -7.3 
R137A,T138A,Q139A NA NA -1.02 
Conserved amino acid differences between EBOV and RESTV VP24 
T131S 
 
-1.295  -0.317  -0.42  
N132T 
 
-0.617  -2.65  -1.22  
M136L 
 
-0.814  0.166  0.18  
Q139R 
 
-1.058  -0.995  1.59  






5.4.3. Molecular Dynamics Analysis 
To further our analysis molecular dynamics simulations were performed on the 
EBOV V24- KPNA5 complex and the model of RESTV VP24 with KPNA5. 
Simulations over 600ns were obtained with the trajectories trimmed using the last 
320ns (280-600ns).  RMSD of the main chain C-Alphas was stable for both 
complexes (Supplementary Figure S2). The RMSD of the RESTV VP24-KPNA5 model 
is greater than the EBOV complex, (Supplementary Figure S2), this could indicate a 
difference in the interaction between RESTV VP24 and KPNA5 but could also 
partly reflect that the simulation is based on a model rather than a solved structure, 





which may result in greater movement to accommodate the best conformation. 
For VP24 some minor differences in fluctuation (i.e. Root mean squared fluctuation 
Ð RMSF) were observed between the RESTV and EBOV proteins. One of these 
differences coincide with the interface site at residues 113  (Figure 5.4A).  Residue 113 
is located in an alpha helix at the interface. For KPNA5 there are larger differences in 
RMSF in four regions, three of which coincide with the complex interface (Figure 
5.4A). The most pronounced difference is around residues 477 and 479 ( a loop 
region between two alpha helices) , where there is very little fluctuation of KPNA5 in 
the EBOV VP24 complex (around 1 ) but in the RESTV VP24 complex there is a 
peak of 8 . The greater fluctuation in KPNA5 suggests that the interaction with 
RESTV VP24 differs from that with EBOV VP24.  
 
 
Analysis of the secondary structure (using DSSP Ð see methods) during the 
simulation revealed minor changes in the secondary structure occurring at the 
interface site (Supplementary figure S3). The most important changes were found 
around residue 76 where there is a prevalence of turns in EBOV becoming coils in 
RESTV. Residues 133 and 134 (shown in figure S3), as well as residue 146, which are 
proximal to the binding interface lose their bend and beta bridge structure to become 
unstructured in the RESTV complex The largest changes in secondary structure were 
found in KPNA5, particularly in two regions between residues 365-375 and 385-395 
(figure S3), the second region which is involved in binding VP24, losses itÕs alpha 
helical structure after 220 ns in the RESTV complex. 
 
Cross correlation analysis was performed to consider how the proteins move in 
relation to each other. Using a threshold of 0.7 to explore the correlated motions, the 
RESTV complex has more unrelated motions, meaning there is much greater 
movement of VP24 and KPNA5 away from each other (figure 5.4B). Additionally, the 
RESTV complex showed a higher number of correlated motions and this probably 
reflects the adaptation movements that VP24 and KPNA5 undergo when they try to 
form a complex.   To further support our analysis Principal Component Analysis 
confirmed the different movements in the two complexes as shown in figure 5.4C-D; 





we calculated Principal components one and two and projected the RESTV principal 
components onto the EBOV ones. (figure 5.4D). This projection shows that the 
movements are in different directions (figure 5.4D). We scaled principal components 
1 and 2 using gromacs tools and we projected the eigenvectors into a porcupine 
visualisation (see figure 5.4C).  The first three eigenvectors describe 47.6% of the 
conformational variance for the EBOV complex and 48.80% or the RESTV 
simulation. This denotes great conformational changes in both cases with 1.2% more 
flexibility.  
 
Gromacs Hydrogen bond analysis identified an average of 14 interface hydrogen 
bonds for the EBOV complex and only 11 H-bonds for the RESTV complex, (using 
3.8  for donor/acceptor distance and 40  for the cut-off of the angle; Figure 5.5). 
This agrees with the PISA analysis which found fewer hydrogen bonds in the 
RESTV starting model.  
 
  





Figure 5.4. Molecular dynamics simulations of Ebola and Reston virus VP24 interaction with 
KPNA5. A) RMSF graph is shown, where in black line the fluctuation for EBOV complex and in red 
line the one for RESTV are shown. B) The cross correlation analysis is shown in both complexes; red 
lines represent the correlated movements whereas the blue lines represent the anticorrelated ones; C) 
Principal Component Analysis is shown in porcupine visualization for both complexes. D) Principal 
Component Analysis Projection for EBOV complex (from white to black) and for the RESTV (from 















Figure 5.5: H-bond analysis during MD simulations. In black the EBOV complex and in red the 
REST one. The Gaussian curves represent the mean of H-bonds occurring at the Interface during 600 
ns of simulation.  
 
 
5.4.4. Analysis of mutations in the EBOV VP24-KPNA5 complex 
The mutagenesis studies performed by Xu et al., (Xu, Edwards, Borek, et al., 2014b) 
provide an opportunity to perform simulations and match them with experimental 
data, which can be used to make further inferences about the RESTV VP24-KPNA5 
simulations. The R137A and F134A,M136A, R137A-Q139A mutations are known to 
have a significant effect on the binding of EBOV VP24 and KPNA5. 200 ns MD 
simulations were performed for R137A and for F134A,M136A and 100 ns simulation 





for the others. Additionally Q139A is known to individually have a minimal effect on 
binding and this was used as a control. Initial RMSD and RMSF analysis showed 
greater changes for the R137A and F134A-M136A mutations, while the simulation 
with the Q139A and R137A-Q139A mutations behaved similarly to the wild type 
complex (Figure 5.6), particularly with the RMSD and RMSF of the complex with 
R137A-Q139A showing very little difference to the wild type complex. This is 
surprising given that this combination of mutations is known to reduce binding of 
VP24 and KPNA5. In all simulations greater fluctuations in VP24 was observed 
around the site of the mutation (Figure 5.6) . Mutation R137A causes an increase in 
fluctuation of almost 1  in the proximal residues at the binding interface. The same 
is shown for mutations F134A-M136A, where the change is larger ( 2 ) and the 
upper peak in KPNA5 reaches almost 12 .  
Cross correlation Analysis showed correlated and anti-correlated moves in the 
mutated complexes (Figure 5.7 and Supplementary Figure S9). For mutation R137A 
(Figure 5.8) there were very few correlated movements between the two proteins, 
instead there were strong anti-correlated movements a few residues from the 
mutation, suggesting that it may have an allosteric effect. These anti-correlated 
motions suggest that the two proteins are moving away from each other and this 
agrees with experimental evidence as this mutation nearly abolished interaction 
between VP24 and KPNA5. 
 
Principal component analysis for this complex with mutation R137A revealed a large 
change in the contributions to the variation from the first three principal 
components; 56.1% of the movement is explained by the first principal component 
compared to 33.4% for the wild type complex.  Projection of the first two principal 
components onto those for the wild type complex demonstrates that the movement 
of the proteins differs (Figure 5.7). 
 
The correlation analysis for the complex with F134A and M136A mutations 
identified that most correlated movements are intra chain, with very few correlated 
movements between the two proteins (supplementary figure S9). Again the presence of 
many anti-correlated movements between the two chains indicates that they are 





moving apart and this is in agreement with experimental evidence that these 
mutations largely remove binding to KPNA5.Alanine 134 is located in a big web of 
anti-correlated movements, whereas Ala 136 is involved in correlated movements. 
Residue136 is mapped onto the cross correlation map.  Principal Component 
Analysis (see Table 5.3) demonstrated that the proteins move away from each other 







Figure 5.6: Root mean squared fluctuation of Ebola VP24-KPNA5 complex with point mutations. 
The dots under the lines represent the location of the mutations within protein VP24; the two protein 
in the complex are separated by a black line. A) RMSF mutation R137A is shown in red line and the 
EBOV wild type one. B) RMSF for mutation Q139A is shown in blue line and the EBOV wild type 
one. C) RMSF for mutations F134A,M136A are shown in magenta and the EBOV wild type one; D) 
RMSF for mutations R137A-Q139A are shown in yellow line. 
 






Figure 5.7. Molecular dynamics simulation of Ebola virus VP24 complex with KPNA5 with point 
mutations (R137A) in VP24. A) The cross correlation analysis is shown: in red lines the correlated 
movements and in blue lines the anticorrelated ones; protein VP24 is shown in blue cartoon and 
KPNA5 in gray cartoon; the mutation is shown in yellow sphere. B) Porcupine visualization of the 
Principal Component Analysis: protein VP24 is shown in gray cartoon and KPNA5 in blue cartoon; 
the mutation is shown in yellow spheres whereas the cones represent the amplitude of the movements 
according to the PCA. C) PCA projection of the wild type EBOV complex (from white to black) and 




















Figure 5.8: Residue R137 changes its conformation at zero (A) and at 600 ns (B). This last allows the 
interaction with KPNA5, giving a H-bond and a Salt Bridge with residue Asp 480.  









EBOV - % 
of variance 







% of variance 
R137A-Q139A - % 
of variance 
1 33.4 56.1 28.8 50.30 27.3 
2 48.1 64.2 51.1 65.8 37.6 




5.3.5. Solvation properties at the interface 
We calculated the solvation properties of the interface in the EBOV VP24 with 
human KPNA5 complex and in RESTV VP24 with human KPNA5 complex and 
estimated the water density on a grid of points constructed around the residues at the 
interface. We were interested in understanding how the water molecules were 
distributed at the interface and how they contributed to the binding of VP24 and 
KPNA5 (Figure 5.3). In figure 5.9 the spheres represent the most visited grid points 
coloured from red to blue, with red being a lower value for the visited grid point and 
blue a higher number of water visits. In this way we could define the red spheres as 
density of Òdynamical waterÓ visits and the blue spheres as ÒpermanentÓ water visits.    
Our findings showed that in the EBOV complex residues N185 H186 E203 P204 
and D205 are visited by permanent waters (Figure 5.9A).  Additionally in the Reston 
complex we found residues at the interface visited by permanent waters E203 P204 
D205 D124 and R137 (Figure 5.8B). This analysis revealed regions with permanent 
water visits in both the EBOV and RESTV complexes with overlap between both 
complexes (permanent waters at E203, P204 and D205 in both complexes).  These 
residues belong to a loop interacting with KPNA5 defying a cavity where the water 
molecules are trapped.  
Furthermore we performed the same analysis for the EBOV complex with the 
mutation R137A and we found that in this complex the interface is visited by 
ÒdynamicalÓ waters only and no region solvated by permanent waters has been 
identified. This was due to the fact that, during the simulation, protein VP24 moved 





apart from KPNA5 opening a cavity where the waters can enter and be dynamic due 
to the loss of physical restrictions (Figure 5.9C and Figure 5.10).   
                        A) 
B)  
 
                                C) 
 
 





Figure 5.9: The spheres represent the most visited grid points coloured from red to blue, with red 
being a low value for the visited grid point and blue a high number of water visits. In this way we 
could define the red spheres as density of Òdynamical waterÓ visits and the blue spheres as 
ÒpermanentÓ water visits.   A) EBOV VP24 with human KPNA5 complex shows a presence of 
permanent waters that interact with N185 H186 E203 P204 and D205. B) RESTON VP24 with 
human KPNA5 complex shows a presence of permanent waters that interact with residues E203 P204 
D205 D124 and R137. C) EBOV VP24 R137A with human KPNA5 complex shows a presence of 







Figure 5.10: The distance over the time of D205 of VP24 with R396 of KPNA5. The starting 




We started with a hypothesis that the conserved difference between Reston and 
Ebola virus VP24 proteins in the interface site with KPNA5 are likely to alter the 
interaction of Reston VP24 with KPNA5 compared to the interaction of Ebola 
VP24 with KPNA5. We have performed multiple analyses and simulations to gain 
insight into how this interaction may be altered. The molecular dynamics simulation 





of the wild type complexes (Figure 5.4), indicated that there are greater fluctuations in 
KPNA5 when in complex with Reston VP24 than with Ebola VP24. This was 
further backed up by the cross-correlation analysis, which revealed more correlated 
movements in the Reston complex but also many that were anti-correlated.  
 
The analysis of the complexes with mutations that significantly reduce Ebola VP24 
binding with KPNA5 can be used to put these results into context. The cross 
correlation analysis for the complexes with F134A/M136A and R137A mutations 
contained many more anti-correlated movements and the proteins move away from 
each other (Figure 5.7, figure S9). In contrast while there are many anti-correlated 
movements between Reston VP24 and KPNA5, there are also many correlated 
movements. This may therefore suggest that there is greater interaction between 
these two proteins than the mutated Ebola VP24 proteins where binding is largely 
lost. It may be possible that such a change is possible to affect the ability of Reston 















 This thesis has presented four pieces of work that are all related to genetic variation. 
Three of them focussed on analysis of genetic variants in Ebolaviruses with the aim 
of determining how they alter pathogenicity in different species. This chapter 
considers those chapters together and also compares the work in Chapter three with a 
similar study that also compares Ebola and Reston viruses.  
 
6.1 Is protein VP24 responsible for Ebolavirus pathogenicity? 
6.1.1 Combined analysis in our studies suggested that VP24 is a determinant 
for Ebolavirus pathogenicity. 
Chapter three represents the beginning of our Ebolavirus research, which led onto the 
research detailed in chapters four and five. In combination these studies represent a 
comprehensive computational analysis of Ebolavirus genomes, their variation and 
the effects on the encoded proteins, ranging from analysis between different 
Ebolavirus species to mutations induced in adaptation experiments in rodents. The 
central theme throughout this research has been to understand molecular 
determinants of Ebolavirus pathogenicity.  
 
The central finding in Chapter three was that there are very few differences between 
human pathogenic Ebolavirus species and Reston viruses (there are fewer than 200 
SDPs) and the analysis pointed largely at VP24 as having a role in pathogenicity, due 
to the presence of multiple SDPs in the interface site with KPNA5. This hypothesis 
was supported by information from mutagenesis studies where Ebola virus VP24 
interaction was disrupted by changes to residues that agree with some of the 
observed SDPs. However, the mutagenesis studies mutated pairs or trios of residues 
and each of these only partially overlaps with the SDPs. 
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This led into the research detailed in Chapter five, with the aim of using more detailed 
analysis of the VP24 and KPNA5 interface, particularly the use of molecular 
dynamics to study the interaction. This analysis supports our hypothesis in chapter 
three that the interaction between VP24 and KPNA5 differs for Ebola and Reston 
virus VP24. In Chapter three we proposed that the different amino acids present in 
Reston VP24 were likely to impair the interaction with KPNA5 and thereby prevent 
the virus from inhibiting the human interferon response. The molecular dynamics 
analysis of the Reston VP24 with KPNA5, supports our hypothesis; compared to 
the Ebola VP24 complex there are many more anti correlated movements between 
the two subunits. However, there are also correlated movements, overall suggesting 
that the two proteins may interact but with reduced affinity. The comparison of this 
simulation with simulations of Ebola virus VP24 that are known to disrupt binding 
further support this observation, as they clearly demonstrate the anti-correlated 
movements that are introduced between the two proteins. In effect we use this 
comparison to interpret the results of the simulation for Reston VP24 with KPNA5.  
 
While Chapter three utilised the difference in human pathogenicity between 
Ebolavirus species, Ebolaviruses are not pathogenic in rodents. As presented in 
Chapter four this has enabled experiments in rodents (primarily Guinea pigs) to induce 
pathogenicity through multiple passaging of Ebola virus through multiple 
generations of test animals. Our analysis of the mutations present in these different 
studies highlighted that very few mutations may be required for adaptation of Ebola 
virus to a new species. This agrees with our analysis in Chapter three, where it seems 
that only a few variants may render Reston viruses non-pathogenic in humans. 
 
Additionally analysis of the adaptation experiments highlighted mutations in VP24, 
with it being mutated in all of the four studies (Dowall et al., 2014; Ebihara et 
al.,2006; Cross et al.,2015; Volchkov et al., 2000). 





Figure 6.1: VP24 SDPs and adaptation mutations mapped into its complex with KPNA5. Protein 
VP24 is shown in gray cartoon and KPNA5 in blue. SDPs are shown in red sticks while adaptation mutations in 
yellow sticks.  
 
The location of the VP24 SDPs and the mutations from the adaptation experiments 
were mapped onto the VP24 structure (Figure 6.1). This demonstrates that many of 
the adaptation mutations are in close proximity to the SDPs or are in the interface 
site with KPNA5 (e.g. T187I and H186Y). Additionally we observed that the SDPs 
and rodent adaptation mutations had similar effects by either altering hydrogen 
bonding with KPNA5 or removing hydrogen bonds within VP24. This observation 
further supports the argument that VP24 has an important role in determining 
pathogenicity. 
 
The combination of the findings from Chapters three, four and five provides strong 
evidence for VP24 having an important role in determining host pathogenicity. It 
now remains for experimental validation of these findings, which is now being 




6.1.2 Comparison of Chapter 3 with Cong et al.,  
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Another study has also recently compared the genome sequences of Ebola and 
Reston viruses (Cong, Pei, & Grishin, 2015). Cong et al., used a total of 124 
Ebolavirus genomes (compared to 196 that we considered). Our analysis identified 
SDPs between the human pathogenic species and the Reston species. Cong et al., 
used a similar approach, they identified identified positions in the proteins where 
there is greater conservation among the human pathogenic Ebolavirus species than 
between the Reston genomes. Using this approach they identified 215 differentially 
conserved positions. In contrast we identified a smaller number of SDPs 189. 
Analysis of the positions identified by the two studies indicates that the greater 
number of sequences used in our study removes some of the positions that classed 
as conserved by Cong et al. 
 
Cong et al., also performed modelling of protein structures and mapping of the 
differentially conserved positions onto the structures. They used a different 
approach to us, using HHpred (Sding, et al., 2005) and iTASSER (Roy et al., 2010). 
They identified a model for part of the RNA-dependent RNA polymerase catalytic 
domain (L protein) and also a model for the N-terminal zinc finger domain of VP30. 
The template used to model L was not identified by Phyre2 when we performed 
modelling and this appears to be because the structure had just been released and 
may not have been added to the fold library (when modelling was later performed 
for the work in Chapter four, a template was identified and the model used in the 
analysis). Additionally the template used for the N-terminal domain of VP30 is of 
low quality with hhblits only returning a 52% probability that the query and template 
are homologous. Cong et al., propose that functional residues (i.e. the Zinc binding 
residues) are conserved therefore increasing the confidence that the template and 
query are homologous. 
 
Comparison of the SDPs from  Chapter three with the positions identified by Cong et 
al., demonstrated a considerable overlap of 133  positions, 6 in VP24, 16 in VP35, 
16 in VP30, 7 in VP40, 19 in NP, 16 in GP and 53 in L (Table 6.1). Cong et al., did 
not consider sGP (without sGP we identified 180 SDPs) explaining some of the 
difference. The positions that were present in one study but not the other were 
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investigated to identify if there was an explanation for the different results. While 
many of the SDPs are completely conserved as one amino acid in Reston viruses 
and completely conserved as a different amino acid in the human pathogenic 
species, there are SDPs where there is a little variation in the amino acids observed. 
Comparing the positions between the two studies we found that such positions 
explain the different findings.  
 
In our analysis, these positions would be less confident SDPs as they are not 
completely conserved in each group. So the different results obtained can be 
explained by both the different methods used and the different sets of sequences. 
Cong et al., used fewer sequences, so there will be some positions that are conserved 
in their set but in our larger set of sequences are more variable. The opposite is also 
true, some positions that are variable in the Cong et al., set, with more sequences 
present in our analysis, this variability could be reduced sufficiently for it to be 
predicted to be an SDP. Additionally, both studies used different methods to 
identify the differentially conserved positions, so there will be some positions that 
are predicted by one method but not the other regardless of the different sequences 
used. It is not possible to easily to split the effects of the different methods and 
sequences.  
Table 6.1: Comparison of SDPs in our study and in Cong et al.  
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Despite identifying a larger number of differentially conserved positions and 
modelling more of the Ebolavirus protein structures, Cong et al., mapped only 43 of 
the 215 positions they identified onto protein structures. 
 
Cong et al., also focused on protein-protein interfaces and like our study identified 
six differentially conserved positions in interfaces. These include the differences 
present in VP24 that we propose may be relevant to the different pathogenicity 
observed between species. However, they propose that these differences may modify 
the binding between VP24 and KPNA5 but that this is likely to be limited to an 
effect on immune suppression that is unlikely to affect virus pathogenicity.  
 
When considering protein-protein interfaces Cong et al., used the knowledge that 
Reston viruses are pathogenic in primates but not humans. So they considered the 
variability of the host proteins that Ebolaviruses interact with and investigated how 
these interaction partners vary between human and primates. They observed that 
host interaction partners of VP24, VP30 and VP40 are very similar between human 
and primates and therefore these proteins are unlikely to have a role in the different 
Ebolavirus pathogenicity. They found, there is greater sequence divergence in the 
host interaction partners of VP35 and  GP. Based on this they identified two clusters 
of residues that they propose may alter Ebolavirus pathogenicity. The first cluster of 
differentially conserved residues is located in the C terminal region of GP and the 
second cluster is in VP35. We also identified same residues in GP, however we were 
cautious about interpreting their possible effect as their function is unknown and 
while they are present in the glycan cap none of the residues are glycosylation sites or 
close to glycosylation sites. This made it difficult to interpret how they may alter GP 
function and pathogenicity.  
 
The VP35 cluster of residues identified by Cong et al., consists of A290V, A291P, 
V314A and Q329K. With the exception of A291P, these positions were also 
identified in our study, we observe variability between the human pathogenic species 
at position 291 and it is therefore not predicted to be an SDP. These changes had 
previously been identified in experimental research  (Leung et al., 2015), and are 
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thought to stabilise the protein structure. The experimental study also observed 
reduced binding of VP35 to dsRNA and weaker inhibition of interferon signalling 
(Leung et al., 2015). The authors of this study thought that these effects were unlikely 
to explain the lack of Reston virus pathogenicity in humans (Leung et al., 2015). 
 
In summary, both studies used very similar approaches but resulted in different 
interpretations. Our analysis highlighted VP24 as the availability of a complex 
structure with a host protein provided good evidence. If such data had been available 
for the other Ebolavirus proteins it is possible that other positions would have been 
identified that are likely to alter pathogenicity. While neither study is conclusive, they 
both provide avenues for wet lab experiments to validate the hypotheses. 
 
6.2 Limitations of this study 
Much of this thesis focusses on analysing Ebolavirus genetic variation. Chapter three 
identified a set of 189 SDPs, a subset of which are likely to explain the difference in 
human-pathogenicity between Reston viruses and the other four Ebolavirus species. 
Structural analysis was only able to map 47 of these SDPs onto protein structures. 
This initially limits the ability to analyse approximately three quarters of the SDPs 
identified. So while our structural analysis has identified a number of candidate SDPs 
for association with pathogenicity, it possible that others that it was not possible to 
analyse also have a role. Further determination of Ebolavirus protein structures or 
the availability of homologues to use as templates will reduce this problem. However, 
it is predicted that approximately 20% of the Ebolvirus proteins are disordered 
(Cong et al., 2015), so for some SDPs it may never be possible to model their effect 
on protein structure. 
 
Additionally the analysis in Chapters three to five is limited by our knowledge of the 
biology of Ebolaviruses. Our understanding of their function is still limited, although 
there has been a surge in Ebola related publications since the 2014 outbreak 
(Michaelis et al., 2016). Again as our understanding of Ebolavirus biology and 
protein function advances, the number of potential molecular determinants of 
Ebolavirus pathogenicity will be reduced. 
Chapter 6: Discussion  
 133 
 
This thesis presents purely computational research and as such demonstrates the 
strengths of such analyses to provide insight into large scale genomic data. However, 




6.3 Future Work 
 
The research in this thesis presents a number of hypotheses that need to be tested. 
These are detailed below: 
1 There are now many more Ebola virus sequences available (Pickett et al., 2012). 
These datasets provide approximately a further 506 sequences. The analysis 
performed in Chapter three could be repeated using this much larger dataset. This 
would provide much greater detail on variation present within the Ebola virus 
genome and could reduce the number of SDPs identified, thus enabling us to 
exclude some of the potential explanations for altered pathogenicity identified in 
chapter three. 
2 Extensive molecular dynamics simulations were performed on the VP24 
interaction with KPNA5. However, these could be expanded to investigate the 
affinity of the Ebola and Reston VP24 with KPNA5 using Òpulling apartÓ 
experiments, where the two molecules are pulled apart to measure the affinity 
between them. Such experiments are computationally expensive and could not be 
performed in this current analysis. 
3 Although much of the research has pointed to VP24, chapter three identified 
SDPs in other proteins, including VP40, VP35 and GP that could have an effect 
on protein function and therefore pathogenicity. These could also be 
experimentally investigated. 
4 Considering the role of protein VP24 in interfering with IFN signaling inhibition 
it will be interesting to look at sequence changes also in the partner protein 
KPNA5 in rat, hamster and pigs. This will advance our knowledge and could 
shed light on the mechanism of pathogenicity among Ebolaviruses.   
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5 We have proposed that VP24 has an important role in determining pathogenicity 
and these findings could be experimentally investigated. While Ebola is a 
category four pathogen, it is possible to perform in vitro experiments with 
individual Ebolavirus proteins, making such studies feasible. Ultimately such 
experimental work is required to test the hypotheses made in this thesis. For 
example testing the ability of Reston VP24 to bind human karyopherin proteins, 
would test the proposal that mutations in Reston VP24 alter binding to 
karyopherins. Similar experiments could be performed to test the effects of 
mutations in VP24 that occur during Ebola virus adaption experiments in 
rodents. Does the wild type Ebola VP24 bind rodent karyopherins and is there 
greater affinity with the mutated forms of VP24? This research has now started 
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Supplementary methods and Tables 
 
The text and tables below explain the groupings used for the different amino acid 
properties and how they were converted to features for input into the support vector 
machine (SVM). Supplementary table 1 displays the full list of features input into the 
SVM. The weight of each of the features used in the SVM was calculated using the 
script provided with SVMlight, which calculates the weighted sum of the support 
vectors. It shows that the Jensen Shannon conservation score has the highest 
weighted followed by the binding site and interface site features and solvent 
accessibility features. Conservation (Jensen Shannon divergence) has been used 
previously by other methods including SIFT and PolyPhen and it is not surprising 
that it is weighted highly. The weighting of the interface and binding site features 
demonstrates that they used by VarMod to make predictions and are more 




Appendix 1: Chapter 2 Supplementary Materials  
 153 
 
Feature Value range SVM weight 
js convergence score 
(conservation) 0-1 
1.83 
   
amino acid charge change see supplementary table 2 0.08 
amino acid mass change See supplementary table 3 0.08 
amino acid functional group 
change 
1 where functional change, 0 
otherwise (see Supplementary 
table 4) 
0.08 
   
distance to binding site  
0-1 (actual distance divided by 
25, values greater than 1 are 
rounded down to 1) 
1.31 
3DLigandSite average distance to 
ligands  0-1 (value/ 2) 
1.51 
3DLigandSite number of ligands 
that bind to this residue num/50 
0.80 
   
distance to  interface site 
0-1 (distance/25, values greater 
than 1 round down to 1) 
1.23 
   
DSSP -secondary structure- B 0/1 (1 if ss is B, 0 otherwise) 0.47 
DSSP -secondary structure- G 0/1 (1 if ss is G, 0 otherwise) 0.09 
DSSP -secondary structure- I 0/1 (1 if ss is I, 0 otherwise) 0.26 
DSSP -secondary structure- T 0/1 (1 if ss is T, 0 otherwise) 0.13 
DSSP -secondary structure- S 0/1 (1 if ss is S, 0 otherwise) 0.11 
DSSP -secondary structure- BL 0/1 (1 if ss is BL, 0 otherwise) 0.20 
DSSP -secondary structure- H 0/1 (1 if ss is H, 0 otherwise) 0.13 
DSSP -secondary structure-E 0/1 (1 if ss is E, 0 otherwise) 0.02 
  0.48 
DSSP -secondary structure Type - 
Heilx 
0/1 (1 if ss type is is H, 0 
otherwise) 0.49 
DSSP -secondary structure Type 
Ð Strand 0/1 (1 if ss is B, 0 otherwise) 0.45 
DSSP -secondary structure Type - 
Coil 0/1 (1 if ss is B, 0 otherwise) 0.08 
distance from end of secondary 
structure 
0 - 0.5 (0.5 in the middle, 0 at 
end of secondary structure 
element) 0.26 
DSSP - solvent accessibility 0-1 (solvent accessibility / 300) -1.05 
Supplementary Table 1. The SVM features used in VarMod are listed with the value ranged used for 
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Supplementary Tables 2-4 relate to the change in amino acid properties of the 
variants. Supplementary Table 2 shows the amino acid charge groups and 
Supplementary table 3 shows the value for the amino acid charge feature for changes 
between these groups. Supplementary table 4 shows the groups of amino acids based 
on functional groups present in the side chain. The feature associated with functional 
groups is either 0 (no change in functional group), 1 (change in functional group). 
 
Charge group Amino acids 
Positive charge  R, H, K 
Negative charge  D, E 
Negative polar  N, Q 
Positive polar  S, T 
Hydrophobic  G, A, V, I, L, M, F, Y, W, C, P 







Negative polar  Positive polar Hydropho
bic 
Positive charge 0     
Negative charge 1 0    
Negative polar 0.5 0.25 0   
Positive polar 0.25 0.5 0.75 0  
Hydrophobic 1 1 0.75 0.75 0 
 




Functional group Amino acids 
Positive  R, H, K 
Carboxylate D, E 
Phenyl  F, Y, W 
hydroxyl S, T, Y 
Amido N, Q 
Other/none G, A, V, I, L, M, C, P 
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Supplementary Methods - Subsampling of sequence data 
 
The sensitivity of the SDP analysis to the number of sequences available was considered by 
subsampling the sequences. Sampling was performed for; only the human pathogenic group; only the 
Reston group; and for both groups simultaneously. Subsampling was performed using between 10%-
90% of sequences in the group, increasing in 10% increments. For each percentage setting the group 
was sampled 50 times. Where both groups were sampled simultaneously they were done so with the 
same percentage of sequences i.e. at 20% sampling the SDPs were predicted each time using 20% of 
the human pathogenic sequences in one group and 20% of the Reston sequences in the other. For 
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each sample s3det was run to predict SDPs using the same settings as for the full dataset. Completely 
conserved SDPs are also compared to those that are not completely conserved. the The total number 
of SDPs predicted when sampled is shown in supplementary Figure 6. When the sequences of human 
pathogenic Ebolaviruses were sampled, while the number of Reston sequences remained constant, we 
observed that the number of SDPs predicted decreased as the proportion of sequences sampled 
increased. We further observed that even when a very high proportion of sequences was sampled 
(70%-90%), that there was still some variation in the number of SDPs, indicating that there was still 
further information present in the excluded sequences. When the Reston virus sequences were 
sampled, the pattern observed varied between the proteins (Supplementary Figure 6B). For GP, L and 
VP30, sampling resulted in more SDPs being predicted than in the full dataset, with the number 
reducing as the proportion of sequences sampled increased. For NP, sampling the Reston sequences 
generated some samples where fewer SDPs than the total present in the full dataset were predicted 
and other samples where a larger number of SDPs were predicted. This is possible for SDPs that are 
not completely conserved in the two groups, as sampling may generate some sets of sequences where 
these positions appear variable and others where they are conserved. For VP35, sampling led to fewer 
SDPs being predicted until 90% of sequences were used. The number of SDPs in VP24 and VP40 
was invariant across all samples. When sampling both groups (Supplementary Figure 6C) we found 
that the number of SDPs predicted very quickly converged to the number of SDPs present in the full 
dataset. 
 
We then considered the number of SDPs predicted that are present in the full dataset and those that 
are present only in sampling (Supplementary Figure 7). When the human pathogenic sequences were 
sampled (Supplementary Figure 7A), we found that the vast majority of SDPs in the full data set were 
predicted at all sampling levels. We also found that when a small proportion of sequences were 
sampled, that many new SDPs were predicted, which for some proteins (e.g. GP, NP and VP40) may 
be greater than the total number of SDPs present in the full dataset. This may not be too surprising 
given that positions that are variable in the full dataset may appear to be conserved when a small 
sample of sequences was taken. As the proportion of sequences sampled increased, very few new 
SDPs were predicted. Sampling the Reston sequences (Supplementary Figure 7B) we again found that 
the vast majority of SDPs present in the full dataset was present in all samples. The number of new 
SDPs present in samples was much smaller than for sampling of the human pathogenic sequences, 
which is likely to be due to the smaller number of Reston sequences, resulting in fewer samples where 
positions are conserved that are not conserved in the full data set. When both groups were sampled, 
results were very similar to that observed when the human pathogenic group was sampled 
(Supplementary Figure 7C). 
Finally, we considered the number of SDPs in the sampling sets that are completely conserved and 
those that are not (Supplementary Figure 8). In conjunction with the data from Supplementary Figure 
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7, this shows that sampling generates new SDPs that are completely conserved (i.e. only one amino 
acid in each group) and also some where there is variation within one or both groups. As the 
proportion of sequences sampled increased these numbers quickly converged to the numbers 
observed in the full dataset. Some of these included SDPs which in some samples were completely 
conserved but as further sequences were added, variation was introduced and they were no longer 
completely conserved. In such cases there was a change ranking for the SDP, as when completely 
conserved it was ranked 1, and this ranking was reduced once the position was not completely 





Supplementary Figure 1. Phylogenetic tree of the Ebolavirus genomes and individual proteins. 
Bayesian and Maximum Likelihood phylogenetic trees are shown for the Ebolavirus genomes and 
each of the Ebolavirus proteins. A) genome Bayesian tree. B) Genome maximum likelihood tree, C) 
Bayesian tree for protein L, D)Maximum likelihood tree for protein L, E)Bayesian tree for protein 
GP, F)Maximum likelihood tree for protein GP, G)Bayesian tree for protein NP, H)Maximum 
likelihood tree for protein NP, I)Bayesian tree for protein VP24, J)Maximum likelihood tree for 
protein VP24, K)Bayesian tree for protein VP30, L)Maximum likelihood tree for protein VP30, 
M)Bayesian tree for protein VP35, N)Maximum likelihood tree for protein VP35, O)Bayesian tree for 
protein VP40. P)Maximum likelihood tree for protein VP40. All trees use Ebola virus as root (EBOV, 
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Fig S1B.  
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Fig S1C.  
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Fig S1D.  
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Fig S1E .  
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Fig S1F.  
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Fig S1G.  





Fig S1H  
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Fig S1J.  
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Fig S1K.  
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Fig S1M.  
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Fig S1N.  
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Fig S1O.  
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Supplementary Figure 2. Ebolavirus protein consensus sequences and SDPs. The consensus 
sequence for each Ebolavirus species is shown for each Ebolavirus protein. The row above the 
alignment indicates positions that are 100% conserved across all Ebolavirus sequences (black) or 
specificity determining positions (SDPs) that discriminate Reston viruses from the four human 
pathogenic Ebolavirus species (red); R, Reston virus; E, Ebola virus; S, Sudan virus; B, Bundibugyo 
virus; T, Taϊ Forest virus. A) for VP24, B) for GP, C) for VP40, D) VP35, E)VP30, F) sGP, G) NP, 
H)L. 
 
A Ð VP24 
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B - GP 


















C Ð VP40 





D Ð VP35 








E Ð VP30 
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F Ð sGP 
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G Ð NP 
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H Ð L 
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Supplementary Figure 3. Solvent Accessible surface area for Ebolavirus SDPs. Histograms 
showing the Solvent Accessible surface area in square ngstroms of SDPs. Values are calculated for 
the Ebola virus structure and residues. 
 







Supplementary Figure 4. GP SDPs. A) Heatmap of intra- and inter-species GP sequence identity 
(EBOV, Ebola virus; BDBV, Bundibugyo virus; SUDV, Sudan virus; TAFV, Taϊ Forest virus; 
RESTV, Reston virus). B) Monomeric representation of GP with GP1 (grey) and GP2 (blue). D) 
EBOV GP trimer (PDB code: 3CSY) with SDPs colored red. The three GP1 chains are colored grey. 
The three GP2 chains are colored blue, green and yellow. C) Electrostatics surfaces for the EBOV 
structure (3CSY) and a model of a RESTV GP trimer based on 3CSY.  
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Supplementary Figure 5. GP SDPs are located outside the putative NPC1 binding site. GP 
SDPS are shown in red. The putative NPC1 binding site is shown in cyan. 
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Supplementary Figure 6. SDP prediction with subsampling of Ebolavirus sequences. The two 
groups of sequences Ôhuman pathogenicÕ and Reston (Ônon human pathogenicÕ) were sampled and 
SDP predictions made (see materials and methods). The boxplots show the distributions of the 
number of SDPs predicted in the simulations where A) only human pathogenic sequences were 
sampled, B) only Reston sequences were sampled and C) both sets were sampled. Sampling was 
performed for samples consisting of between 10%-90% of sequences (x axis). Red lines indicate the 
number of SDPs predicted in the full dataset without sampling. Note the scale of the Y-axis varies 
between each plot. 
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Supplementary Figure 7. Change in SDP prediction with subsampling of Ebolavirus 
sequences. The two groups of sequences Ôhuman pathogenicÕ and and Reston (Ônon human 
pathogenicÕ) were sampled and SDP predictions made (see materials and methods). The boxplots 
show the number of SDPs predicted in each sampling that are also in the full dataset (red) and 
new SDPs that are predicted only in subsamples (blue). The black horizontal line indicates the 
number of SDPs predicted using the full dataset. Subsampling performed for  A) only human 
pathogenic sequences were sampled, B) only Reston sequences were sampled and c) both sets 
were sampled. 
 
A. Human pathogenic sequence sampled. 
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C. Both groups sampled 
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Supplementary Figure 8. Analysis of completely conserved SDP with subsampling of 
Ebolavirus sequences. The two groups of sequences Ôhuman pathogenicÕ and and Reston (Ônon 
human pathogenicÕ) were sampled and SDP predictions made (see materials and methods). The 
boxplots show the number of SDPs predicted in each sampling that are are completely conserved 
(red) and not completely conserved (blue). The red horizontal line indicates the number of 
completely conserved SDPs present in the full dataset and the blue line represents the equivalent 
for SDPs that are not completely conserved. Subsampling performed for A) only human 
pathogenic sequences were sampled, B) only Reston sequences were sampled and c) both sets 
were sampled. 
 
A. Human pathogenic sequence sampled. 
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B. Reston Sequences Sampled 
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C. Both groups sampled 
 










% of positions 
with variation 
All species 2597 4555 
 
64% 










4426 2726 38% 
Tai forest virus 4480 2672 37% 
Reston virus 4466 2686 38% 
 
Supplementary Table 1. Variation within the Ebolavirus genomes. The number of positions in the 
Ebolavirus protein multiple sequence alignments that are completely conserved and those that have 
variation are shown. 
























17 M17 L17 L17 L17 L17 2 70 
-0.444 
(destabilising) 1 
22 I22 V22 V22 V22 V22 3 0 
-0.916 
(destabilising) 1 
31 I31 V31 V31 V31 V31 3 17 
-0.193 
(destabilising) 1 
131 S131 T131 T131 T131 T131 1 36 
-1.394 
(destabilising) 1 
132 T132 N132 N132 N132 N132 1 9 
-1.121 
(destabilising) 1 
136 L136 M136 M136 M136 M136 2 2 
-1.7 
(destabilising) 1 
139 R139 Q139 Q139 Q139 Q139 1 132 
0.05 
(stabilising) 1 
226 A226 T226 T226 T226 T226 0 2 
-0.935 
(destabilising) 1 
248 L248 S248 S248 S248 S248 -2 -  1 
 
Supplementary Table 2. VP24 SDPs. The position in the multiple sequence alignment, the amino 
acid position, and amino acid present in each of the species is shown. The BLOSUM62 score 
represents how frequently such amino acid changes are observed in nature. SASA is the solvent 
accessible surface area, which is only available for SDPs that could be mapped to protein structure. 
SASA was calculated using the protein structure with PDB code 4M0Q. RESTV, Reston virus; 
EBOV, Ebola virus; B, Bundibugyo virus; SUDV, Sudan virus; TAFV, Taϊ Forest virus. The s3det 























53 N53 T52 T52 T52 T52 0 -  1 
54 L54 V53 V53 V53 V53 1 -  1 
64 I64 T63 T63 T63 T63 -1 -  1 
94 D94 E93 E93 E93 E93 2 -  1 
97 N97 T96 T96 T96 T96 0 -  1 
99 H99 R98 R98 R98 R98 0 -  1 
108 R108 K107 K107 K107 K107 2 -  1 
112 I112 S111 S111 S111 S111 -2 -  1 
117 S117 K116 K116 K116 K116 0 -  1 
121 S121 A120 A120 A120 A120 1 -  1 
151 I151 T150 T150 T150 T150 -1 7 
0.455 
(stabilising) 1 
158 R158 Q157 Q157 Q157 Q157 1 70 
-0.493 
(destabilising) 1 
160 L160 I159 I159 I159 I159 2 6 
-0.859 
(destabilising) 1 
197 H197 R196 R196 R196 R196 0 83 
-1.291 
(destabilising) 1 
206 D206 E205 E205 E205 E205 -2 148 
-0.373 
(destabilising) 1 
263 A263 R262 R262 R262 R262 -1 106 
-0.969 
(destabilising) 1 
269 Q269 S268 S268 S268 S268 0 -  1 
 
 
Supplementary Table 3. VP30 SDPs. The position in the multiple sequence alignment, the amino 
acid position, and amino acid present in each of the species is shown. The BLOSUM62 score 
represents how frequently such amino acid changes are observed in nature. SASA is the solvent 
accessible surface area, which is only available for SDPs that could be mapped to protein structure. 
SASA was calculated using the protein structure with PDB code 2I8B. RESTV, Reston virus; EBOV, 
Ebola virus; B, Bundibugyo virus; SUDV, Sudan virus; TAFV, Taϊ Forest virus. The s3det column 


























27 T15 S26 S26 S26 S26 1 -  1 
49 D37 E48 E48 E48 E48 2 -  1 
77 E65 D76 D76 D76 D76 2 -  2 
86 K74 E85 E85 E85 D86 1 -  3 
93 M81 S92 S92 S92 S92 -1 -  1 
98 T86 V97 V97 V97 I98 0 -  3 
102 N90 T101 T101 T101 A102 0 -  3 
107 A95 S106 S106 S106 S106 1 -  1 
122 I110 V121 V121 V121 M122 3 -  3 
155 S143 A154 A154 A154 A154 1 -  1 
160 V148 T159 T159 T159 T159 0 -  1 
161 D149 E160 E160 E160 E160 2 -  1 
168 K156 G167 G167 G167 G167 -2 -  1 
175 A163 S174 S174 S174 S174 1 -  1 
182 L170 I181 I181 I181 I181 2 -  2 





















Supplementary Table 4. VP35 SDPs. The position in the multiple sequence alignment, the amino 
acid position, and amino acid present in each of the species is shown. The BLOSUM62 score 
represents how frequently such amino acid changes are observed in nature. SASA is the solvent 
accessible surface area, which is only available for SDPs that could be mapped to protein structure. 
SASA was calculated using the protein structure with PDB code 4IBB. RESTV, Reston virus; EBOV, 
Ebola virus; B, Bundibugyo virus; SUDV, Sudan virus; TAFV, Taϊ Forest virus. The s3det rank 
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122 V122 I122 I122 I122 I122 3 -  1 












269 Q269 H269 H269 H269 H269 0 -  1 




325 D325 E325 E325 E325 E325 2 -  1 
 
Supplementary Table 5. VP40 SDPs. The position in the multiple sequence alignment, the amino 
acid position, and amino acid present in each of the species is shown. The BLOSUM62 score 
represents how frequently such amino acid changes are observed in nature. SASA is the solvent 
accessible surface area, which is only available for SDPs that could be mapped to protein structure. 
SASA was calculated using the protein structure with PDB code 1ES6. RESTV, Reston virus; EBOV, 
Ebola virus; B, Bundibugyo virus; SUDV, Sudan virus; TAFV, Taϊ Forest virus. The s3det column 
shows the ranking of the SDPs by s3det. 
 




















4 G4 R4 R4 R4 R4 -2   1 
16 D16 E16 E16 E16 G16 2   2 
30 T30 S30 S30 S30 S30 1   1 










































416 N416 K416 K416 K416 K416 0   1 
421 Q421 Y421 Y421 Y421 Y421 -1   1 
426 E426 D426 D426 D426 D426 2   1 
435 N435 D435 D435 D435 D435 1   1 
443 E443 D443 D443 D443 D443 2   1 
453 I453 T453 T453 T453 T453 -1   1 
492 E492 D492 D492 D492 D492 2   1 
497 A497 P497 P497 P497 P497 -1   2 
535 (-) P526 P526 P526 P526    1 
572 S563 T563 T563 T563 T563 1   1 
574 V565 I565 I565 I565 I565 3   1 
611 T602 P602 P602 P602 N602 -1   4 
651 Q641 N641 N641 N641 K641 0   2 
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726 N716 D716 D716 D716 D716 1 123 
0.141 
(stabilising) 1 





Supplementary Table 6. NP SDPs. The position in the multiple sequence alignment, the amino acid 
position, and amino acid present in each of the species is shown. The BLOSUM62 score represents 
how frequently such amino acid changes are observed in nature. SASA is the solvent accessible 
surface area, which is only available for SDPs that could be mapped to protein structure. SASA was 
calculated using the protein structure with PDB code 4QB0 for the C terminal and 4YPI for the N 
terminal regions. RESTV, Reston virus; EBOV, Ebola virus; B, Bundibugyo virus; SUDV, Sudan 
virus; TAFV, Taϊ Forest virus. The s3det rank column shows the ranking of the SDPs by s3det. The 

























2 G2 M1 M1 M1 M1 -3   1 
3 S3 G2 V2 E2/G2 G2 0   8 
32 I32 F31 F31 F31 F31 0   1 












197 A197 S196 S196 S196 S196 1   1 
208 D208 E207 T207 E207 T207 2   9 
211 T211 S210 S210 S210 S210 1   1 










L307 S308 S308 S308 -1   2 
326 G326 R325 V325 R325 V325 -2   9 
355 L355 H354 R354 H354 Q354 -3   9 
404 P401 Q403 N401 Q397 S401 -1   9 
419 E412 S418 A409 S412 T409 0   9 




H517 H516 H516 H516 H516 2   6 
519 K499 R498 R498 R498 R498 2   1 
521 K501 R500 R500 R500 R500 2   1 




542 V522 Q521 Q521 Q521 L521 2 19 
0.037 
(stabilising) 6 




605 L585 I584 I584 I584 I584 2   1 
628 S608 D607 D607 D607 D607 0   1 
643 E623 K622 K622 K622 K622 1   1 
659 H639 Q638 Q638 Q638 Q638 0   1 
663 L643 D642 D642 D642 S642 -4   6 
665 L645 W644 W644 W644 W644 -2   1 
680 I660 T569 T569 T569 T569 -1   1 
 
Supplementary Table 7. GP SDPs. The position in the multiple sequence alignment, the amino acid 
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position, and amino acid present in each of the species is shown. The BLOSUM62 score represents 
how frequently such amino acid changes are observed in nature. SASA is the solvent accessible 
surface area, which is only available for SDPs that could be mapped to protein structure. SASA was 
calculated using the protein structure with PDB code 3CSY. RESTV, Reston virus; EBOV, Ebola 
virus; B, Bundibugyo virus; SUDV, Sudan virus; TAFV, Taϊ Forest virus. The s3det rank column 




















47 G2 M1 M1 M1 M1 -3  1 
77 I32 F31 F31 F31 F31 0  1 
83 I38 V37 V37 V37 V37 3 21 1 
91 A46 V45 V45 V45 V45 0 84 1 
121 I76 V75 V75 V75 V75 3 61 1 
242 A197 S196 S196 S196 S196 1  1 
256 T211 S210 S210 S210 S210 1  1 
306 L261 I260 I260 I260 I260 2 20 1 
315 S270 T269 T269 T269 T269 1 48 1 
 
Supplementary Table 8. sGP SDPs. The position in the multiple sequence alignment, the amino 
acid position, and amino acid present in each of the species is shown. The BLOSUM62 score 
represents how frequently such amino acid changes are observed in nature. SASA is the solvent 
accessible surface area, which is only available for SDPs that could be mapped to protein structure. 
SASA was calculated using the Phyre2 structural model that used template structure 3s88I. RESTV, 
Reston virus; EBOV, Ebola virus; B, Bundibugyo virus; SUDV, Sudan virus; TAFV, Taϊ Forest virus. 
The s3det rank column shows the ranking of the SDPs by s3det. The s3det column shows the ranking 
of the SDPs by s3det. 
 
 






















67 T66 V66 V66 V66 V66 0   1 
110 H109 Q109 Q109 Q109 Q109 0   1 
137 L136 I136 I136 I136 I136 2   1 
147 V146 L146 L146 L146 L146 1   1 
222 S221 A221 A221 A221 A221 1   1 
224 L223 Q223 Q223 Q223 Q223 -2   1 
228 Q227 H227 H227 H227 H227 0   1 





284 V283 L283 L283 L283 L283 1   1 
313 F312 Y312 Y312 Y312 Y312 3   1 
327 S326 A326 A326 A326 A326 1   1 
331 D330 T330 T330 T330 T330 -1   1 
351 D350 E350 E350 E350 E350 2   1 
362 S361 T361 T361 T361 T361 1   1 
366 F365 L365 L365 L365 L365 0   1 
380 I379 V379 V379 V379 V379 3   1 
448 H447 Q447 Q447 Q447 Q447 0   1 
451 S450 P450 P450 P450 P450 -1   1 
466 N465 D465 D465 D465 D465 1   1 
690 S689 E689 E689 E689 E689 0   1 
848 A847 S847 S847 S847 S847 1   1 
869 A868 S868 S868 S868 S868 1   1 
897 Y896 F896 F896 F896 F896 3   1 
926 F925 L925 L925 L925 L925 0   1 
955 S954 A954 A954 A954 A954 1   1 
996 T995 S995 S995 S995 S995 1   1 
1025 N1024 T1024 T1024 T1024 T1024 0   1 
1074 K1073 R1073 R1073 R1073 R1073 2   1 
1120 S1119 A1119 A1119 A1119 A1119 1   1 
1164 A1161 F1163 F1163 F1163 F1163 -2   1 
1190 S1187 D1189 D1189 D1189 D1189 0   1 
1215 S1212 A1214 A1214 A1214 A1214 1   1 
1218 K1215 R1217 R1217 R1217 R1217 2   1 
1238 E1235 D1237 D1237 D1237 D1237 2   1 
1256 V1253 I1255 I1255 I1255 I1255 3   1 
1355 K1532 R1534 R1534 R1534 R1534 2   1 
1367 A1354 T1366 T1366 T1366 T1366 0   1 
1396 T1393 S1395 S1395 S1395 S1395 1   1 
1409 M1406 I1408 I1408 I1408 I1408 1   1 
1415 L1412 I1414 I1414 I1414 I1414 2   1 
1437 N1434 S1436 S1436 S1436 S1436 1   1 
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1462 Q1459 K1461 K1461 K1461 K1461 1   1 
1474 C1471 S1473 S1473 S1473 S1473 -1   1 
1489 Y1486 L1488 L1488 L1488 L1488 -1   1 
1500 L1497 I1499 I1499 I1499 I1499 2   1 
1507 A1504 S1506 S1506 S1506 S1506 1   1 
1510 V1507 I1509 I1509 I1509 I1509 3   1 
1539 S1536 A1535 A1535 A1535 A1535 1   1 
1627 Y1624 L1624 L1624 L1624 L1624 -1   1 
1631 S1628 C1628 C1628 C1628 C1628 -1   1 
1786 I1760 V1762 V1762 V1762 V1762 3   1 
1874 T1848 V1850 V1850 V1850 V1850 0   1 
1897 S1871 T1873 T1873 T1873 T1873 1   1 
1941 N1914 R1916 R1916 R1916 R1916 1   1 
1966 R1939 E1941 E1941 E1941 E1941 0   1 
2033 I2006 L2008 L2008 L2008 L2008 2   1 
2069 I2042 L2044 L2044 L2044 L2044 2   1 
2102 T2075 S2077 S2077 S2077 S2077 1   1 
2123 D2096 E2098 E2098 E2098 E2098 2   1 
2130 L2130 Q2105 Q2105 Q2105 Q2105 -2   1 
2133 E2106 Q2108 Q2108 Q2108 Q2108 2   1 
2156 F2129 Y2131 Y2131 Y2131 Y2131 3   1 
2182 V2155 L2157 L2157 L2157 L2157 1   1 
2193 N2171 R2168 R2168 R2168 R2168 0   1 
2200 K2173 R2175 R2175 R2175 R2175 2   1 
2202 F2175 L2177 L2177 L2177 L2177 0   1 
2211 L2184 M2186 M2186 M2186 M2186 2   1 
 
Supplementary Table 9. L SDPs. The position in the multiple sequence alignment, the amino acid 
position, and amino acid present in each of the species is shown. The BLOSUM62 score represents 
how frequently such amino acid changes are observed in nature. SASA is the solvent accessible 
surface area, which is only available for SDPs that could be mapped to protein structure. SASA was 
calculated using the Phyre2 structural model which used template 4n48A (Òcap-specific mrna (Òcap-
specific mrna (nucleoside-2'-o-)-methyltransferase 1 protein in2 complex with capped rna fragmentÓ). 
RESTV, Reston virus; EBOV, Ebola virus; B, Bundibugyo virus; SUDV, Sudan virus; TAFV, Taϊ 
Forest virus. The s3det rank column shows the ranking of the SDPs by s3det. The s3det column 
shows the ranking of the SDPs by s3det. 
 
 







Res RESTV Res 
Mutation 
position Mutation Effect 
GP Q638 H 638 Q → V 
No effect on release of 
soluble GP1,2delta. 
GP R498 K 498-501   
RTRR → 
ATAA 
No effect on cleavage 
between GP1 and GP2. 
GP D642 L 642 D → V 
No effect on release of 
soluble GP1,2delta. 
VP24 M136 L 134/136 F-A/M-A 
Near complete loss of 
KPNA5 binding * 
VP24 Q139 R 137-139 
RTQ → 
AAA 
Near complete loss of 
KPNA5 binding * 
 
Supplementary Table 10. SDPs that coincide with known mutagenesis data.  Functional data 
extracted from UniProt unless stated. Res, residue; EBOV, Ebola virus; RESTV, Reston virus 
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PROTEIN SPECIES OLIGOMERIC 
STATE 
PDB/TEMPLATE REGION IN 
SEQUENCE 
GP EBOV Trimer of 
Heterodimers 
3CSY (structure) 31-310 
502-599 
sGP EBOV Dimer 3s88I (model) 32-287 
sGP RESTV Dimer 3s88I (model) 33-288 
L EBOV Monomer 4n48A (model) 223-328 
NP (C-
terminal) 
EBOV Monomer 4QB0 (structure) 645-739 
NP (N-
terminal) 
EBOV Monomer 4YPI (structure) 39-384 
VP24 EBOV Heterodimer 4M0Q (structure) 10-231 
VP24 EBOV Heterodimer 4U2X (structure) 16-231 
VP24 RESTV Dimer 4D9O (structure) 10-231 
VP30 EBOV Dimer 2I8B (structure) 140-266 
VP30 RESTV Dimer 3V70 (structure) 142-272 
VP35 EBOV Heterodimer 4IBB (structure) 218-340 
VP35 EBOV Dimer of 
heterodimers 
3L25 (structure) 209-340 
VP35 RESTV Dimer of 
heterodimers 
3KS8 (structure) 208-329 
VP40 EBOV Monomer 1ES6 (structure) 44-321 
VP40 EBOV Dimer 4LDB (structure) 44-319 
VP40 EBOV Hexamer 4LDD (structure) 45-188 
VP40 EBOV Octamer 4LDM (structure) 69-188 
VP40 RESTV Monomer 1es6A (model) 44-321 
 
 
Supplementary Table 11. Protein structures available for Ebolavirus Proteins. EBOV, Ebola 
virus; RESTV, Reston virus 
 











Note- Ebola virus GP structure has R31 rather 
than F31. Surface residue close to interface with 
GP2 in the trimer.  
Unclear what functional effect may be if any. Unclear 
I38 V37 
Surface residue, appears to be a conservative 
change of amino acid that could be well tolerated Unlikely 
A46 V45 
Also a surface residue. Conservative change of 




Surface residue, conservative change of amino 
acid . Change should be well accommodated Unlikely 
L261 I260 
One of three SDPs located in the glycan cap 
region of GP1. The glycan cap binds the host cell 
receptor(s) but is highly glycosylated so it is not 
clear if the amino acids directly contact the host 
cell. Surface residue in a cavity. It is part packed 
quite tightly with residue F234, V236, T240 but 
should be possible to accommodate change to 
Leu in Reston virus. Could there be a role with 
the three SDPs combined in this region.  possible* 
S270 T269 
Located at the top of the structure, is a surface 
residue (with side chain pointing to the solvent) 
representing a conservative amino acid change. 
Again could it have a role in conjunction with the 




Also located in the glycan cap and also a surface 
residue. Present in loop so unlikely to alter 
structure but could have a functional role, and 
alters charge on the protein surface. possible* 
D515 N514 
Surface residue, results in loss of negative charge 
in Reston virus GP. Located at the end of a beta 
sheet. Seems unlikely to have a structural effect. 
Possible combined effect with adjacent L547V? Unlikely 
V522 Q521 
Close to trimer interface (GP2-GP2) but directly 
within the interface. Not clear what effect this 
change would have on protein structure Unclear 
V548 L547 
Surface residue at end of a beta sheet. Appears to 
be minor change in amino acid. Possible 
combined effect with adjacent N514D? Unlikely 
L585 I584 
Largely buried amino acid. At the interface with 
GP1 (in the same GP monomer). EBOV I584 
interacts with F572,  not clear if this interaction 
would change in with Leu in Reston virus. Unlikely 
 
Supplementary Table 12. Structural analysis of GP SDPs. Details of the structural analysis are 
included with an assessment of whether the amino acid change is likely to have an effect on the 
protein. Four categories are used for the effect column unlikely (the change seems unlikely to alter the 
structure/function), unclear (the change could be functional but there is limited evidence), possible 
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(more confident that there is an effect than the unclear group) and probably (highly confident that the 
change will have a structural/functional effect). 
 










R39 forms a H bond with D71. Change to K is likely to 




Unusual to see Pro in a sheet. The amino acid is on the 
protein surface and it there is nothing to suggest that a 
change to Ser would alter the protein Unclear 
V56 I56 
I56 is largely buried and packed against other sidechains. 
While change to Val would reduce the size of the side 
chain, it seems likely that it would be accommodated 
within the structure. Also V64I is adjacent to this SDP. Unlikely 
I64 V64 
In a surface loop facing the helix containing I56V. 
Possible co-evolution with I56 Ð reduce size in one, 
matched with increased size in the other.  Unlikely 
K105 R105 
The side chain guanidino group of R105 provides a 
hydrogen bond with the side chain of Q38 as well as with 
the local backbone NH of G103 to provide a stabilized 
region of the protein. Although the mutation R105K 
appears conservative and maintains the side chain 
positive charge, the ability to form multiple hydrogen 
bonds is reduced due to resonance stabilization in the 
guanidino group being lost in the transfer to the lysine 
side chain amino group. This has the potential to weaken 
interactions in this region. Possible 
L137 M137 
M137 is located at the end of helix and packs against an 
adjacent helix. The conservative change to L137 in 
Reston virus seems unlikely to have a significant effect 
on structure/function Unlikely 
Y212 F212 
A minor change in side chains. P212 is located in an 
alpha helix and the sidechain is largely buried. The 
change to Y212 in Reston virus is unlikely to have a 
significant effect on protein structure/function Unlikely 
R274 K274 
K274 is located in the VP35 binding site. K274 forms a 
hydrogen bond with VP35 D46 and a change to Arg 
should be able to maintain this interaction. Unlikely 
A279 S279 
S279 is located in an alpha helix on the protein surface. 
The change to A279 in Reston virus would introduce a 
hydrophobic amino acid on the protein surface that 
could have an effect on protein structure.  Unclear 
R374 K374 
K374 is located in an alpha helix on the protein surface. 
It is not unlikely that the change to R374 in Reston virus 
will alter protein structure. It is a conservative change of 
side chain. Unlikely 
R705 A705 
A695 is located on the protein surface so the charge 
introduce by the change to R695 in Reston virus should 
be tolerated. Proximity of Reston virus R705 to E694 
may result in a salt bridge that would reduce flexibility in 
Reston virus NP. There could different hydrodynamic 
volumes between the Reston virus and pathogenic NP 
proteins as well as in the pathogenic ebolaviruses 
exposing residues that remain buried in the Reston virus 
NP. The salt bridge could make RESTV more 
thermostable (and possibly more resistant to proteolysis 
and denaturants). Possible 
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N716 D716 
Present in a surface loop this change will change the 
charge properties. Should be considered with adjacent 
amino acid, which is also an SDP. Overall we see the 
removal of a negatively charged amino acid with two 
polar side chains. Unclear 
N717 G717 
Adjacent to D716N pSDP. The loss of Gly would 
change the turn from type1 to a type 2 turn. Also See 
comment above. Unclear 
 
Supplementary Table 13. Structural analysis of NP SDPs. Details of the structural analysis are 
included with an assessment of whether the amino acid change is likely to have an effect on the 
protein. Four categories are used for the effect column unlikely (the change seems unlikely to alter the 
structure/function), unclear (the change could be functional but there is limited evidence), possible 
(more confident that there is an effect than the unclear group) and probably (highly confident that the 
change will have a structural/functional effect). 










Present in dimer interface (only for one of the 
subunits as the dimer is asymmetric). Forms 
hydrogen bonds with R301, R311 and W313 
(RESTV numbering). Distances between atoms 
are slightly different between the 2 species. 
W324 3.1A (2.8 in Ebola virus), R301 3.2A (2.9 
in Ebola virus) R322 2.8 and 3.0 (both 2.8A in 
Ebola virus). Also close to A303 across 
interface, they could compensate or presence 
of both changes could have greater effect on 




Present in a surface loop packs against adjacent 
helix, conservative change of hydrophobic 
amino acid. Could be some local 
conformational changes and is located adjacent 
to the linker between the two subdomains, 
which is in RESTV has a short alpha helix that 
is not present in EBOV. 
Unclear 
A303 V314 
Present in a surface loop near the VP35 dimer 




Located at the end of a beta sheet. Adjacent to 
His285 in next strand. His285 is completely 
conserved in all Ebolavirus species. So Reston 





Supplementary Table 14. Structural analysis of VP35 SDPs. Details of the structural analysis are 
included with an assessment of whether the amino acid change is likely to have an effect on the 
protein. Four categories are used for the effect column unlikely (the change seems unlikely to alter the 
structure/function), unclear (the change could be functional but there is limited evidence), possible 
(more confident that there is an effect than the unclear group) and probably (highly confident that the 
change will have a structural/functional effect). 
 
 





consensus Comments functional effect 
I151 T150 
The side chain is largely buried and it 
appears that Reston virus I151 would be 
tolerated although a hydrogen bond with 
the backbone of the previous turn of the 
helix will be lost. Unlikely 
R158 Q157 
Located in a surface loop, will increase 
surface charge. It is possible that Reston 
virus forms a salt bridge with D159, which 
would increase stability and reduce 
flexibility in this area of the protein. This 
SDP is in a region of SDPs and very close 
to another SDP (I159L). So possible effects 
may be compensated by other changes. Unlikely 
L160 I159 
Located in a surface close to another SDP 
(see above). Appears to be a conservative 
change that given the other species specific 
changes in this area it seems unlikely that it 
will have a functional effect on the protein. unlikely  
H197 R196 
Surface residue so change in size/shape 
should well accommodated, positive charge 
maintained in side chain. Unlikely 
D206 E205 
Exposed surface residue, conservative 
change of amino acid. Unlikely to alter 
protein structure. Unlikely 
A263 R262 
This residue is present in the dimer 
interface. In Ebola virus VP30 R262 
hydrogen bonds with the backbone of 
A141 and G140. Reston virus A263 will be 
unable to hydrogen bond. This is likely to 
reduce the affinity of the dimer (given that 
it is symmetrical and so the Ebola virus 
R262 in each subunit forms hydrogen 
bonds with  the other subunit. The Reston 
virus dimer has been observed to be 
rotated relative to the Ebola virus. The loss 
of the hydrogen bonds may explain this. Probable 
 
Supplementary Table 15. Structural analysis of VP30 SDPs. Details of the structural analysis are 
included with an assessment of whether the amino acid change is likely to have an effect on the 
protein. Four categories are used for the effect column unlikely (the change seems unlikely to alter the 
structure/function), unclear (the change could be functional but there is limited evidence), possible 
(more confident that there is an effect than the unclear group) and probably (highly confident that the 
change will have a structural/functional effect). 
 











Present in a surface loop (although only third amino 
acid in structure). Reston virus V46 introduces a 
hydrophobic amino acid on surface, could affect 
stability but no evidence for this. Unclear 
T85 P85 
Ebola virus P85 is in a S-G-P-K beta-turn, proline 
confers backbone rigidity and change to Thr in 
Reston virus would introduce backbone flexibility 
and provide a side chain with H-bond donor. 
Located in the Ebola virus octamer interface, will 
result in changes to this interface and likely alter the 
octamer structure. In an octamer structure (if it 
were to remain similar to the Ebola virus octamer), 
T85 could hydrogen bond with the backbone of 
L117 or the sidechain of R137. probably  
V122 I122 
This change appears to be conservative substitution 
of two hydrophobic amino acids. Ebola virus I122 
is packed with other hydrophobic residues and it 
appears that the region would be able to 
accommodate the change to Reston virus V122 







Located in a surface loop. Based on the Ebola virus 
structure, the Reston virus N201 side chain would 
be likely to point into the protein structure. But not 
clear what effect this would have on the protein 
structure, if any given that the structure has gaps in 
this region so cannot be confident. Unclear 
L209 F209 
Packed in a largely hydrophobic region the SDP 
results in a reduction in side chain size in Reston 
virus. The smaller Leucine may adopt different side 
chain conformations to aid stability. Ebola virus 
F209 does not interact with other aromatic side 
chains so the structure is unlikely to be adversely 
affected by the swap to Leucine. Surrounding 
hydrophobic residues are aliphatic (I261, I285, 
V298, A318, P317) so the change to Leucine could 
be well accommodated. Unlikely 
P245 Q245 
Located at the end of an alpha helix, the Reston 
virus P245 would break the helix and shorten it to 
either L244 or more likely M241, which is a better 
C-capping residue.  This could have a destabilizing 
effect on the two helices in this region and the base 
of the hydrophobic core because secondary 
structure will most likely change to accommodate 
the inflexible Proline. Probably 
Q269 H269 
A surface residue, loss of charge to polar side chain. 
This is a highly charged region with E265, R270, 
K274, K275. So the positive charge would be 
reduced in Reston virus VP40.  Unclear 
V293 I293 
Packs with other hydrophobic residues. Appears to 
be a conservative change Unlikely 
 
Supplementary Table 16. Structural analysis of VP40 SDPs. Details of the structural analysis are 
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included with an assessment of whether the amino acid change is likely to have an effect on the 
protein. Four categories are used for the effect column unlikely (the change seems unlikely to alter the 
structure/function), unclear (the change could be functional but there is limited evidence), possible 
(more confident that there is an effect than the unclear group) and probably (highly confident that the 

















Located in a helix. Appears to be a conservative change in 
amino acid. No suggestion from structure that it would alter 
structure/function. Unlikely 
I22 V22 
Located in a helix and is fairly tightly packed against the 
adjacent helix but would expect the pocket to accommodate the 
change.  Unlikely 
I31 V31 
Located in a sheet facing a loop. Side chain is relatively exposed 
so structure should be able to accommodate. Adjacent in space 
to another SDP (132)  Unlikely 
S131 T131 
Ebola virus T131 forms hydrogen bonds with the side chains of 
T129, W125 and with the backbone of H133. Model of Reston 
virus VP24 suggests S131 would continue to interact with the 
same residues. This residue is on the edge of the KPNA5 
binding site. Appears to be a conservative change of amino 
acid. Probable 
T132 N132 
Exposed polar residue exchanges for another polar residue. 
Unlikely to affect structure. Adjacent in space to an SDP 
(V31S) and in sequence to 131. Unlikely 
L136 M136 
Part of the interface site with KPNA5. Mutagenesis of M136 in 
combination with other residues resulted in loss of KPNA5 
binding34. Although it appears to be a conservative substitution. Probable 
R139 Q139 
Interface residue. In Ebola virus Q139 forms an H bond with 
the backbone of R137. This is likely to be lost in Reston virus 
VP24 with the longer R139 side chain. Change will also 
introduce positive charge at interface site. Probable 
A226 T226 
Located in a helix facing a sheet. Ebola virus T226 forms a 
hydrogen bond with the backbone of D48. Reston virus A226 
will not be able to form this hydrogen bond. This is likely to 
reduce the stability of the protein and increase flexibility. Probable 
 
Supplementary Table 17. Structural analysis of VP24 SDPs. Details of the structural analysis are 
included with an assessment of whether the amino acid change is likely to have an effect on the 
protein. Four categories are used for the effect column unlikely (the change seems unlikely to alter the 
structure/function), unclear (the change could be functional but there is limited evidence), possible 
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(more confident that there is an effect than the unclear group) and probably (highly confident that the 
change will have a structural/functional effect). 




Region Residue Conservation  
1 L136 SDP 
1 R139 SDP 
1 S140 Not an SDP but conserved S in Reston viruses and 
mainly R in Ebola viruses, not conserved enough to be 
SDP 
   
2 L107 Vary in species specific manner 
2 H109 Vary in species specific manner 
2 T116 Vary in species specific manner 
2 G120 Not an SDP Ð G in Reston viruses and Ebola viruses 
(mainly), differs in others 
   
3 S184  
3 T185 Not an SDP. T in Reston viruses, mainly N in other 
species 
3 H186 Vary in species specific manner 
3 T187 Not an SDP, primarily T in most species (A in Sudan 
viruses) 
3 F197 Vary in species specific manner 
   
4 V201 Vary in species specific manner 
   
5 S50 Not an SDP 
 
Supplementary Table 18. Residues in VP24 previously identified to differ between Reston viruses 
and Ebola viruses and/or Sudan viruses. Zhang et al., identified five regions that differed between 
Reston viruses and Ebola viruses and/or Sudan viruses7 .The five regions are listed along with 
conservation information i.e. whether the position is an SDP, varies in a species specific manner (i.e. 
not an SDP, but a different residue is conserved in each of the different species) or otherwise 
conserved. Region one is part of the KPNA5 (karyopherin α5) binding site and region two is thought 
to be part of the STAT1 binding site7.  
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Mutation Location/Comments Relationship 
to SDPs 
From Volchhkov et al.,43 Ð experiment 1 
M71I Surface residue. Not clear what functional effect would be. Not close 
L147P Part of an alpha helix, the proline would be expected to break 
the helix and could lead to conformational changes that would 
alter function. 
Close to SDPs 
L17M, V22I 
T187I Adjacent to interface site. T187 forms Hydrogen bonds with the 
backbone of H186 and E203. Mutation to I would remove these 
hydrogen bonds and reduce stability/increase flexibility in this 
area. (Also close to L26F mutation from a separate study) 
Not close 
 
From Volchhkov et al., 43 Ð experiment 2 
H186Y Present in interface with KPNA5. Forms a hydrogen bond with 
the backbone of T434 in KPNA5. Mutation to Tyr would still 




From Ebihara et al., 44 
T50I The side chain of Ebola virus T50 can hydrogen bond with the 
backbones of Q36 and K52. Removal of these interactions with 
mutation Ile will reduce stability/increase flexibility. 
Close to SDP 
T226A 
 
From Dowall et al., 45 
L26F Largely buried side chain. Increase in size to phenylalanine could 
require some conformational change. Interesting that is located 
close to T187I (see above). 
Close to V22I 
F29V* Largely buried side chain. Reduction in size would create space 
and therefore likely to result in some conformational change?  





A43P* Close in space to L26F (see above). Present in a turn.  
K218R* Appears to be a conservative change. K218 is present in the 
KPNA5 interface. Is close to M436 and D489. Possible 
electrostatic interaction. Possible the mutation to R enables this 
interaction to continue in the different species. 
 
 
Supplementary Table 19. VP24 Mutations occurring in adaption of Ebola virus to rodent 
species. The location of the mutation and how it may alter structure and function is listed with details 
of proximity to SDPs. *indicates that after passage one the predominant amino acid at that position 
was the wild type 44. In the Dowall et al.45, study L26F is the only mutation where the mutation is 
predominantly maintained in in all passages. Separate experimental evidence suggests that the L26F 
mutation along results in pathogenicity in guinea pigs37. 
 
Appendix 2: Chapter 3 Supplementary Materials  
 227 
 













Appendix 2: Chapter 3 Supplementary Materials  
 231 
 
Supplementary Table 20. Information on the 196 complete  genomes. Genomes were 








Protein Effective number of 
sequences 
Effective number of 
human pathogenic 
sequence 
Effective number of 
Reston virus sequences 
GP 95.15 86 4 
L 99.2 78 7 
NP 148.96 133 7 
VP24 88.2 79 7 
VP30 96.04 84 7 
VP35 99.96 87 7 
VP40 90.16 80 7 
 
 
Supplementary Table 21. Effective number of independent sequences in the dataset. The 
effective number of independent sequences present in the multiple sequence alignments for each of 
the Ebolavirus proteins is shown. Values were calculated using hmmer (see material and methods). 
 
 







Morena Pappalardo, Francesca Collu, James Macpherson, Martin Michaelis, Franca Fraternali, 
Mark N Wass, in preparation. 
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 Figure S1 Comparison of the Hbonds at the interface in the EBOV complex (A) and in the RESTV 
(B) respectively t zero and 600 ns.  


















Figure S2: RMSD over time plot on the left; on the right the histogram of RMSD, showing the 
distances of the conformations from the starting one, during the simulation. 







Figure S3 : DSSP graph of EBOV-VP24-KPNA5 and RESTV-KPNA5. We split proteins VP24 
from the KPNA5. Residues at the interface were mapped using a yellow circle.   
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Figure S4 a) EBOV complex and B) RESTV complex. Changes in secondary structure, coming from 
DSSP analysis were mapped onto the 3D structures. Differences found in regions around residue 134 
in VP24 (loop coloured in blue for EBOV and in red for the RESTV) and around region 385-395 in 
the KPNA5, where a loss of Alpha Helix is shown in the RESTV complex; this last difference is 











































Figure S5: A) number of H-bond over time plot. In black circles the EBOV and in 
red circles the RESTV complex are shown. The number of H-bonds is constant 
during the 600 ns simulation. B) The probability to find H-bonds during the 
simulations suggestes that EBOV shows a greater H-bonds number (black Gaussian) 





















Figure S6: Radius of Gyration showed a constant compactness in both complexes 














Figure S7: RMSD over time and RMSD histogram showed higher values for R137A 
and F134A-M136A. Again the RMSD in the left graph does not match that on the 
right. 
 










Figure S8: 200 ns trajectories RMSD and RMSF for EBOV WT (black lines), 
R137A-VP24-KPNA5 (red lines) and F134A-M136A-VP24-KPNA5 (purple lines). 
 
 





Figure S9: Principal Component Analysis A) in F134A-M136A-VP24-KPNA5 and B) Cross 
correlation analysis. Correlated movements are shown in red lines and anti-correlated ones in blue. 
Protein VP24 (blue cartoon) and the mutations F134A-M136A (yellow spheres) at the interface with 
KPNA5 (gray cartoon) are likely be in a more correlated region. C) Porcupine plot shows large 
movements during the simulation, occurring both in the VP24 and in the KPNA5.   
 
 
 
 
 
